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Bone metastases are a frequent clinical complication associated with cancer. The 
aim of this PhD thesis was to set up a model system for the study of tumour cell – bone cell 
interactions in vitro, ex vivo and in vivo and to use this system to test the efficacy of a novel 
therapeutic agent for the treatment of osteolytic bone disease. 
 Co-culture or conditioned medium studies using human or mouse cancer cell lines 
were used to develop an in vitro model system of tumour cell – bone cell interactions. This 
showed that osteolytic tumour cells enhance osteoclast formation, fusion and resorption 
through the production of various factors that act directly on osteoclasts and their 
precursors. And in addition, that osteolytic tumour cells also enhance osteoclastogenesis 
indirectly via increasing the production of RANKL in osteoblasts. Other effects on 
osteoblasts included reductions in differentiation, migration and adhesion. Successful ex 
vivo and in vivo models for the study of tumour – induced osteolysis were created using 
adapted organ cultures and intratibial injection techniques respectively. 
 IGF-1 and its receptor are known to play important roles in both bone metabolism 
and breast cancer. Therefore a study of the effects of IGF-1 receptor inhibition on tumour 
cell – bone cell interactions was performed. In vitro studies showed that the novel IGF-1 
receptor tyrosine kinase inhibitor PQIP significantly inhibited IGF-1 and breast cancer 
enhanced osteoclast formation. Western blot analysis suggested this may be due to the 
inhibition of both IGF-1 and cancer conditioned medium induced PI3k/Akt activation. 
Moreover, treatment of osteoblasts with PQIP inhibited cancer cell conditioned medium 
induced increases in RANKL production. Ex vivo studies using human MDA-MB-231 – mouse 
calvarial organ co-cultures demonstrated that MDA-MB-231 cells caused osteolysis and this 
was completely prevented by PQIP without affecting cancer cell viability. Furthermore, 
XXIV 
 
once daily oral administration of PQIP significantly decreased trabecular bone loss and 
reduced the size of osteolytic bone lesions following mouse 4T1 breast cancer cell 
intratibial injection in mice. Quantitative histomorphometry showed a significant reduction 
in breast cancer-induced osteoclast number and activity. Consistent with the significant 
inhibition of osteoblast differentiation, spreading, migration and bone nodule formation 
observed in vitro, PQIP also inhibited osteoblast number and bone formation in vivo. No 
inhibition of in vivo tumour volume was observed. These findings clearly suggest that oral 
PQIP treatment reduced the rate of cancer associated bone turnover.  
 In conclusion, this thesis successfully demonstrates a model system for 
investigating tumour cell-bone cell interactions in vitro, ex vivo and in vivo. Using this model 
system I showed that pharmacologic inhibition of IGF-1 receptor kinase activity using PQIP 
inhibits osteoclast and osteoblast changes induced by breast cancer cells in vitro and in vivo 
and prevents osteolysis ex vivo and in vivo. This indicates that PQIP and its novel derivatives 
which are now in advanced clinical development may be of value in the treatment of 
















Bone is a specialised connective tissue that together with joint tissues makes up the 
skeleton. The structure and functions of bones differs greatly from the lay view of them as 
fixed rigid organs simply providing structure to the body. In fact the bone 
microenvironment is a highly dynamic and constantly redeveloping region that not only 
supports structure but has a variety of other functions including; aiding mobility, providing 
protection for internal organs, storing minerals and growth factors, and allowing 
haematopoiesis (1).  
The skeleton is traditionally thought to contain two types of bone, flat bones such 
as the skull, scapula or ilium, and long bones such as the tibia, femur and radius. These two 
types differ both in structure and the way they are formed during development.  Flat bones 
are derived entirely by intramembranous ossification, where bone forms by direct 
mineralization of mesenchyme tissue. Long bones, on the other hand, form mainly through 
the process of endochondral ossification, where a pre-existing cartilage structure is 
digested by chondroclasts and replaced with bone (1). Three further sub-categories of bone 
also exist, which accomadate bones that do not fit exactly into either the long bone or flat 
bone categories. These are short bones which are similar to long bones but are as wide as 
they are long; examples include tarsals and carpals, irregular bones which have complex, 
irregular shapes such as the vertebrae or sacrum, and sesamoid bones such as the patella, 
which are embedded in tendons.  
 Once formed, long bones have a cylindrical shape with a central medullary cavity 
that hosts the haematopoietic bone marrow. They consist of a long bony tube called the 
diaphysis attached to wider extremities, the epiphyses, by an intermediary zone called the 
metaphysis (Figure 1.1). A layer of hyaline cartilage, known as the growth plate, separates 
the metaphysis and epiphysis during growth. Once growth is complete this also mineralises 
leaving behind the epiphyseal line. Flat bones consist of two layers of bone enclosing a thin, 




Structurally, bone consists of two tissues types; cortical or compact bone and 
trabecular or cancellous bone. Cortical bone forms the dense outer shell of bones, while 
the more metabolically active trabecular bone consists of interconnected ‘spongy’ 
trabeculae adding strength by spanning across the medullar cavity of flat bones and at the 
end of the long bones (Figure 1.1). 






 Cortical bone, or compact bone, is highly mineralized bone that makes up around 
85% of the skeleton and undergoes minimal remodelling (1). It forms the cortex of most 
bones and is there to protect organs, allow movement and store minerals. In humans and 
other large mammals, cortical bone is found as a series of cylindrical structures parallel to 
the long axis of the diaphysis called osteons or Haversian systems (Figure 1.1). Each osteon 
is several millimetres long and consists of compact repeated layers of calcified bone matrix, 
called lamellae, concentrically surrounding a central vascular canal known as the Haversian 
canal (2, 3). At the edges of cortical bone the series of osteons are surrounded by multiple 
external and sometimes internal circumferential lamellae layers as well as the outer 
periosteum membrane. The Haversian canals allow blood and nerve vessels to pass through 
the bone and to the cells within. They are connected to one another and the periosteum 
blood and nerve vessels by transverse or obliquely situated canals that perforate the 
concentric lamellae, these are called perforating canals or Volkmann’s canals. As layers of 
successive lamellae are layed down osteocytes become trapped between the concentric 
layers in lacunae. The osteocytes are connected to one another and the Haversian canal by 
numerous minute interconnecting cannals called canniculi which contain fine cytoplasmic 
extensions of the osteocytes (2, 3). 
 The ‘spongy’ trabecular bone makes up the remaining 15% of the skeleton, and is 
found throughout flat bones, but only at the extremities of long bones. It is surrounded and 
filled by bone marrow, which makes it metabolically more active (1). Trabecular bone is also 
composed of osteons but, as opposed to cortical bone, the lamellae run parallel to each 
other. In addition, while 80-90% of the cortical bone is mineralized, only 15-25 % of 
trabecular bone is mineralized (Figure 1.1). 
 Bone matrix comprises of two components, the organic matrix and the inorganic 
mineralised matrix. 90% of the organic bone matrix is made of type I collagen fibres found 
in the osteons mentioned above (1). The remaining 10% consists of non-collagenous 
proteins, including proteoglycans, osteopontin (OPN), osteonectin (OSN), osteocalcin 
(OCN), and fibronectin. The main purpose of these highly specialized proteins is either to 





 The main component of the inorganic mineralised matrix is crystals of 
hydroxyapatite [Ca10(PO4)6(OH)2] orientated in the same direction as the organic collagen 
fibres (1). It has dual purposes; firstly it adds strength to the organic matrix allowing bone 
to serve its roles of providing structure and protection. Secondly, the inorganic mineralised 







1.2 Bone Cells 
 
 Bone cells are highly specialised cells that develop skeletal structure by bone 
modelling and maintain the integrity of this structure through a constant cycle of bone 
remodelling. The main bone cell types are the bone-resorbing osteoclasts, the bone-




 Osteoblasts are mononuclear bone cells that produce the matrix constituents 
required for bone formation. They are found as clusters of cuboidal cells along the bone 
surface and are characterised by a round nucleus opposite the bone surface, extensive 
endoplasmic reticulum and an enlarged Golgi complex (1). This allows osteoblasts to 
produce and secrete large amounts of connective tissue matrix (1). 
 Osteoblasts are mesenchymal cells derived from mesodermal and neural crest 
progenitor cells called mesenchymal stem cells (MSC) found in the bone marrow. These 
cells also give rise to a range of other cell types, including, chondrocytes, adipocytes and 
myocytes (1, 4). A combination of various hormones, growth factors and transcription 
factors control the osteoblast lineage pathway transforming MSCs into osteoprogenitors, 
preosteoblast, mature osteoblasts, and finally bone lining cells or osteocytes (Figure 1.2). 
 While Bone Morphogentic Proteins (BMP) are thought to initiate the initial 
transformation from MSC to osteoblast, the major transcription factor responsible for the 
commitment of MSCs towards the osteoblastic lineage is Runt-related transcription factor 2 
(Runx2) (5). Mice deficient in Runx2 do not develop mature osteoblasts, and as a result 
these mice are unable to form mineralised bone (6, 7). Runx2 regulates a variety of 
osteoblast specific genes including the gene coding another protein essential for osteoblast 
differentiation, the zinc finger transcription factor Osterix (Osx). This controls the 
expression of a variety of osteoblastic genes, including type 1 collogen (Col1a1), and causes 
osteoprogenitor cells to further differentiate into osteoblasts (Figure 1.2) (8, 9). Both Runx2 




11). This promotes osteoblast differentiation at the expense of other progeny cells of 






A variety of external factors influence the differentiation, survival and function of 
osteoblasts by either altering the expression of Runx2 or Osx, or by reducing activity of the 
pro-adipogenesis factor PPARγ2 (12). Factors that up regulate osteoblast differentiation 
include several endocrine system proteins such as parathyroid hormone (PTH) and its 
related protein (PTHrP) (13-15), oestrogen (16), and vitamin D3 (17, 18), as well as growth 
factors and cytokines (12) including Insulin-like Growth Factor 1 (IGF-1) (19), BMPs (20-22), 
Transforming Growth Factors (TGFs) (23), Fibroblast Growth Factors (FGFs) (24) and Indian 
hedgehog (Ihh) (25).  Conversely, pro-inflammatory cytokines, including Tumour Necrosis 
Factor Alpha (TNFα), inhibit Runx2 expression and so down regulate osteoblastagenesis 
through the activation of the NFκB signalling pathway (26, 27) (Figure 1.3). 
 Osteoblasts serve two physiological functions, one direct and anabolic and the 
other indirect and catabolic. Osteoblasts anabolically synthesize new bone through the 
secretion of the unmineralised organic bone matrix called osteoid (28). Osteoid consists of 
type 1 collagen, but also contains some specialised bone matrix proteins, including OCN, 
OPN and BSP that aid in ossification, regulate bone formation, and allow other osteoblasts 
to adhere to the matrix. Importantly, osteoblasts also produce alkaline phosphatase (ALP) 
which aids bone formation by breaking down pyrophosphate and other such inhibitors of 
bone matrix mineralisation. ALP is also used as a serum marker for osteoblast activity (1). 
 The catabolic role of osteoblasts is to support osteoclastogenesis through the 
stimulation of the differentiation of osteoclast pre-cursors and the activation of mature 
osteoclasts. This is achieved through the production of the key osteoclastic factors, 
Macrophage Colony Stimulating Factor (M-CSF) and Receptor Activator of Nuclear Factor 
Kappa-B Ligand (RANKL) (1). Osteoblasts also produce Osteoprotegerin (OPG), a decoy 
receptor for RANKL, which negatively regulates osteoclastogenesis (1). Through the 
expression of these proteins, osteoblasts are able to use paracrine signalling to control 
osteoclast formation and bone resorption (29). 
 Osteoblasts are not terminally differentiated, despite their non-proliferative status. 
Once their have performed their primary role they have three different possible fates. They 
can become buried within the bone matrix as osteocytes, they can undergo apoptosis, or 
they can become quiescent bone lining cells (30). These bone lining cells cover 95% of 




elucidated, are thought to protect bone from either resorption or formation as well as play 





Figure 1.3 Diagram demonstrating key signalling pathways involved in osteoblast 
differentiation and function. See text for more details. Abbreviations: ER is oestrogen receptor, 
BMPs is Bone Morphogenic Proteins, TGFβ is Tumour Growth Factor Beta, IGF-1 is Insuilin-like 
Growth Factor 1, PTH is ParaThyroid Hormone, PTHRP is ParaThyroid Hormone Related Protein, 
FGFs is Fibroblast Growth Factors, ET-1 is EndoThelin 1, MAPK is Mitogen Activated Protein Kinase, 







 Osteocytes are terminally differentiated cells of the osteoblast lineage located 
within the bone matrix and account for more than 90% of bone cells found in the adult 
skeleton (33, 34). During the bone formation phase, 10-20% of mature osteoblasts become 
encased in the newly formed osteoid (1). These cells then begin to transform from 
polygonal cells, forming dendritic process which extend towards the mineralising front, 
followed by further dendrites which extend in the opposite direction, to either the vascular 
space or the bone surface (35). As the developing osteocyte becomes embedded deeper 
into bone it also undergoes various biochemical changes; alkaline phosphatase production 
declines, while osteocalcin and casein kinase II increase (35), transitioning its function away 
from that of the osteoblast. Currently there is debate over whether the recruitment of cells 
to become osteocytes is a passive process, and it is the act of being encased in osteoid that 
initiates the transformation (36), or an active process with signalling from existing 
osteocytes driving the conversion of active osteoblasts into osteocytes (37). 
 While osteocytes are becoming embedded in bone their dendritic processes have 
been extending through the new and old bone. This allows the osteocyte to join the “so-
called” lacunocanalicular system. This system consists of osteocytes in lacunae connected 
to each other and bone lining cells through their dendrites, which pass through the bone in 
a network of fluid filled canaliculi tunnels (1, 38-40).  The main functions of this system are 
thought to include a mechanosensory function and regulatory control of mineral 
homeostasis, as well as some control over both bone resorption and formation (reviewed in 
(33)).   
 Osteocytes are thought to regulate bone remodelling in a number of ways. Living 
osteocytes have been shown to support osteoclast formation by expressing RANKL, as well 
as supporting osteoblast differentiation (41).  However, it is regulation of their death that is 
thought to give osteocytes greatest control over remodelling. Upon undergoing apoptosis, 
apoptotic bodies are released that express RANKL, therefore leading to the recruitment of 
osteoclasts (42). Osteocyte apoptosis occurs in response to microdamage of the bone. At 
these sites osteocytes express pro-apoptotic factors, while 1-2mm from the site they 




the release of osteolytic factors nearby that may cause the resorption of healthy bone (43). 
It has been hypothesised that the presence of healthy osteocytes also inhibits bone 
resorption through an unknown mechanism, potentially by releasing anti-resorptive factors 
such as TGFβ (44). This is supported by work demonstrating that the selective deletion of β-
catenin in osteocytes, so preventing the Wnt signalling necessary for their normal function, 
results in increased osteoclast activity and porous bones (45). The role of osteocytes in 
regulating bone resorption has recently been shown to be far more important than 
previously thought as Nakashima et al (2011) demonstrated that osteocytes produce a 
much higher amount of RANKL than osteoblasts, the cells currently thought to be the main 
regulators of osteoclast formation. In addition, they showed that osteocytes supported 
osteoclast formation better in vitro and that mice with RANKL conditionally knocked out 




Figure 1.4. Images showing Osteocytes in lacunae and their dendritic 
network through the lacunocanalicular system. See text for more details. 
A)Adapted from Weinstein et al Endocrinol Metab. 2000;85:2907-2912. B) Adapted 




Osteocytes also regulate bone formation through the expression of Sclerostin 
(SOST). SOST is a negative regulator of Wnt signalling which is critical for osteoblast 
differentiation. Osteocyte SOST expression is known to be reduced in response to increased 
mechanical loading when bone becomes damaged (47-49). Osteocytes are also known to 
express a number of other factors that promote mineralisation (50), including Phosphate-
regulating neutral Endopeptidase on chromosome X (PHEX) (51), Dentin Matrix Protein 1 
(DMP1)(52), Matrix Extracellular Phosphoglycoprotein (MEPE)(53), and Fibroblastic growth 
factor 23 (FGF23) (54). DMP1, PHEX and FGF23 also contribute to controlling the levels of 
phosphate reabsorbed by the kidney, so regulating mineral homeostasis (55).  
 In addition to recruiting osteoclasts or osteoblasts, osteocytes are also capable of 
remodelling their own environment to a limited extent (56). This is achieved through the 
addition and/or subtraction of mineral within the lacunae and canaliculi by an unknown 




Osteoclasts are one of the most distinct and highly specialised cells in the human 
body. They are terminally differentiated, giant, multinucleated and highly motile cells that 
express various osteoclasts specific proteins such as tartrate-resistant acid phosphatase 
(TRAcP) and are formed by the fusion of multiple mononuclear monocyte/macrophage 
precursor cells (1, 58). Osteoclasts are specialised for one main purpose, the resorption of 
bone. This is achieved through dissolving the hydroxyapatite mineral component of bone 
and degrading the organic bone matrix (1). 
 Over the past three decades, there was much debate over the precise origins and 
lineage of osteoclasts, but in recent years it has become accepted that they are cells of 
hematopoitic descent. It has been demonstrated that to become osteoclasts cells must 
start as hematopoietic stem cells (HSC), which then progress through the colony forming 
units for granulocytes (CFU-GM) and macrophage (CFU-M) to become pre-osteoclasts and 




osteoclastagenic cytokines is required for this differentiation path to reach completion, M-
CSF and RANKL (58, 60, 61) (Figure 1.5). 









Secreted by osteoblasts and their precursors, M-CSF binds to its receptor, c-Fms, 
found expressed in all cells of the osteoclast lineage from early pre-cursors to mature 
osteoclasts (62). This stimulates signalling pathways that promote proliferation, 
differentiation and survival of osteoclast and their precursors (63, 64). 
 Once cells have committed to becoming pre-osteoclasts they start to express RANK, 
the RANKL receptor. The binding of RANKL to RANK stimulates various signalling pathways 
including the AP-1 and NFκB pathways, which in the absence of granulocyte-macrophage 
colony stimulating factor (GM-CSF), causes cellular changes that allow the mononuclear 
pre-osteoclasts to fuse together to form bone resorbing multi-nucleated mature osteoclasts 
(63, 64). In the presence of GM-CSF osteoclast pre-cursors are driven to become dendritic 
cells (65). RANKL is found in both soluble and membrane bound components produced by 
osteoblasts, osteocytes and activated T-cells (66), though it has recently been 
demonstrated that osteocytes are likely to be the major source of RANKL (46). 
 Various other factors are known to modulate the formation, fusion, function and 
survival of osteoclasts. These include Osteoprotegerin (OPG) which is a soluble decoy 
receptor for RANKL, and completes the RANK/RANKL/OPG axis recognised as the dominant 
regulator of osteoclastogenesis (1, 67).  The rate of osteoclast formation is greatly 
determined by the ratio of RANKL to OPG present in the bone microenvironment (68). 
TNFα, IL-1 and PGE2 are known to activate transcription factors that promote osteoclast 
formation and survival (69, 70), whereas IL-6 and IL-11 act on osteoclast pre-cursors 
enhancing cell survival and proliferation (71). Finally, TGFβ has been found to increase the 
expression of RANK in osteoclast precursors (72) (Figure 1.6). 
The process of bone resorption involves four key processes after the initial 
formation of osteoclasts. This starts with the attachment of the cell to the bone surface, 
followed by polarisation of the cell and the development of ruffled border and a sealing 
zone, then the secretion of acid and enzymes that resorb bone and finally the removal of 











It is not known what attracts osteoclasts to a particular bone site, but some 
research suggests that this may be linked to osteocyte cell death (42, 75). Once osteoclasts 
have reached the site to be resorbed, they become polarised and produce actin rich 
structures called podosomes which fix the cell to bone via an attachment of vβ3-integrins 
to Arg-Gly-Asp (RGD) peptides moderated by the activity of c-Src (59, 76).  This forms a tight 
circular ‘actin ring’ sealed by proteins such as CD44 (77) and known as the sealing zone 
which is completely isolated from the extracellular space. Within this ‘zone’ the complex 
finger-shaped folded membrane projections known as the ruffled border forms; it is this 
that is the major resorbing organelle (1, 59).  
 Bone resorption occurs in the isolated compartment of the ‘sealed zone’ where 
osteoclasts secrete protons, chloride ions and acidic vesicles containing such proteins as 
Matrix Metaloprotease 2 (MMP-2) and cathepsin K (63, 78-81). Protons are produced 
through a two-step reaction; firstly, carbonic anhydrase catalyses the hydration of carbon 
dioxide into carbonic acid (H2O +CO2 -> H2CO3). This then dissociates into a bicarbonate ion 
and proton (H2CO3 -> HCO3
- + H+), both products of which are useful to osteoclasts (82). The 
hydrogen ion is taken by the ATP-consuming proton pump known as vacuolar ATPase (V-
ATPase) which passes the ion through the ruffled border and into the sealed zone. In 
contrast, the bicarbonate ion is excreted through the apical membrane. This occurs through 
a chloride/bicarbonate anion exchanger bringing the chloride ions (Cl-) required into the 
osteoclast (83). The secretion of protons out of the cell means that in order to maintain 
charge equilibrium and intracellular pH the negatively charged chloride ions are soon 
passively passed out of the cell again and into the sealed zone through the CLCN7 chloride 
channel. 
      The presence of large quantities of both H+ and Cl- present in the sealed zone 
causes hydrochloric acid to form. This has the effect of lowering the pH to approximately 
4.5 and causes the breakdown of hydroxyapatite mineral component of bone into Ca2+, 
HPO4
2- and H2O (59). Once the mineral component has been removed, the organic collagen 
fibres and other matrix proteins are exposed. Enzymes such as MMP2 and cathepsin K that 
are released from the ruffled border then degrade the organic bone matrix components 
(59, 84) completing the resorption of the bone within the sealed zone. Degraded resorption 




specialised membrane domain on the opposite side of the cell called the functional 
secretory domain (FSD). This releases the waste products into the extracellular fluid (85) 
(Figure 1.7).   
 




 Along with visual identification, the most commonly used method of identifying 
osteoclasts is through stains and antibodies that bind to the TRAcP isoform TRAcP5b (Figure 
1.8). It is therefore worth noting that the function of TRAcP is still not fully understood and 
that other isoforms of the enzyme are highly expressed in other cell types, such as dendritic 
cells (86). TRAcP -/- mice exhibit only a mild osteopetrotic phenotype and so it is thought 
that it is unlikely TRAcP plays a vital role in resorption or osteoclast formation and survival 
(86, 87).  One possibility that has been hypothesised that it may in fact play a role in antigen 
processing and so rather than directly effecting resorption may protect against an auto-
immune response to the products of bone resorption (58). 
 
  
Figure 1.8 A Photomicrograph showing multinucleated osteoclasts 
stained for tartrate-resistant acid phosphatase (TRAcP). See text for more 






 In addition to bone, cartilage is also synthesised and deposited by specialised cells 
found in the bone microenvironment; chondrocytes (Figure 1.9). Like the bone matrix, the 
basic structure of cartilage is formed from an extracellular matrix mainly consisting of 
collagen, though this tends to be type II or type X collagen rather than the type I found in 
bone. Structural proteins such as elastin and proteoglycans, mainly aggrecan, are also 
present (88, 89). Three distinct types of cartilage are found in the mammalian body, 
distinguished by their differing extracellular matrix components. Hyaline cartilage is typical 
cartilage, while elastic cartilage has additional elastin fibres and fibrocartliage contains 
regions of organised fibrous tissue (89, 90). They are found in various places throughout the 
body, including for hyaline cartilage the larynx, trachaea, bronchus, articular cartliage and 
at the growth plates of long bones during development. Elastic cartilage is found in 
locations such as the ears, the larynx and epiglottis and fibrocartliage in locations such as 
the intravertebral discs and the meniscus (1). 
 Chondrocytes are similar to osteoblasts in many ways, but in stead of producing 
bone, produce cartilage. Chondrocytes and osteoblasts are both derived from MSCs, both 
secrete an extracellular matrix that forms tissue (osteoid from osteoblasts and the 
cartliagenous matrix from chondrocytes), both produce matrix vesicles, and both have 
prominent golgi aparatus, endoplasmic reticulum and large numbers of mitochondria to 
facilitate their functions. However unlike osteoblasts, chondrocytes are generally found 
within lacunae in the cartilage, rather than on the surface of bone, and are the only cell 
types to be found within their environment (91). The Sex determining region Y-Box (Sox) 
family of developmental transcription factors are the key drivers of chondrocyte 
development; causing them to be the first skeletal cells to arise during development. Sox9 
induces the differentiation of MSCs into chondrocytes and activates the expression of 
aggrecan and type II collagen (92, 93). Sox 5 and 6 bind to Sox9 and enhance its 
transactivation function increasing differentiation and proliferation (94). All three also 
inhibit premature chondrocyte hypertrophy, the final cellular form of chondrocytes and a 
terminal differentiation that leads to endochondral bone formation. Once cartilage 
formation is complete, Runx2 and other factors stimulate the chondrocytes to become 




(VEGF) that stimulates blood vessel development, bringing in haematopoietic and 
osteoprogenitor cells into the environment and allowing bone development (91). 













 While not directly involved in bone modelling or remodelling, adipocytes are one of 
the most numerous cell types found in the bone marrow of long bones. They are derived 
from the same MSCs as the osteoblast lineage and their differentiation rate directly affects 
that of osteoblasts. Many studies have shown that as adipocyte differentiation increases, 
osteoblast differentiation decreases. In undifferentiated MSCs, the pro-adipogenic 
transcription factors CCAAT-enhancer binding proteins α and β, and peroxisome 
proliferation-activated receptor γ (PPARγ) counteract each other. PPARγ suppresses 
osteoblast differentiation by down regulating Runx2 expression, while Runx2 and Osx 
suppress adipocyte differentiation (12, 96). Once other signals tip the balance of 
transcription factor expression in one direction or the other MSCs begin to differentiate 
down either the adipocyte or osteoblast cell lineages.  
 In addition to PPARγ, a number of factors are known to play an essential role in 
regulating adipogenesis (97). These factors include the pro-adipogenic cyclic AMP response 
Figure 1.9 Histology image of chondrocytes in their 
lacunae. 





element-binding protein (CREB), Kruppel-like factors (KLFs) and various others (reviewed in 
(96)). 
 It has long been established that adipocyte number negatively correlates to the 
amount of haematopoietic activity within bone marrow (98). They were thought to play a 
simple passive space filling role in bone marrow, forming in response to gaps left where 
there were fewer haematopoietic cells (98). However, recent work has demonstrated that 
adipocytes may in fact function as direct negative regulators of haematopoiesis (98-100). In 
this they would seem to continue their counteraction of the cells of the osteoblast lineage, 
which are known to support formation of the haematopoietic stem cell niche (99, 100). 
  
Figure 1.10 A photomicrograph of 
Adipocytes stained with oil red.  







 The formation of bones during development occurs in two different ways: through 
the conversion of a cartilage template to bone, called endochondral ossification, or by the 
direct replacement of mesenchyme tissue with bone, called intramembranous ossification. 
This involves both bone modelling and remodelling, as bone is layed down by osteoblasts 
and removed by osteoclasts. Bone modelling is the uncoupled action of osteoblasts and 
osteoclasts which allows the shaping, growth and repair of bones; this means there is a net 
loss of material in one area, and a net gain in another.  Bone remodelling on the otherhand 
is coupled, with the amount of bone resorbed and the new bone formed being equal in any 
one location. 
 
1.3.1 Endochondral ossification 
 
 During early embryonic development most of what will become the appendicular 
and axial skeleton consists of a hyaline cartilage template to be replaced by bone.  
Ossification occurs at ossification sites, of which, in a typical long bone, there are three 
divided into two distinct types, a primary ossification site in the diaphysis separated from 
two secondary ossification sites at the epiphysis by the cartilage growth plate (1). 
 As the type II collagen cartilage template enlarges, chondrocytes at the centre 
differentiate into hypertrophic chondrocytes that are 5-10 times larger and are known to 
instead produce type X collagen (91, 101). They also secrete matrix molecules that aid in 
the recruitment and differentiation of osteoblast and osteoclast precursor cells including 
OPN, BSP and OSN (102). In addition, these hypertrophic chondroclasts release angiogenic 
factors, such as VEGF, which cause the vascularisation of the cartilage template (103). This 
serves two purposes, it allows the transportation of bone cell precursors into the 
environment and it also reduces the level of hypoxia in the area; a hypoxic environment is 
known to stimulate chondrocyte proliferation (104). 
As the hypertrophic chondrocyte zone is invaded by bone cells and blood vessels, 




provisional cartilage matrix, eventually removing up to 80% of it (105). Newly arisen 
osteoblasts use the remaining template as the basis for bone formation, producing osteoid 
that becomes the primary ‘woven’ bone. This is not yet mature lamellar bone and is 













































































































 This conversion of cartilage to bone first occurs at the primary ossification site in 
the centre of what will become the bone (Figure 1.11). As ossification continues and the 
bone marrow cavity expands towards the epiphyses, chondrocytes at the epiphyseal 
margin undergo rapid proliferation. This causes the formation of distinct longitudinal 
columns of chondrocytes that form a barrier between the epiphysis and the primary 
ossification site (102). This is known as the growth plate and during growth the rate of 
chondrocyte proliferation and cartilage production within it balances the replacement of 
cartilage with bone. This allows the longitudinal growth of the diaphsis of the bone, while 
maintaining the width of the growth plate. Later in development the secondary ossification 
centres form within the epiphyses, and are separated from the primary ossification site by 
the growth plate. This process is dependent on various growth factors stimulating 
chondrocyte proliferation, and so when the production of these growth factors declines at 
the onset of puberty the ossification rate begins to overtake the rate of cartilage 
production. Eventually the growth plate is reached by the ‘ossification edge’ and the 
dyaphysis becomes fused to the epiphysis completing bone growth (102, 103, 107).  
 
1.3.2 Intramembraneous ossification 
 
 The development of flat bones occurs through the direct conversion of 
mesenchymal tissue to bone by intramembranous ossification. It should be noted that 
unlike other flat bones, the cranial bones originate from the neural crests. 
 While endochondral ossification required a hypoxic environment and is organised 
into distinct ossification centres, intramembraneous ossification requires vascularisation 
and occurs across various points of the tissue simultaneously (1). In certain embryonic 
tissues, MSCs proliferate, condense and form compact nodules of cells. Some MSCs in this 
nodule differentiate to form blood vessels, while others become the first osteoblasts. The 
newly formed blood vessels allow the tissue to be further infiltrated by osteoblasts and 
other bone cell precursors. These osteoblasts then secrete osteoid inside of the nodule 
which then is mineralised to become the first bone. As the calcification occurs bony spicules 
radiate out from the point of ossification, and the whole region of bone spicules is 




bone spicules fuse together forming ‘woven’ bone which is then repeatedly remodelled by 





1.3.3 Mineralisation, the Bone matrix and Matrix vesicles 
 Whichever of the two ways bones are formed, one of the vital aspects is the way in 
which tissue becomes mineralised and the inorganic bone matrix forms. As discussed 
above, osteoblasts produce osteoid, the unmineralised bone matrix, and chondrocytes 
produce the cartliagenous matrix. The regulation of the production of osteiod and 
cartliagenous matrix is well understood, however questions remains over precisely how 
these then become mineralised by the inorganic part of bone or cartliage and whether or 
not this process occurs via an active and regulated process or simply occurs in an inactive 
continuous process over time. It now seems likely both processes are involved to some 
extent. 
Figure 1.12 A photomicrograph of a flat bone undergoing intramembraneous 
ossification. See text for details. 




 The organic part of both bone and cartilage consist mainly of collagen fibres but 
these are interspersed with the non-collageneous proteins that make up ~10% of the bone 
protein content. These have a wide variety of functions, but are vitally involved in the 
process of mineralisation and the conversion of cartilage to bone. The non-collagenous 
proteins can be subdivided into 5 categories, serum derived proteins, the proteoglycans, 
the glycoproteins, the γ-carboxylated (gla) proteins and other proteins including lipids and 
enzymes (109, 110). 
Serum derived proteins make up 25% of noncollageneous proteins. These are 
mostly acidic proteins such as albumin that bind to the bone matrix due to a high affinity 
for hydroxyapatite. While not endogeneously produced by bone cells these can still 
influence mineralisation, for example albumin can inhibit hydroxyapatite crystal growth 
(110).  
 Proteoglycans are heavily glycosylated proteins consisting of a core protein 
attatched to acidic polysaccharide side chains. Various members are found in the bone 
matrix including Versican, Decorin, Asporin, Fibromodulin, Biglycan, and Osteoadherin. 
These seem to have a number of different functions including, the allocation of space to 
become bone during early bone formation and chondrogenesis (Versican), the regulation of 
collagen fibrillogenesis and structure (Decorin, Biglycan, Asporin, Fibromodulin), limb 
patterning (Perlecan), and the attatchment of cells to the bone matrix (Osteoadherin) (109, 
110).      
 The most diverse group of non-collageneous proteins found in the bone matrix are 
the glycosylated proteins. These include alkaline phosphatase which breaks down 
pyrophosphate, OSN which binds to growth factors and may influence the cell cycle, and 
importantly the small integrin-binding ligand, N-glycosylated (SIBLING) proteins. The 
SIBLING proteins all contain an RGB sequence that allows cells to attatch to them through 
integrin cell surface receptors. This allows cells, especially osteoclasts, to bind to and 
interact with bone. SIBLING proteins include OPN, BSP and DMP-1 (109, 110). 
 The matrix gla-containing proteins are three proteins, matrix gla protein, OCN, and 
protein S, which undergo post-translational modification by γ-carboxylases. The gla 




unclear. Matrix gla may be involved in the regulation of cartilage metabolism, while OCN is 
known to act as a hormone in glucose metabolism and may act as a coupling factor in bone 
remodelling, regulating osteoclast and their pre-cursors (109, 110). 
 As state above, many of these organic matrix components are thought to facilitate 
and condition the mineralisation of bone. This process occurs in two steps, starting with the 
formation of hydroxyapaptite crystals within matrix vesicles. Matrix vesicles are small (20-
200 nm) spherical, lipid bilayer bounded, bodies that are formed by polarised budding from 
the plasma membrane of chondrocytes and osteoblasts (111, 112). These matrix vesicles 
have a different composistion to their parent membranes with a far higher amount of 
alkaline phosphatase, as well as other components such as phosphatidylserine, annexins, 
nucleotide pyrophosphatase phosphodiesterase 1, and the type III Na+/PO4
3- cotransporters 
Pit1,2 and Phospho-1 (113). These facilitate the accumulation of calcium and phosphates 
within the matrix vesicles until their concentrations exceeed the solubility point of CaPO4 
and this is deposited within the matrix vesicles as hydroxyapatite. This becomes a primary 
mineral nucleation point and allows secondary mineralisation to build on the existing 
hydroxyapatite crystal (111-113). 
 This second stage of mineralisation occurs when the forming hydroxapatite crystals 
breech the matrix vesicle membrane and expand into the extracellular space. This 
expansion occurs due to the maintainance of high levels of Ca2+ and PO4
3- in the 
extracellular space by ion pumps on osteoblasts (112). Hydroxapatite crystals then form 
clustered around the initial matrix vesicle crystals and fill the space between collagen fibrils. 
This process then continues with clusters from multiple primary nucleation sites combining 
until the organic bone matrix is fully mineralised (111-113).   






1.4 Bone Remodelling 
 
 Bone is not dormant once it has been formed through the process of modelling. 
Instead, throughout life the skeleton is continuously broken down and reformed through 
the coordinated actions of osteoclasts and osteoblasts. This is called bone remodelling. 
Over time bone becomes damaged, this may occur through exercise, or in response to 
mechanical stresses and mechanical loading. In order to maintain the shape, strength and 
integrity of the whole bone the damaged parts of it must be continuously removed and 
replaced. This occurs to the extent that the entire adult human skeleton is replaced every 
ten years (114). To achieve this, discrete packets of remodelling are used, called bone 
remodelling units (BMU), which are geographically and chronologically isolated from all 
other remodelling packets (1). Within each BMU the cellular activity of osteoclasts and 
osteoblasts is coupled so that the net amount of bone remains the same. Outside of bone 
that is in the resting phase, all bone will be undergoing one of three bone remodelling 
processes. These are; bone resorption, where bone is digested by osteoclasts, the reversal 
phase, where bone resorption is coupled to bone formation, and bone formation, where 
osteoblasts synthesise new bone (1, 115) (See Figure 1.13). 
 
1.4.1 Bone Resorption 
 
 The lining cell layer covering quiescent bone is disrupted in response to unknown 
signals thought to be generated by osteocytes, lining cells themselves, or pre-osteoblasts 
(116). This initiates the resorption phase. To prepare the bone for resorption MMPs, 
collagenase and gelatinase are first produced by lining cells (117). This leads to a thinning of 
the osteoid layer. Next, the key osteoclastogenic factors RANKL and M-CSF are produced by 
osteocytes (41), osteoblasts and lining cells (61, 118-120). This causes an expansion in the 
osteoclast progenitor pool and triggers the formation of multi-nucleated osteoclasts. 
Finally, lining cells detach from the surface of the bone to be resorbed, allowing the forming 
osteoclasts access to the now osteoid free mineralised bone surface (115, 118). 
 The multinucleated osteoclasts bind to the bone surface, allowing them to polarise 




matrix proteins (OPN and vitronectin in particular) are recognised by osteoclast podosomes 
containing actin filaments and α√β3 integrin, allowing the formation of an actin ring (115, 
121). This actin ring, aided by proteins such as CD44 (77), causes an intimate binding of the 
cell and the bone surface. The bind is so close that the area beneath the actin ring is 
completely isolated from the extacellular fluid. This isolated region is known as Howship’s 
lacuna or the sealing zone (122). 
 The ruffled border of the osteoclast forms inside the sealed zone, allowing the 
osteoclasts to secrete protons and chloride ions into the area. This is done through V-
ATPases and passive chloride channels respectively (82, 83). As a result, a localised 
extremely acidic environment is created where pH can be as low as 4.5. At such a low pH 
the mineralised component of the bone matrix breaks down; hydroxyapatite crystals are 
converted into Ca2+, HPO4
2- and H2O (59). This exposes the organic bone matrix, which is 
subsequently degraded by the release of vesicles from the ruffled border. These vesicles 
contain factors such as Cathepsin K and MMP9 which digest collagen I through the release 
of carboxyterminal peptides, thereby removing the major organic component of bone (63, 
78-81, 123). 
By this point, while the bone matrix may have been destroyed, resorption is not 
over, as the broken down fragments of both the mineral and organic components remain 
within the lacunae. To complete bone resorption these components must be removed from 
the freshly resorbed area. To do this osteoclasts ingest these fragments through 
endocytosis. The vesicles containing the waste products are then secreted through the FSD 
at the apical membrane and into the extra cellular compartment at the opposite side of the 
osteoclast to the bone surface (85).  
Overall, bone resorption lasts for about ten days and ends when the osteoclasts 
have achieved the required erosion depth. Once this has occurred, the osteoclasts begin to 







1.4.2 Reversal Phase 
 
 The reversal phase is the process that couples the bone resorption phase to the 
bone formation phase and is thought to last about 9 days in humans. Osteoclasts undergo 
apoptosis and osteoblast precursors migrate to the newly resorbed bone. Mononuclear 





remaining organic residues and causes the formation of the cement line which marks the 
limits of bone resorption and joins the new bone to the old (1, 115, 124). 
 The processes that trigger the reversal phase are poorly understood, but several 
mechanisms have been proposed. First, it may simply be that osteoclasts have a finite 
lifespan and die after a set amount of time or resorption activity has passed (115). 
Secondly, it has been observed that a high concentration of calcium builds up in the 
resorption lacunae over time, this causes an inhibition of osteoclast activity and a 
reorganisation of actin that leads to podosome disassembly and subsequently cell death 
(125). Lastly, it may be that the build up of factors released from the bone matrix, such as 
TGFβ and IGF-1, causes the inactivation of osteoclasts and signals osteoblasts to migrate to 
the freshly resorbed region (126, 127). 
 
1.4.3 Bone Formation 
 
 The final stage of the remodelling cycle is the deposition of new bone to replace 
that which was resorbed. This is the bone formation phase. The first stage of this is the 
recruitment of osteoblast precursor cells to the site of resorption. The migration of these 
cells is mediated by chemotactic agents released from the bone matrix by resorption (128). 
The most likely factors involved are the pro-osteoblast factors TGFβ and IGF-1, which are 
abundantly found in the bone matrix.  
 Once the osteoblast progenitor cells have reached the freshly resorbed site they 
proliferate and differentiate into mature osteoblasts. This is again mediated by factors 
released from the bone matrix during resorption, further coupling the bone formation to 
bone resorption. Factors thought to play roles in osteoblast precursor proliferation include 
IGF-1 and 2, FGFs, TGFβ and its superfamily, and platelet-derived growth factors (PDGFs) 
(115). The differentiation to mature osteoblasts is also stimulated by many of these same 
factors, in particular IGF-1 and BMP2 (a member of the TGFβ superfamily) are important. 
 The formation of new bone by osteoblasts is initiated by the production of the 
organic components of the bone matrix. This mostly consists of type I collagen interspersed 




proteoglycans (28). To complete the process, this unmineralised osteoid is transformed into 
mineralised bone. ALP, produced by osteoblasts, breaks down pyrophosphate inhibitors of 
mineralisation, which both induces mineralisation and provides inorganic phosphate for the 
process (1). The extracellular phosphate and calcium ion levels are maintained by 
osteoblast ion transporters, allowing hydroxyapatite crystals to form continuously within 
the osteoid. This gives it rigidity and strength as it is converted into fully mineralised bone. 
 Once the appropriate amount of bone has been formed, the osteoblasts stop 
producing any new bone. The precise mechanisms by which bone formation is terminated 
are currently unknown, but it has been hypothesised that it may be due to factors such as 
SOST released by osteocytes. SOST inhibits osteoblast activity and may lead to osteoblasts 
becoming lining cells (129). Osteoblast apoptosis, triggered by various bone derived factors, 
may also be one of the key mechanisms by which bone formation is terminated. Overall the 
bone formation phase lasts around three months and ends with 65% of osteoblasts 
undergoing apoptosis while the rest are converted into lining cells or buried in the newly 
formed matrix as osteocytes (130). The bone then enters the resting phase again, with the 
quiescent lining cells awaiting the initiation of the next remodelling cycle. 
 
1.4.4 Resting phase 
 
 During this phase, lining cells cover the surface of bone and osteocytes are buried 
within newly filled resorption lacunaes. Bone remains in this state for an indefinite time 





1.5 Cancer and Bone 
 
 Cancer cells are groups of cells that have mutated in such a way that they undergo 
abnormal explosive proliferation and fail to undertake properly controlled apoptosis. 
Cancer occurs in the bone microenvironment in two different ways. It can originate from 
bone cells leading to primary bone cancer diseases such as multiple myeloma, 
osteosarcoma, or Ewing’s sarcoma. More commonly though, malignant cancer cells arrive 
in the bone microenvironment as metastatic cells that have migrated from a primary 
tumour to form a secondary malignancy within bone. In either case they cause damage to 
the surrounding bone by either, in the case of some primary tumour, producing abnormal 
bone tissue, or more commonly through the disruption of the bone remodelling cycle in the 
surrounding bone. This leads to an imbalance with either excess bone formation, or bone 
resorption resulting in the formation of osteoblastic, osteolytic or mixed lesions. These can 
be asymptomatic or cause symptoms ranging from pain and loss of strength or movement, 
to deformity and pathological fractures. 
 
1.5.1 Primary bone tumours 
 
 Primary cancers of bone are relatively rare tumours that appear in two types, 
benign or malignant. In general, with certain exceptions, most types are far more common 
among children and juveniles than adults; this is most probably related to the reduction in 
bone metabolism as bone modelling finishes at the end of growth (131). Symptoms include 
bone pain, abnormal bone growth and skeletal fractures. 
 
1.5.1.1 Benign primary bone tumours 
 
 Benign tumours include neoplasms, such as osteoid osteoma, osteochondroma, 
and osteoblastoma, as well as a variety of cysts, including enchondroma. Giant cell tumour 
of bone is also generally considered a benign tumour, but can rarely become malignant. 




considered serious and are left to regress on their own or if it is thought necessary may be 
removed through surgery. 
   
1.5.1.1.2 Osteoid osteoma 
 
 Osteoid osteomas are benign bone forming tumours of less than 2cm in size that 
are found in long bone cortex of young adults (132).  They are more common in men than 
women by a ratio of 3:1 and account for almost 13% of benign bone tumours (133). They 
consist of a network of ‘woven’ trabeculae of variable degrees of mineralisation, 
surrounded by osteoblasts with scattered osteoclast-like multinucleated giant cells (134). 
Many osteoid osteomas spontaneously regress and they are never life threatening, but they 
can cause extreme pain. Standard treatments are pain relief by NSAID treatment, or 
removal through either traditional surgery or advanced minimally invasive techniques such 




 Osteoblastomas are similar to osteoid osteomas both clinically and histologically 
but have the potential for progressive growth (132, 136). Like osteoid osteomas they 
generally occur in young adults and occur more often in men but are characterised as being 
larger than 2cm in size and cause a dull pain that is not treatable with NSAIDS (136). These 
tumours consist of woven bone rimmed by osteoblasts and containing abundant 
osteoclasts. They affect the surrounding cortical bone, leading to either excess bone growth 
or focal lytic lesions. Overall prognosis is good as with the exception of rare variants 
metastasis is virtually unknown, and even in these variants metastatic potential is low. 







1.5.1.1.4 Fibrous dysplasia 
 
 Fibrous dysplasias (FD) represent between 5 and 7% of benign bone tumours and 
are caused by a local failure of the ability to produce lamellar bone (132, 138, 139). This 
results in the formation of immature woven bone that cannot be properly remodelled and 
becomes enmeshed in dysplastic fibrous tissue. Most cases are identified before the age of 
30 and there is no gender preference. It is divided into monostotic (60% of cases) or the 
more serious polyostotic (40% of cases) which is often a symptom of a more serious 
underlying condition such as endocrine dysfunction or McCune-Albright syndrome (140). 
While monostotic FD is often asymptomatic, it generally causes localised thinning of the 
surrounding cortex and abnormal bone mineralisation which may result in pain, deformity, 
fractures and loss of strength (132).  Generally FD is not life threatening but in 2.5% of cases 
may progress to become malignant osteosarcoma or fibrosarcoma (138). Bisphosphonates 
are successfully used to manage the condition in many cases, but surgery followed by bone 




 Osteochondroma is one of the most common bone tumours, representing over a 
third of all benign tumours (132). It occurs exclusively in bones formed by endochondral 
ossification and is generally found within the first two decades of life, most commonly in 
men (132). Tumours are contiguous with the underlying bone and consist of a cartilage 
capped bony projection with a marrow cavity that usually points away from the nearest 
joint due to muscle pull (132). In most cases these tumours are isolated and asymptomatic 
but can be curatively removed by complete surgical excision if needed (132). In 15% of 
cases multiple osteochondroma may be present, which can be related to an autosomal 
dominant condition called Hereditary Multiple Osteochondromas (HMO) (132). This 








 Enchondromas are intramedullary masses of hyaline cartilage that comprise 15% of 
benign bone tumours. These tumours do not appear to have an age or sex preference, but 
do appear to arise in distinct locations; 41% occur in the small bones of hands or feet (132). 
Most cases are isolated and only very rarely undergo malignant transformation into a 
chondrosarcoma. However, certain rare disorders cause multiple enchondromas to arise 
and hugely increase the risk a malignancy developing; these are Ollier’s disease and 




 Chondroblastoma is a neoplasm of cartilage lineage generally found in the 
epiphysis and representing about 5% benign bone tumours. It is twice as common in men 
and usually occurs in teenage years (132). They consist of polygonal cells with defined 
cytoplasmic borders interspersed with randomly distributed giant osteoclast-type cells, and 
cause lytic lesions that can lead to joint swelling and a reduced range of movement.  
Surgery is used to remove the neoplasm, but tumours recur in 14-18% of cases and can 
rarely lead to benign pulmonary metastases (132). 
 
1.5.1.1.8 Chondromyxoid fibroma 
 
 One of the least common bone tumours, chondromyxoid fibroma only accounts for 
2% of benign bone tumours. It is composed of lobules of loose myxoid stroma separated by 
fibrous septa that contain giant multinucleated osteoclast-like cells and causes sharply 
defined lytic lesions. Treatment is surgical removal and bone grafting, though recurrence 





1.5.1.1.9 Giant Cell Tumour of bone 
 
 Giant Cell Tumour of bone (GCT) is a common benign bone tumour comprising 
about 22% of benign bone tumours. The tumour is composed of mononuclear cells 
surrounding uniformly distributed giant osteoclast-like cells, which cause osteolytic lesions 
and can lead to reactive bone formation. It is locally highly aggressive and can destroy 
cortical bone allowing it to extend into local soft tissues causing severe bone pain, swelling 
and loss of joint movement. Malignant transformation is rare, but benign lung metastasis 
may occur in 2% of cases. Treatment has typically been surgical removal followed by bone 
graft, but in recent years adjuvant treatment with anti-resorptive drugs such as 
bisphosphonates or the anti-RANKL drug denosumab are becoming more common. Clinical 
trials are currently underway to determine the efficacy of surgery versus adjuvant 
management. 
 
1.5.1.1.10 Benign notochordal cell tumour 
 
 Benign notochordal cell tumours (BNCT) were only characterised in 1999 and so 
prevalence is unknown. They consist of a small tumour of notochordal origin with sheets of 
intraossious cells resembling mature adipocytes that do not cause bone destruction, hence 
many BNCT are asymptomatic. No treatment is normally necessary and often only clinical 





1.5.1.2 Malignant primary bone tumours 
 
 Like benign bone tumours, malignant bone tumours are rare cancers accounting for 
less than 0.2% of cancers in the developed world (145). They are however far more serious 
illnesses, and can cause severe bone pain, lytic lesions, pathologic fractures, restricted 
movement and skeletal deformities. Malignant bone tumours commonly metastasise to 
other skeletal sties, as well as to other organs, most commonly the lungs. All forms are life 
threatening illnesses with 5 year survival rates ranging from 10% to 90% depending on type 
of tumour and severity at diagnosis (145).  The most common malignant primary bone 
tumours are osteosarcoma, chondrosarcoma, fibrosarcoma and Ewing’s sarcoma. Common 
treatments are adjuvant chemotherapy followed by surgical removal of the tumour, and 
regular clinical follow up to check for relapse. No current  therapies are effective at treating 
metastatic malignant bone tumours and much current work is focused on finding 




 Osteosarcoma is the most common malignant primary bone tumour and has an 
estimated incidence of about 4/million/year cases worldwide (146). It occurs most often in 
young adults, although it can occur at any age (147). Other bone disorders such as Paget’s 
disease of the bone or fibrous dysplasia may increase the risk or an osteosarcoma 
developing, as does exposure to radiation (145, 148, 149). Osteosarcomas are characterised 
by the production of malignant osteoid from osteoblastic cells that causes woven bone to 
be laid down in abnormal locations. Various cartilage or fibrous tissue may also be present 
as chondroblastic and fibroblastic cells are also found in osteosarcoma in varying amounts. 
They most often initially form inside the cavity of long bones where they may cause 
osteolytic, osteoblastic or mixed lesions leading to bone pain and deformity. However, at 
diagnosis 20% of patients have at least one lung metastasis and a further 40% will develop 
one or more through the course of the disease (146). 80% of metastases associated with 
osteosarcoma are found in the lungs and it is these metastases that cause most deaths 




surviving at least 5 years. Once a metastasis occurs though this survival rate drops to just 
20% (146). Treatments are neoadjuvant chemotherapy followed by surgical excision of the 
primary tumour and secondary tumours. This is generally followed up by further 
chemotherapy to lower the risk of relapse. Even so 30-40% of patients will relapse and have 
metastatic disease within 3 years (150, 151). 
 
1.5.1.2.2 Ewing’s Sarcoma 
 
 Ewing’s sarcoma is the second most common malignant primary bone tumour in 
young adults, with an estimated 1-3/million/year cases worldwide (145). It exclusively 
effects adolescents and is 50% more common in men (152). Interestingly, Ewing’s sarcoma 
is extremely rare in children of black African decent (153). It is known to be caused by a 
specific translocation between chromosomes 11 and 22 that causes a fusion of Friend 
leukemia integration 1 transcription factor (FLI1) and the EWSR1 gene resulting in the 
production of a chimeric fusion protein (154). Ewing’s tumours consist of small round lumps 
of uniform round cells of no recognisable bone cell type. They cause pain and deformity of 
the bone as local osteoblasts and osteoclasts react to the tumour by forming new lamellar 
bone in abnormal locations (145). This may lead to pathologic fracture. At diagnosis up to 
30% of patients have at least one metastasis, most commonly in the lung, though at a far 
lower rate than seen in osteosarcoma (145, 155, 156). Survival rates are similar to 
osteosarcoma. If the tumour is restricted to one bone site then 75% of patients will survive 
5 years or more, however for patients that present with metastases or distant relapse, 
current treatments are ineffective and less than 10% will survive for 5 years (155, 157). 
Treatments are neoadjuvant chemotherapy followed by surgical removal of the tumour and 










 Chondrosarcomas are unusual amongst bone tumours as they are more common in 
adults than children. They are the third most common malignant bone tumour, but the 
second most common in adults mainly afflicting those between 30 and 60 with a 2:1 sexual 
prevalence towards men (145, 158, 159). They occur in cartilage and arise from 
chondrocytes, generally causing slow growing masses of neoplastic hylaine cartilage tissue 
that can spread to local tissues, or to the lungs (158). They cause severe bone pain and can 
lead to loss of movement and deformity. 90% are conventional chondrosarcoma and are 
not associated with a pre-existing tumour; however 10% are secondary chondrosarcoma 
and arise due to the transformation of a benign bone tumour such as an osteochondroma 
(145, 159).  Regardless of origin over 90% of chondrosarcoma have low metastatic potential 
and are usually successfully treated (159). The remaining 10% are more lethal as they are 
faster growing and commonly metastasize to the lungs and other sites. Treatment is 
difficult as these tumours are highly resistant to both chemotherapy and radiotherapy. So, 
while the slow growing nature of most chondrosarcoma means that surgical removal is 
curative in many cases (90% 5-year survival rate), in cases where metastasis or recurrence 
occurs prognosis is very poor and survival rates are thought to be as low as 10% of patients 
living beyond 2 years (158, 160). 
 
1.5.1.2.4 Fibrosarcoma of bone 
 
 Fibrosarcomas are a relatively uncommon primary malignant bone tumour with 
only 0.5/million/year cases occuring worldwide (161). These tumours are more commonly 
found in adults and have a slight sexual bias towards men (162). As a malignancy of soft 
tissues fibrosarcoma are not specific to bone and can commonly arise in other tissues. They 
derive from mesenchymal fibroblasts, the cells that produce the extracellular matrix, and so 
produce excess collagen fibres. However, this is not the main cause of problems within 
bone, it is the presence of rapidly proliferating spindle shaped fibroblast-like cells (161, 
162). Fibrosarcoma normally occur within the intramedullary cavity of long bones where 




fractures. Most (75%) fibrosarcoma of bone are highly metastatic tumours and are not 
easily treatable. Common treatment is surgical removal combined with chemotherapy. In 
this case 5 year survival rates are about 20%, with patients who presented with a low grade 
fibrosarcoma having an increased survival rate of 50%. 18% of patients suffer a relapse 
after surgery (162). 
 
1.5.1.2.5 Multiple Myeloma 
 
  Multiple myeloma arises from plasma cells within the bone marrow and therefore 
it is not recognised as a true primary bone cancer. Despite this, it is often considered as one 
as the cancerous cells accumulate within the bone marrow. It is far more common than all 
other primary bone tumours occurring on average in 4/100,000 people/year and 
representing approximately 1% of all cancers in the developed world (163). It is more 
common in men than women at a ratio of 1.5:1 and occurs almost twice as often in patients 
of black African origin (163, 164). Osteoytic lesions are very commonly associated with 
multiple myeloma, occurring in 80% of patients due to increased bone resorption and 
decreased bone formation (165). This loss of bone can cause bone pain, may lead to 
osteoporosis, and can cause pathological fractures of the long bones and compression 
fractures in the spine [reviewed in (166, 167)]. Myeloma and stromal cells secrete local 
factors such as TNF-, interleukins and RANKL which increase osteoclast formation and 
activity (168, 168-172). Myeloma cells also inhibit the production of OPG by stromal cells 
thereby further enhancing bone resorption (171). Multiple myeloma is considered incurable 
in most cases and median survival rates range between 29 months and 68 months 
depending on the severity of the cancer at diagnosis (173). Until recently the most common 
treatment was chemotherapy using drugs such as thalidomide that can suppress or delay 
the disease, however the vast majority of patients relapse following this treatment, and the 
drugs have severe side effects (163). Recent advances in stem cell treatments and novel 
therapeutics have lead to increases in survival times, and the hope of future increases in 






1.6 Bone metastasis 
 
 Bone metastasis is the migration of tumour cells from a distant primary site to form 
a secondary tumour within the bone microenvironment. Secondary bone tumours are far 
more common than primary bone cancers, in fact representing >99% of malignant bone 
tumours (174). Metastatic cancers originating in the breast, prostate, kidney, thyroid and 
lung all have a remarkably high rate of metastasis to bone, and it is thought to cause more 
than 350,000 deaths every year in the USA (175-177). In fact, bone metastases are the most 
common metastasis site associated with the three most common human cancers, breast, 
prostate and lung (178).  The cancers that most often metastasise to bone are breast and 
prostate cancers with an incidence of at least 80% in metastatic breast cancer patients and 
68% in prostate cancer patients (176, 177, 179). These are followed by lung and kidney 
carcinomas, as well as melanomas, which metastasise to bone in 36%, 35%, and 35% of 
cases respectively (180). Lesser, but still significant, frequencies are found in other cancers. 
Bone metastases are associated with increased morbidity, severe bone pain, 
skeletal fractures, hypercalcemia, nerve compression and in most cases eventually death 
(181). They are virtually incurable in most cases and as such the majority of current 
therapies are palliative. These treatments are often designed to prevent pain by reducing 
tumour burden, inhibiting tumour associated bone pathologies and preventing the 
progression and further metastasis of the cancer (180, 182, 183). Median survival times are 
variable and depend on the primary tumour type as well as site and number of bone 
metastases. On average breast and prostate cancer patients live longer after diagnosis of a 
bone metastasis, while lung cancer and other primary tumour patients have far shorter 
survival times. For example, analysis of patients with spinal bone metastases demonstrated 
median survival times of 14.1 months for breast cancer patients, 9.2 months for prostate 
cancer patients and only 3.8 months for other cancers and 2.9 months for lung cancer 
patients (184). 
 The precise reasons why bone is such a common site of metastasis are not known 
but it has been hypothesised that it is due to the conditions found within the bone 
microenvironment. In 1889 the ‘seed and soil’ hypothesis of metastasis was proposed by 




chance but that when spreading tumour cells grow preferentially in hospitable and 
habitable environments. He argued that cancer cells are like ‘seeds’ that are cast onto the 
‘soil’ of the body, while the ‘seeds’ may land across all of the ‘soil’, they only grow where 
the ‘soil’ is fertile and that different ‘seeds’ need different types of ‘soil’. In other words, 
metastatic tumour cells spread through all locations in the body, but only form secondary 
tumours where the environment is ‘fertile’ and allows them to proliferate.  
The anatomical/mechanical hypothesis on the other hand argues that it is the location of 
organs that explains the patterns of metastasis (186). This maintains that the first organ 
that metastatic cells come into contact with is the most likely site of metastasis and 
explains why the lungs, kidneys and liver are common sites for certain tumours due to their 
locations in the circulatory system. A combination of both hypotheses is likely to be true in 
reality. However, in the case of bone metastases where the locations of tumours frequently 
correspond with the most metabolically active areas of bone, the ‘seed and soil’ theory 
seems to be the more likely explanation for most cases.  
 
1.6.1 Mechanisms of Metastasis 
 
 Before secondary bone tumours can arise, cancer cells must leave the site of the 
primary tumour and migrate to the bone through the process of metastasis. This process is 
the same as for other types of metastasis and involves cancer cells undergoing a series of 
specific steps that facilitate their migration away from the original tumour location.  These 
steps are as follows: invasion of local surrounding tissue, intravasation, translocation 
through the bloodstream or lymphatic system to distant bones, extravasation into that 
tissue, adaptation to the bone microenvironment and finally colonisation of the bone (187-
189) (Figure 1.14). 
 The invasion of local tissue, that is the first step in the process of metastasis, is 
facilitated by changes within the cancer cells that allow them to migrate and invade. These 
traits allow the malignant cells to degrade and move through the extracellular matrix of the 
tissue surrounding the primary tumour and local blood or lymphatic vessels. In most 




main role in these cell transformations (189). Over 80% of malignant tumours are of 
epithelial origin, and these cancers include those that metastasise to bone most frequently 
(189).   
Epithelial tissues generally consist of polarised tightly cohesive thin sheets of 
epithelial cells separated from stroma by a basement membrane. This tight cohesion allows 
the barrier function of the epithelium and is due to the actions of intercellular adhesions 
facilitated by interactions between various factors including cadherin, and catenin proteins 
(190, 191). In order to become invasive, most cancer cells must lose their epithelial 
phenotype and become more mesenchymal in nature. This requires mutations that down 
regulate or remove cadherin expression, particularly of E-cadherin, as well as other 
structural proteins, causing the cells to lose polarity and the tight bonds to adjacent cells 
(189). This leads to further changes that give the cancer cells an invasive phenotype. These 
changes include the up regulation of MMPs (192-194), which allows for stromal matrix 
degradation, the up regulation of VEGF (189, 195), which stimulates neoangiogenesis 
attracting new blood vessels to the primary tumour site, and the suppression of responses 
to apoptotic signals, which allows cells to survive in the blood stream (189, 195).  
Interestingly, transcriptional repression of various cell-cell adhesion complexes (and so 
EMT) can be driven by various cytokines and pathways known to be involved in both bone 
metastases and normal skeletal bone remodelling, including TGFβ, IGF-1 and the Wnt 
signalling pathway (189). Together, these factors cause cells to undergo EMT and ultimately 
develop an invasive phenotype.  
 Once cells have developed an invasive phenotype they are able to successfully 
invade through local tissues and enter local blood or lymph vessels, a process called 
intravasation. The blood stream is a hostile environment for most cell types and it is 
thought that, even with the advantages of a mesenchymal phenotype, less than 1 in 1000 
cancer cells that enter the blood stream survive to form a micrometastasis (196). Most 
malignant cells that do reach the bone do so by arresting their circulation in the sinusoid 
vessels of the bone marrow, attach to the endothelium of the capillary and undergo 
extravasation into the bone marrow (189). 
 Once in the bone marrow, malignant cells do not necessarily then go on to form a 




extavasated, while others may become dormant and not proliferate in their new 
environment (189). Interestingly, tumours that do successfully grow and colonise the bone 
marrow tend to have mixed phenotypes consisting of both mesenchymal and epithelial 
cells that are similar to those found in their original primary tumour site. This is often 
explained by the theory that factors found in the bone microenvironment allow cells to 

















































































































1.6.2 Types of Bone Metastasis 
 
 Malignant cancer cells in bone are traditionally divided into two types depending 
on how they disrupt bone remodelling. These are osteolytic (lytic) metastases that cause 
excess bone resorption and osteoblastic (sclerotic) metastases that cause excess bone 
formation. In reality, both processes are normally present to some extent in any skeletal 
site afflicted with a metastasis, but for simplicity metastases are clinically divided into 
‘lytic’, ‘sclerotic’ or ‘mixed’ subtypes, depending on their pathologic appearance (175, 197, 
198). Breast cancers commonly lead to lytic metastases, while prostate cancers typically 
cause sclerotic metastases (198-200). However, it should be noted that 25% of breast 
cancer patients with bone metastases will have sclerotic lesions in addition to their 
osteolytic metastases, and that many prostate cancer patients have lytic lesions (198, 201). 
 No matter what the type of metastasis, tumour cells disrupt the remodelling cycle 
and cause the release of factors that allow the tumour cells to proliferate, and so cause 
more disruption of the remodelling cycle. This is known as the ‘vicious’ cycle of bone 
metastasis. Four major components make up the contributors to the ‘vicious cycle’; tumour 
cells, osteoclasts, osteoblasts and the bone matrix. Each affects one or more of the other 
contributors in various ways summed up in Figures 1.15 and 1.16. 
 
1.6.2.1 Osteolytic bone metastasis 
 
 Osteolytic bone metastases are formed by malignant tumour cells colonising the 
bone microenvironment and secreting factors that directly or indirectly enhance 
osteoclastic bone resorption. These factors include cytokines and growth factors such as 
IGF-1, TGFβ, M-CSF, VEGF, PTHrP, MMPs and Interleukins (ILs). Some of these factors 
directly stimulate the maturation of osteoclast precursors to become mature osteoclasts, 
while others increase the activity and survival of the mature osteoclasts. Some factors 
instead act on osteoblasts, causing either an increase in the production of osteoclastagenic 
factors or a reduction in the expression of factors that inhibit osteoclast formation. PTHrP is 
the most studied factor and is known to induce osteolysis by increasing osteoblast 




(202, 203). IL-8, IL-11 and M-CSF all directly promote osteoclast differentiation and 
function, where as IL-6, Cyclooxygenase-2 (COX2) and TGF-β indirectly increase production 
of factors such as PTHrP or PGE that stimulate RANKL production by osteoblasts (204).  
 This cancer-induced imbalance in bone remodelling leads to an increase in 
osteolysis and a loss of bone. As a result bone derived growth factors trapped within the 
bone matrix are released into the local bone microenvironment. Some of these growth 
factors, including IGFs, TGFβ, and BMPs, then cause an increase in tumour cell proliferation, 
survival and migration (205). In addition to the factors released, other changes in the bone 
microenvironment caused by increased bone resorption facilitate the proliferation and 
survival of the tumour cells. An acidic environment provides a survival advantage to certain 
tumour cells, while the high levels of extracellular calcium stimulate tumour cell growth 
through the MAPKinase signalling pathway (205). A reduction in trabecular number and 
mass also gives tumour cells the space to expand and grow (205). Either stimulated by 
growth factors or due to the environmental changes, the result is an increase in the number 
of tumour cells present. This in turn results in an increase in the production of osteolytic 
factors from the bone metastasis, and so an increase in the amount of local bone 
resorption. In many tumours the release of osteolytic factors is even further increased 
through induction by the same growth factors and environmental conditions that cause an 
increase in tumour cell number. For example, high calcium levels are known to increase 
PTHrP production, as does TGFβ (204).   
 In essence, the osteolytic vicious cycle comprises tumour cells entering the bone 
microenvironment and causing an imbalance in bone remodelling that favours bone loss. 
The loss of bone then releases factors and causes the environment to change so that the 
proliferation of tumour cells is increased. With more tumour cells present, the imbalance in 
bone remodelling is worsened leading to progressively more bone loss and greater 


























































































1.6.2.2 Osteoblastic bone metastasis 
 
 Osteoblastic bone lesions are mainly characterised by increased bone formation 
and have their own cycle causing bone remodelling imbalances and tumour proliferation. 
While purely osteoblastic metastases are possible, one of the reasons mixed metastases are 
most common is due to the coupling of bone formation and bone resorption. The key 
osteoclastic factor RANKL, and other osteclastogenic factors such as M-CSF, are produced 
by osteoblasts and so any significant increase in the number of mature osteoblasts is 
therefore likely to eventually lead to increased levels of bone resorption in addition to 
enhanced bone formation. 
 In the same way that the osteoclastic vicious cycle works, the osteoblastic cycle 
begins when tumour cells colonise the bone microenvironment and begin to release factors 
and cytokines that induce or increase bone formation. This includes IGF-1, uPA, BMPs, Wnt 
signalling factors and ET-1 (reviewed in (204)), some of which will be explored in more 
detail later. Some of these factors directly stimulate the proliferation, differentiation and 
function of osteoblasts, while others do so indirectly through actions that reduce the 
inhibition of stimulatory factors or activate other latent factors. ET-1 and IGF-1 are the most 
widely studied factors in osteoblastic metastases, and are both known to directly stimulate 
the proliferation and function of osteoblasts and in the case of ET-1 reduce apoptosis (206). 
The precise mechanisms that allow the vaso-constrictor ET-1 to stimulate bone formation 
are unknown but are likely to be related to its causing nuclear translocation of NFATc1. IGF-
1 is known to stimulate both the MAPKinase and PI3K/Akt signalling pathways in 
osteoblasts, as well as causing an increase in the expression of Runx2 in osteoblast 
precursors, so stimulating osteoblast proliferation, differentiation, function and survival. 
IGF-2, BMPs, and TGFβ are also known to directly stimulate osteoblasts, while the 
proteases uPA and PSA cause the activation of TGFβ and the release of IGF-1 from IGF 
binding proteins (IGFBPs), and so indirectly stimulate osteoblasts (204, 205).  
 The overall effect of this cancer-induced induction of osteoblast function is 
enhanced bone formation. How this causes an increase in tumour proliferation is less well 
understood, but is thought to be related to the large number of growth factors present in 




in the surrounding area will further release these factors from mature bone. In some cases 
factors released and/or changes in the environment such as lower pH, or higher calcium 
levels may cause whole tumours or parts of tumours to change from being an osteoblastic 
tumour to becoming an osteolytic tumour (204, 205). However, the precise mechanisms 








































































































































































1.6.3 Factors involved in the vicious cycle of bone metastasis 
 
 Many of the factors involved in the local molecular control of bone remodelling are 
the same factors that are important for bone metastasis, only the most key factors will be 
discussed in this section. 
 
1.6.3.1 OPG/RANK/RANKL 
 The most important factors that are involved in the regulation of bone remodelling 
are OPG, receptor activator of NF-B (RANK), and its ligand RANKL. These are all members 
of the tumour necrosis factor (TNF) superfamily of proteins and are recognised as the key 
factors responsible for regulation of osteoclast formation, function and survival in health 
and disease (1) (Figure 1.17). 
 RANKL is a type II homotrimeric transmembrane protein that can be found in either 
a membrane bound or a secreted form (207). It is expressed in tissues throughout the body, 
but is particularly highly synthesized in bone, bone marrow and lymphoid tissues (208, 
209). In bone, RANKL is produced mainly by osteoblasts, osteoblast precursors, osteocytes 
and T lymphocytes. Until recently it was thought that the main source was osteoblasts but 
it has lately been discovered that osteocytes are capable of producing RANKL at levels 10-
fold higher than osteoblasts (46). When it binds to the RANK receptor, RANKL stimulates a 
number of signalling cascades vital for osteoclast differentiation, survival and activity. Of 
particular importance is the NF-B signalling pathway. In cells of the 
macrophage/monocyte lineage (osteoclast precursors), RANKL stimulates the 
differentiation of these cells into pre-osteoclasts and then mature osteoclasts. It has been 
demonstrated that RANKL is both necessary and sufficient for osteoclast formation, and 
experiments using knockout mice demonstrated that in its absence no osteoclasts form in 
vivo leading to an extreme osteopetrosis phenotype, with problems in both tooth eruption 
and B and T cell development (67). Human cases of RANKL deficiency or mutation are rare, 
but do occur. Patients present with osteopetrosis and while no human trials have been 




with exogenous RANKL (210). RANKL also stimulates B-cell maturation (211) and it is 
required during the development of both lymph nodes (212) and mammary glands (213). 
 The effects of RANKL-mediated signalling are initiated when RANKL binds to its 
receptor RANK; a type I homotrimer transmembrane protein with a large cytoplasmic C-
terminal domain and an N-terminal extracellular domain (209). RANK is also widely 
expressed but is found at particularly high levels in macrophage/monocyte lineage cells, 
especially pre-osteoclasts and osteoclasts, as well as dendritic, T and B cells (119, 209, 214). 
RANK knockout mice have a similar phenotype to RANKL knockout mice, with severe 
osteopetrosis, and problems with immune cell and lymph node maturation (212, 215). 
 OPG is another receptor for RANKL, however instead of being membrane bound 
and linked to a signalling cascade it is instead a soluble secreted decoy receptor. RANKL is 
prevented from binding to RANK by OPG and so cannot stimulate osteoclast formation. 
OPG is therefore probably the most important negative regulator of bone resorption. It was 
the first of the RANK/RANKL/OPG axis to be identified as important in the control of 
osteoclast formation. OPG was simultaneously discovered by two groups in 1998 (Amgen 
Inc. and more bizarrely Snow Brand Milk Products Co. one of the largest dairy companies in 
Japan) (216, 217). It is unusual for a TNF super family member as it is normally found as a 
secreted protein rather than as a transmembrane protein. Like RANK and RANKL, it is 
widely expressed but is mainly produced in the bone microenvironment. OPG is also known 
to play a role in protecting blood vessels from calcification (218, 219). OPG knockout mice 
have an extreme osteoporosis phenotype due to increased numbers of osteoclasts (220), 
and humans with dysfunctional or hypo-OPG diseases may have a variety of skeletal 
problems including osteoporosis (221), Paget’s disease (222) or idiopathic 
hyperphosphatasia (223). 
 The rate of RANKL binding to RANK is the major determining factor controlling 
osteoclastogenesis, and is controlled by changes in the ratio of available RANKL to OPG 
decoy receptor (224). RANKL to RANK binding stimulates a number of signalling pathways 
including recruitment of TNF receptor-associated factors (TRAFs), the activation of inhibitor 
of κB kinase complex (IKKα,β and γ), and the NFκB transcription factor family (Figure 1.17). 
Inactivation of any of TRAF6, IKK or the NF-B p50 and p52 proteins in mice causes severe 




 Disruption of the RANK/RANKL/OPG axis has been linked to a number of bone 
diseases including bone metastasis. A number of studies have showed that invading tumour 
cells stimulate osteoclastogenesis either directly through the release of RANKL, or more 
commonly, indirectly through the release of a variety of factors that change the rates of 
RANKL or OPG production in bone cells (228-231). In addition RANK expression in tumours 
has been linked to increased rates of metastasis to bone, particularly in breast cancers, and 





Figure 1.17 A diagram demonstrating the effects of the 
RANK/RANKL/OPG axis on osteoclast formation. See text for details. 





1.6.3.2 M-CSF  
 The second essential factor for osteoclast formation is Macrophage Colony 
Stimulating Factor (M-CSF), a disulphide-linked dimeric glycoprotein found in both soluble 
and membrane bound forms (235, 236). It is known to be produced by osteoblasts in both 
forms and acts on pre-osteoclasts causing proliferation, migration and increases in levels of 
RANK expression, leading to osteoclast differentiation (237). It is also thought to support 
osteoclast survival through increasing expression of anti-apoptotic factors such as Bcl-2 
(238). 
 In bone, M-CSF acts through the receptor encoded by the proto-oncogene c-Fms. It 
stimulates a large number of signalling pathways including the essential PI3K/Akt and 
MAPKinase pathways (239). Mice that lack either M-CSF or c-Fms have osteopetrotic 
phenotypes with very few mature macrophage or osteoclasts present, though they do have 
some TRAcP positive cells which would normally indicate osteoclast formation (120, 240-
242). M-CSF and c-Fms are both thought to play a role in the pathophysiology of bone 
metastasis. Specifically, M-CSF has been found to be secreted by various tumour cell types 
(243, 244), and c-Fms is not only a proto-oncogene but has also been linked to increased 
rates of metastasis in various cancers, particularly breast carcinomas (233, 243). 
 
1.6.3.3 PTHrP 
 One of the first factors associated with bone metastases was PTHrP. PTHrP plays a 
key role in osteolytic metastases and has been found to be produced in large quantities by 
a variety of different bone metastasising tumour cell types (245, 246). A correlation 
between PTHrP expression and the frequency of bone metastases in breast cancers has also 
been observed, suggesting a role of this protein in the homing of tumour cells to bone 
(247).  Demonstrating how prevalent, and specific PTHrP is to osteolytic bone metastases, 
studies have shown that 92% of breast cancer bone metastases express PTHrP compared to 
only 50% of primary breast tumours and 17% of metastases in other locations (248). 
Neutralising antibodies to PTHrP have also been reported to inhibit the development and 




Tumour derived PTHrP acts in a paracrine fashion and leads to an increase in bone 
resorption. This occurs as it binds to the type 1 PTH/PTHrP receptor (PTHR1) expressed on 
osteoblasts and stromal cells and causes an upregulation in the production of RANKL by 
these cells. This then leads to localised increases in osteoclast formation and activity. 
 In health, PTHrP is found to be abundantly expressed in tissues that are the target 
of circulating PTH, namely kidney and bone. It is also expressed in particularly high 
concentrations in growth plate chondrocytes and is thought to play a role in promoting 
their proliferation and preventing their differentiation into hypertrophic chondrocytes (1, 
250). As opposed to the catabolic effect seen in bone metastasis, in health PTHrP 
conversely has an overall osteoanabolic effect as it directly stimulates bone formation (1, 
251). This action is through a shared mechanism with PTH, which it shares homology with 
at it’s the N-terminal domain.  Both PTH and PTHrP are thought to regulate bone formation 
through the stimulation of osteoblast differentiation and formation, and it is these that are 
the dominant effects of the two molecules in healthy bone. PTHrP knockout mice have 
severely impaired osteoblast formation, and as a result reduced bone formation resulting in 
an osteoporosis phenotype. It should be noted that PTHrP deficient mice also have reduced 
numbers of osteoclasts due to reduced levels of RANKL production (252).  
 Unlike PTHrP, PTH is a circulating hormone produced by the parathyroid glands and 
is known to be the primary regulator of calcium homeostasis in the body through actions in 
both bone and the kidneys. As a circulating hormone, PTH is not commonly found 
expressed by tumour cells, and is not generally linked to bone metastasis.  Excessive and 
prolonged exposure to PTH can cause bone loss in a similar fashion to PTHrP (1), but 
intermittent treatment with PTH is a common treatment used to increase bone mass, as 





Table 1.1 A table summarising the skeletal effects of locally acting cytokines and growth factors produced by tumour cells during bone 
metastasis. See text for references. ; Increase,  decrease,  unchanged. 
Local cytokines and growth factors Bone formation Bone resorption Tumour growth 
   RANKL    
   OPG    
   M-CSF    
   TNF    
   IL-1    
   IL-6    
   IL-8    
   IL-11    
   IL-17    
   BMP-4    
   BMP-6    
   BMP-7    
   ET-1    
   IFN-    
   TGF-    
   IGF1     
   PDGF    
   FGFs    
   PGE2   or   or  
   NO  or   or   or  
   PTHrP    
   MMPs    






 Transforming growth factor β (TGFβ) is the eponymous factor of the TGFβ 
superfamily known to be involved in the regulation of cell development, differentiation, cell 
cycle control and various other vital cellular functions (255-257). TGFβ was also one of the 
first factors to be associated with the pathophysiology of bone metastases, specifically 
osteolytic metastases. It has been linked to increases in tumour aggressiveness, tumour 
metastasis in general and cell homing to bone in particular (258-262). Expression of TGFβ 
has been specifically correlated to poor patient outcome (263, 264). Studies of both 
pharmacological inhibition and genetic inactivation demonstrate that inhibiting TGFβ 
signalling reduces both the number of bone metastasis that arise and size and damage 
caused by those that do present (260, 265-267). 
 Typically TGFβ derives from two locations in bone metastasis; it can be produced by 
the tumour cells themselves or is released from within the bone matrix during bone 
resorption (258). Whatever the origin, TGFβ stimulates the proliferation and growth of 
tumour cells, particularly in late stage tumour progression (258, 268). Perhaps more 
importantly it also stimulates the tumour cell production of PTHrP, and other osteoclastic 
factors such as IL-11 (269). Therefore, in bone metastasis the direct effect of TGFβ on bone 
cells is not necessarily important, it is the enhancing effect of TGFβ on tumour cells and 
their release of osteolytic factors that makes it important. 
 In health, TGFβ has a very different role in bone as it is thought to be involved in 
the coupling of bone formation and resorption (270). It acts on various bone cells through 
binding to its type II receptors and recruiting its Type I receptor to form a ternary holo-
complex that initiates a signalling cascade through the SMAD proteins (257, 258). In 
osteoclasts and their precursors, TGFβ directly inhibits cell proliferation, differentiation and 
resorption (271). However, TGFβ also indirectly stimulates bone resorption by increasing 
the production of PTHrP by osteoblasts. In this way TGFβ is involved in recruiting osteoclast 
precursors to the site of resorption (270). On the other hand, it directly stimulates bone 





1.6.3.5 IGF-1  
 Insulin-like growth factor-1 (IGF-1) is the most abundant growth factor in the bone 
microenvironment (273). IGF-1, along with its receptor (IGF-1R) and binding proteins 
(IGF1BPs), has long been known to play an important role in bone homeostasis. More 
recently there has been increasing interest in the part the IGF-1 system might play in the 
development of cancers. Breast cancer, prostate cancer and a variety of other tumours 
have all been linked to elevated cellular expression of IGF-1 and its receptor (274, 275). 
Moreover, increased circulating levels of IGF-1 and IGF-1 binding protein 3 have been linked 
to increased risks of breast and prostate cancer development (276-279). Less work has 
been performed studying the direct role of IGF proteins in bone metastasis, but it has been 
shown that various tumour cells that commonly migrate to bone express and secrete IGF-1 
(280), that IGF-1 and IGF-1R regulate the preferential metastasis of some tumours to bone 
(281-283) and can direct the migration of cells to bone (273, 284). 
 In health, IGF-1 is thought to regulate bone remodelling through both endocrine 
and paracrine mechanisms. IGF-1 is expressed by most tissues and is mainly found as 
circulating IGF-1 produced by the liver, allowing it to regulate growth and other functions in 
many different tissues. IGF-1 acts through a complex regulatory network consisting of IGF-
1, its receptor and IGF-1 binding proteins. When IGF-1 binds to IGF-1R it induces various 
signalling cascades including the PI3K/Akt, the MAPKinase and the non-canonical Wnt 
signalling pathway (285, 286). This stimulates cell survival, differentiation and changes the 
expression of various proteins associated with cell survival and inhibition of apoptosis. IGF-
1 is also produced by a variety of different bone cells including osteoblasts, osteoclasts and 
their precursors. It acts on both osteoblasts and osteoclasts, but is thought to be 
particularly important in the regulation of bone formation as it stimulates osteoblast 
differentiation, migration and function (287-289). IGF-1 knockout mice have severely 
reduced bone formation and reduced bone mass, along with various other growth 
abnormalities (290). However, osteoclasts are also stimulated by IGF-1 treatment, which 
induces both osteoclast formation and bone resorption (291-293). In fact genetic 
inactivation of IGF-1 has been demonstrated to protect mice from ovariectomy induced 




act as a chemo-attractant for osteoblasts, it is often considered a coupling factor in bone 
remodeling. 
  In a similar way to TGFβ, IGF-1 is involved in the regulation of several aspects of the 
‘vicious cycle’ of bone metastasis. It is both produced by tumour cells, stimulating both 
bone formation and bone resorption, and is released locally from the bone matrix, the 
largest store of IGF-1 in the body (295). Once released from the bone matrix, IGF-1 acts 
both as a potent stimulator of cancer cell proliferation and survival, and as a chemo-
attractant recruiting further cancer cells into the local area of the lesion. This is true in both 
osteolytic and osteoblastic metastasis, but is thought to be particularly important for 
osteoblastic metastases (296).  
 
1.6.3.6 Interleukins 
  The interleukins (ILs) are a group of 17 related protein types belonging to the pro-
inflammatory chemokines family (288). Their name is derived from the fact that they were 
first seen to be expressed by leukocytes and were at first thought to mainly act on or be 
produced by leukocytes. In fact they have since been found to be expressed by many cells 
within the body, and regulate a number of different processes in various different organs. 
Of particular interest in bone metastases are IL-6, IL-8, and IL-11 all of which have been 
found to be expressed by tumour cells found in bone. 
 The IL-6 family comprises of 10 proteins known to be produced by various cells 
including bone cells such as osteoblasts, macrophage, and monocytes. IL-6 binds to a 
heterotrimeric membrane-associated receptor, consisting of an α subunit (gp80) and two β 
subunits (gp130), which is a member of the class I cytokine receptor family. This activates 
signalling pathways including JAK/STAT, PI3K/Akt and MAPKinase (297). Gp130 is thought 
to be ubiquitously expressed, while gp80 is only found in cells that respond to IL-6.  In bone, 
gp80 is expressed by both osteoclasts and osteoblasts and IL-6 is known to have a dual 
effect, stimulating bone resorption through causing the differentiation of mature 




 In cancer, IL-6 is thought to act via autocrine/paracrine signalling to increase 
tumour cell proliferation, invasion and angiogenesis (301). In bone metastasis, IL-6 mainly 
increases bone resorption through both direct effect on osteoclasts, and indirectly through 
causing increases in the expression of RANKL in osteoblasts and macrophages, as well as 
causing increases in tumour cell production of pro-osteolytic factors such as PTHrP, PGE2, IL 
-8 and IL-11 (299, 300). IL-6 also affects the proliferation of tumour cells and bone 
formation, although its overall effect is probably determined by the balance of interactions 
with other bone metastasis factors (300). 
  IL-8 and IL-11 are both known to stimulate bone resorption in bone metastases, 
causing increased levels of osteolysis (302, 303). IL-8 binds to the CXCR1 receptor on 
osteoclasts and macrophage thereby causing RANKL independent stimulation of osteoclast 
activity (304), while IL-11 is known to mediate osteoclastogenesis acting via the IL-11 
receptor (305). In addition, IL-8 or IL-11 expression in tumour cells has been associated with 
high rates of bone metastasis and both cytokines are also linked to higher levels of 
osteolytic damage (300, 306). During the vicious cycle, IL-8 and IL-11 are produced by 
tumour cells and osteoblasts in response to exposure to prostaglandins (300).  
 
1.6.3.7 TNFα 
 Tumour Necrosis Factor-α (TNFα) is a member of the TNF family that comprises of 
type II homo- or hetero-trimeric transmembrane proteins, many of which are cleaved to 
generate soluble ligands, including RANKL (307). TNFα is a key, but not essential, regulator 
of osteoclastogenesis through its interactions with its receptors; TNF receptor 1 and 2 
(TNFR1 and TNFR2) (307, 308). Binding of TNFα to TNFR1 enhances osteoclast 
differentiation by stimulating signalling through pathways including the NFκB, MAPKinase 
and PI3K/Akt signalling pathways (307, 308). When TNFα binds TNFR2 on the other hand it 
causes inhibition of osteoclastogenesis through unknown mechanism(s) (308, 309). One 
possibility is that TNFR2 induces a ‘ligand passing’ mechanism that causes a local increase in 
TNFα. This then induces apoptosis by TNFR1-mediated mechanism(s) (309).  
 Excessive bone resorption in various diseases is thought to be related, at least in 




relation to post-menopausal osteoporosis, as oestrogen negatively regulates TNFα 
production (310, 311). In cancer, TNFα is thought to play a key role in the development of 
several tumour types including breast cancer, as it is a potent stimulator of tumour cell 
proliferation and a strong inducer of angiogenesis (312, 313). High serum concentrations 
have been linked to progression of cancers, and an increase in aggressive tumour biology.  
In bone metastasis, expression of TNFα has been linked to poor prognosis, increased 
metastasis to bone and increased osteolysis in bone. This appears to be either due to direct 
production of it by tumour cells, or stimulation of its production in bone cells by tumour 
released factors including interleukins (312, 313). In addition to its direct effects on 
osteoclasts it is also thought to stimulate the production of IL-6 (314). Recently it has been 
demonstrated that inhibiting TNFα causes a reduction in the number and severity of bone 
metastases from breast cancers (312). 
 
1.6.3.8 BMPs 
 Bone morphogenetic proteins (BMPs) are a group of 20 highly related cytokines of 
the TGFβ super family. They were initially identified by their shared role in inducing 
endochondral bone formation (300, 315, 316). They bind to type IA, type IB or BMP type II 
receptors inducing signalling cascades through the SMAD and MAPKinase pathways (317). 
In bone, BMPs play an important role in the development of osteoblasts, stimulating cell 
proliferation and bone formation by an autocrine/paracrine mechanism (300, 317). 
 BMPs have been linked to osteoblastic tumours associated with prostate cancer, 
and are thought to be responsible for much of the bone formation caused by prostate 
cancer cells. For example, BMP-4, BMP-6, and BMP-7 have been shown to be produced by 
prostate tumour cells within the bone micro-environment (300, 318, 319). In fact, when 
prostate tumour cells that normally caused osteoblastic metastases were made to over 
express the BMP inhibitor noggin, they lost their osteoinductive properties. In breast 
cancer, current reports are contradictory, with some studies suggesting that BMPs promote 
bone metastasis, while others suggest they inhibit it (reviewed in (320)). BMPs are also 
released from the bone matrix by resorption, and like many other factors, are thought to 




further effect of BMPs is their angiogenic effect which may also contribute to the growth of 
tumours in bone metastasis (321).  
 
1.6.3.9 ET-1 
 Endothelin-1 (ET-1) is a potent vasoconstrictor which stimulates DNA synthesis and 
cell proliferation of various healthy cell types, such as fibroblasts, as well as malignant 
epithelial cells including prostate cancers (300, 322). ET-1 is also thought to indirectly 
promote tumour growth by causing the release of VEGF in response to hypoxia, thereby 
allowing the vascularisation of tumours (300, 322). ET-1 signals through the ETA receptor 
(ETAR) and causes a signalling cascade that can interact with other signalling pathways 
including the PI3K/Akt and MAPKinase pathways (322).  
 ET-1 has two roles in bone metastasis. First, it is linked to increased rates of 
metastasis in tumour cells. This is thought to be due to the fact that it can both induce the 
expression of extra-cellular matrix degrading proteins including several MMPs, and 
stimulates the phosphorylation of Focal Adhesion Kinase (FAK), an action that is linked to 
general tumour cell migration (322, 323). Secondly, ET-1 appears to be a vital factor in the 
development of osteoblastic bone metastases (300, 322, 324). It stimulates bone formation 
by both increasing osteoblast actions and inhibiting the function and migration of 
osteoclasts (322, 324). In osteoblasts, ET-1 increases both proliferation and function.  The 
exact mechanisms behind this are unclear, but it is thought to be related to increasing the 
levels of OPN and OCN expression and through enhancing the effects of other pro-
osteoblast factors (324). Various factors have been shown to induce the production of ET-1 
in tumour cells, including TGFβ, TNFα and IL-1 which are all commonly found in the bone 
microenvironment (322). The key role of ET-1 in osteoblastic bone metastases from 
prostate cancers has been demonstrated by studies showing that inhibiting the actions of 
ET-1 caused reductions in the number of metastases, inhibited tumour growth by inhibiting 
cell proliferation and angiogenesis, and reduced the excess bone formation observed 






 Vascular Endothelial Growth Factor (VEGF) is a critical regulator of blood vessel 
formation, and is involved in the development of vascularisation during bone development 
(325). VEGF is produced by bone cells including chondrocytes and osteoblasts (326), and 
has been shown to directly stimulate bone formation by increasing osteoblast proliferation 
and differentiation (300, 327), as well as stimulating bone resorption by increasing 
osteoclast survival (328). 
 In cancers, increased VEGF has been associated with increased metastasis and rapid 
growth of tumours, as it allows the vascularisation of tumour sites (329). This is probably 
also the major effect of VEGF in bone metastases; however it can also exert direct effects 
on bone as stated above. Either way VEGF is affective at supporting the development and 
progression of both osteolytic and osteoblastic bone metastases(300). 
 
1.6.3.11 Prostaglandins 
 Prostaglandins, and Prostaglandin E2 (PGE2) in particular, are known to have a 
complex role in bone in health and disease. They are enzymatically derived metabolites of 
polyunsaturated fatty acids, in the case of PGE2 the fatty acid is arachidonic acid, and are 
involved in a diverse range of actions in many different tissues (330, 331). PGE2 increases 
both bone formation and bone resorption in vivo, though its overall effect is normally to 
increase the total quantity of bone and it has been particularly linked to fracture healing 
(332-335). PGE2 acts through four G-protein coupled receptors termed E-prostanoid (EP) 1-
4. Of these, EP2 and EP4 are the most widely expressed in bone.  EP2 knockout mice have 
impaired osteoclast formation, due to a reduction in the ability of osteoblasts to stimulate 
osteoclastogenesis by producing RANKL (336). EP4 knockout mice have no bone phenotype 
during growth, but develop accelerated age-related bone loss due to a reduction in 
osteoblast activities. Cell cultures from the EP4 knockout mice demonstrated that bone 
nodule formation was impaired, as was PGE2 stimulated osteoclast formation. In addition 





 In bone metastasis, PGE2 is not normally highly expressed by tumour cells. 
However, Cyclooxygenase-2 (COX-2), which is responsible for PGE2 synthesis, is expressed 
by breast cancer cells, and increased COX-2 expression is induced by other factors produced 
by tumour cells such as TGFβ (300). High COX-2 expression has also been found to be linked 
to the development of several tumours and increased metastasis of cancers including 
metastasis to bone (337-340). Inhibitors of the PGE2 receptors EP2 and EP4 have been 
shown to reduce osteolysis and tumour growth in the bone microenvironment (339, 341). 
 
1.6.3.12 MMPs 
The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that are 
capable of degrading components of the extracellular matrix and various secreted or 
membrane bound proteins including growth factors, cytokines, cell surface receptors, and 
adhesion molecules (342). Surprisingly, MMPs have only a limited involvement in osteoclast 
function and they have been shown to play a minor role in the degradation of the 
extracellular matrix during bone resorption, the cathepsin proteins are far more vital for 
this. MMP-9 and MMP-13 produced by other bone cells have been shown to be involved in 
the differentiation of osteoclasts, and other MMPs have been hypothesised to prime the 
bone surface for resorption (reviewed in (343)). MMP-13 has also been shown to bind to 
receptors on osteoblasts, chondrocytes and fibroblasts. The effect of this is unknown, but it 
has been suggested that these cells internalise and degrade MMP-13 thereby regulating the 
extracellular levels of metalloproteinases (343).  
 MMPs are particularly important in the development of cancers as they have been 
implicated in not only tumour migration and invasion, but also tumour development, 
angiogenesis and apoptosis (344). In bone metastasis, MMP-1, MMP-2, MMP-9, and MMP-
13 have all been linked to metastatic disease caused by either breast or prostate cancers 
(344-349). This is either due to direct MMP production by tumour cells, or activation of 
their production in other cells by factors produced by tumour cells. In addition to their 
direct actions on both bone and tumour cells, they have the added effect of releasing bone 





1.6.3.13 PDGF   
Platelet derived growth factors (PDGF) are a family of growth factors composed of 
polypeptide dimers linked by disulphide bonds (350). PDGFs are synthesised by various cells 
including platelets, fibroblasts and bone cells such as macrophage and osteoblasts (351). 
Acting mainly on PGDFRα and PDGFRβ receptors (352), PDGF causes mitogenic effects in 
numerous cell types including fibroblasts, glial cells, muscle cells and osteoblasts, and is 
responsible for some organogenesis during development, and angiogenesis and wound 
healing after tissue damage (352).  
 In bone, PDGF is particularly important for bone repair after a fracture. Produced in 
high quantities by platelets at the site of a wound or fracture, PDGF stimulates the 
proliferation, differentiation, migration and function of osteoblasts in the area local to the 
wound (352, 353). It has also been found to be produced by osteoclasts, and so may act as 
a coupling factor between bone resorption and bone formation (353). 
 Inhibition of PDGF has been suggested as a treatment for bone metastases 
associated with both breast and prostate cancer, due to its stimulatory effects on 
angiogenesis (354, 355). Targeting PDGF in bone metastasis from breast cancers did not 
directly effect osteolysis, but reduced growth of tumour cells within bone (355). In 
osteoblastic prostate cancers, inhibition of PDGF activity caused not just a reduction in 
tumour growth, but also reduced the cancer induced bone formation observed and in some 
cases prevented the initial development of bone metastases (354, 356). 
 
1.6.3.14 FGFs  
 Fibroblast Growth Factors (FGFs) are a family of 23 structurally related polypeptide 
growth factors that act through the tyrosine kinase FGF receptors (FGFR) 1-4. FGFs are 
known to play various vital roles in embryonic development and tissue repair (300, 357). 
Various FGFs, but FGF-18 in particular, are involved in endochondral ossification, while 
others affect both osteoblast and osteoclast differentiation in the adult bone (358). FGF-2 is 
thought to be one of the major regulators of adult osteoblast differentiation due to its 
action via the JAK/STAT signalling pathway (358). 
 FGFs play an important role in the development of bone metastases associated 




prostate tumours, while FGF-8 has been found to be over expressed in 76% of prostate 
cancer bone metastases (300, 357). In bone, FGF-8 stimulates the differentiation of both 
osteoclasts and osteoblasts and increases the growth of prostate tumour cells. Inhibition of 





1.6.4 Treatment of bone metastasis 
 There are few cases of bone metastases that can be successfully resolved, and as 
such most treatments are palliative, attempting to lessen pain and slow the progress of the 
disease, rather than cure it. Treatments include drugs that directly relieve pain, drugs that 
interfere with the mechanisms of the metastasis that lead to pain, and radiotherapies and 
surgeries to either remove the tumour and/or relieve pain. In most cases a combination of 
therapies will be used to treat a patient. 
 
1.6.4.1 Analgesics 
 Both osteolytic and osteoblastic metastases can be incredibly painful, and so most 
patients are given some form of pain relieving treatment. The form and extent of this 
treatment varies according to the severity of the pain, and type of metastasis. Pain is 
caused directly by the loss of mechanical function due to either bone loss or inappropriate 
bone formation, or indirectly by the release of chemical pain mediators and the 
compression or irritation of nerve fibres.  There are two basic types of pain relieving drug 
used in the treatment of bone metastases, opioid analgesics, and non-opioid analgesics. 
Non-opioid drugs are used for milder pain, and where the patient wishes to avoid addictive 
opioids. These include Tramadol, and NSAIDS including COX-2 inhibitors. Opioids are more 
frequently used in cases of moderate to severe bone pain and include a wide range of drugs 







 Surgery is performed to either remove the area of bone affected by the metastasis 
as a therapeutic treatment, or to relieve pain in the area. In either case it is generally 
undertaken as a way of preventing a pathologic fracture, and allowing stabilisation of the 
afflicted bone region. Surgeries range from vertebroplasty or kyphloplasty stabilisation of 
vertebrae to complete removal of large section of the bone, or even amputation (359). 
Bone grafts or prosthesis are used to replace the lost bone. In most cases surgery is not 
considered a curative intervention, as the nature of the metastatic diseases means that 
recurrence, and multiple metastases in other bones and further organs are likely to occur. 
Instead the life expectancy and impact that surgery will have on the quality of life of a 
patient are considered before determining the type and extent of surgery to perform (360). 
 Developments in new implantable materials and biosynthetic implants have lead to 
the hope that in the future surgery may be able to offer more to bone metastasis patients. 
In particular it has been suggested that it may soon be possible to use biological techniques 
to create natural tissues that could allow fully reconstructed natural bones to be created, 
perhaps even with implants that allow the controlled localised release of anti-cancer 
agents. This would allow the repair and treatment from a surgery that is currently an 
irreparable removal of tissue, with little hope of overall curative affect (360). 
 
1.6.4.3 Radiotherapy 
 Radiotherapy is the use of localised high doses of radiation to cause DNA damage in 
cells leading to apoptosis. Cancer cells are thought to be more susceptible to this than 
healthy cells due to their mutated and dysfunctional DNA damage-repair mechanisms. It 
has become the standard treatment for localised uncomplicated bone metastases that are 
considered painful. Response rates are good with between 50% and 90% of patients 
achieving some pain relief and 10-50% becoming free of pain (361-365). Many patients are 
even able to reduce or in some cases completely stop their use of analgesics. However 
there are many drawbacks to radiotherapy. Recurrence of bone pain is common as the 
metastasis regrows, or recolonizes the site, this leads to further radiotherapy treatment at 




effects are generally radiation related acute toxic effects such as skin reactions, or 
gastrointestinal problems including nausea and vomiting. Increased risk of pathologic 
fractures may possibly also occur after radiotherapy treatment (359, 360).  
 
1.6.4.4 Bisphosphonates  
 The most common bone targeted therapies used for the treatment of bone 
metastases are bisphosphonates. These are a group of analogues of pyrophosphate that 
have had the oxygen atom replaced with a carbon atom and can have various side chains 
attached giving the bisphosphonate compound different potency and side effect profiles   
[reviewed in (366, 367)]. There are three subdivisions of the bisphosphonates defined by 
their side changes. The first generation bisphosphonates, Clodronate and etidronate, had 
simple alkyl side chains, while the second generation, pamidronate and alendronate, 
contained nitrogen and so were known as aminobisphosphonates. The latest generation of 
bisphosphonates is the third generation which contain a cyclic side chain in addition to 
nitrogen and include ibandronate, risedronate and zoledronate (368, 369). 
 Bisphosphonates basic mechanism of action is through their ability to inhibit bone 
resorption. This occurs as they bind strongly to bone, hydroxyapatite in particular, 
throughout the body and are subsequently internalised by resorbing osteoclasts (370). This 
disrupts various osteoclast processes in different ways depending on the type of 
bisphosphonate, generally resulting in cell apoptosis (369, 371)]. The effects of 
bisphosphonates on osteoblasts are more controversial, with some research suggesting 
that they stimulate osteoblast differentiation and function (372, 373), but other work 
showing that they inhibit bone formation and may even cause osteoblast apoptosis (374-
376).  
Both osteolytic and osteoblastic bone metastasis patients can achieve pain relief 
through treatment with bisphosphonates, though effects are far better in osteolytic 
metastases. The reduction in bone remodelling both reduces the risks of any pathologic 
fractures and also may diminish, or at least prevent the deterioration, of the release of 
chemical pain mediators, the irritation of nerves and the loss of mechanical function. As 




are a major limiting factor in bisphosphonates, and may include gastrointestinal upset, 
oesophagitis, renal abnormalities, and in rare cases osteonecrosis of the jaw (366, 368, 
377). Most of these are related to long term use, and as such do not occur often in bone 
metastasis cases, however some trials of high dose zoledronate suffered from increased 
rates of renal abnormalities. 
It has recently been suggested that some bisphosphonates may also have specific 
anti-tumour effects, both by reducing angiogenesis and by directly inhibiting tumour 
growth. In particular, nitrogen-containing bisphosphonates have been demonstrated to 
reduce angiogenesis in vitro, and in vivo, and to prevent tumour associated angiogenesis in 
various different cancer models. The mechanism behind this is thought to be related to the 
reduction in the recruitment of myeloid cells, specifically macrophages, to the tumour site. 
Since these cells produce large amounts of the pro-angiogenic factors VEGF and MMP-9 
tumour vascularisation is inhibited. While more poorly understood, there is growing 
evidence to support bisphosphonate inhibition of tumour metastasis to soft tissues and 
direct in vivo inductions of tumour cell apoptosis in some cases. Mechanisms behind this 
are unclear and while these studies have raised the possibility that bisphosphonates may 
exert an anti-tumour effect, in patients with breast cancer (378-380) the AZURE study 
showed no overall benefit of Zoledronic acid on patient mortality rates. 
 
1.6.4.5 Denusomab 
 Recently, denusomab, a monoclonal human anti-RANKL antibody has been 
developed (381). Denusomab selectively binds to the key osteoclast factor RANKL and 
effectively prevents the differentiation, formation and function of osteoclasts. It has been 
shown to be an effective treatment for the relief of pain associated with both osteolytic 
and osteoblastic bone metastases, and 3 recent stage 3 clinical trials have shown that it is 
more effective than bisphosphonates at reducing both the initial onset of a pathologic 
fracture, and the incidence of multiple fractures (382-384). It had similar side effect profiles 
to the third generation bisphosphonate zoledronate in each case. As denusomab acts on 




giant tumour cells (385). Studies to determine any effects on other tumour types are 
ongoing are currently ongoing (386). 
 
1.6.4.6 Novel treatments 
 A variety of novel treatments for bone metastasis exist, ranging from diverse 
chemotherapies and radiopharmaceuticals targeting the cancer cells, to the recent 
development of a hyperthermia treatment for bone metastases using magnetic materials 
(359, 360, 387). One promising new treatment is the development of SRC inhibitors, initially 
trialled as anti-tumour and anti-metastasis agents, recent investigations using SRC knockout 
mice have shown that inhibiting SRC also reduces osteoclast formation (388). In every case 
the treatment generally is aimed at reducing bone pain, while also lessening tumour 
burden. More research is needed to increase our understanding of the mechanisms behind 
bone metastasis, allowing us to develop treatments that can more effectively treat both the 






1.6.5 Why Study Bone Metastasis? 
While our understanding of the mechanisms behind bone metastasis has evolved 
substantially over the past decades, much still remains unclear. The effect of current 
treatments on patient outcomes has been minimal and it is clear that new therapeutic 
targets are needed to move the aim of treatment away from being purely palliative and 
towards being curative. In bone metastasis a complex web of interacting cell types, growth 
factors and cytokines that lead to multiple possible outcomes is emerging, and better 
research tools are required to investigate this. Research is needed to understand exactly 
how all these elements interact, to identify new therapeutic targets, and to develop novel 
treatments that can address the major clinical problems caused by both osteolytic and 





1.7 Aim of this study 
 The general aim of this thesis was to design, develop and test a model system to 
study the interaction between cancer and bone cells in vitro, ex vivo and in vivo. 
The specific aims of the work reported in this thesis were: 
 To develop a model system for the study of breast and prostate cancer cell – 
induced: 
o bone cell signalling, proliferation, survival and activity in vitro. 
o focal osteolysis in organ cultures of bone. 
o bone cell proliferation and activity in vivo and osteolysis in animal models 
of metastatic bone disease 
 To test this system by using it to examine the effects of a novel potential 
therapeutic agent on the cancer-induced osteoclastic and osteoblast changes 
associated with breast cancer. For this purpose the IGF-1 receptor kinase inhibitor 
PQIP was chosen. This was due to the known effects of IGF-1 on bone cells and in 
the development of breast cancer and bone metastasis, as well as the novelty of 
looking at IGF-1 receptor inhibition in this context in comparison to signalling 
induced by other factors found to be produced by cancer cells in this model, and 















2 Materials and Methods 
 
2.1 Tissue Culture 
 
2.1.1 Tissue culture conditions 
 All tissue culture work was carried out in a sterile laminar flow hood. Cultures were 
kept in incubators with standard conditions of 37˚C in a humidified atmosphere of 5% CO2, 
95% air. A sterilised water bath was used to warm all solutions to 37˚C prior to use and 
plastic-ware was either bought pre-sterilised or autoclaved prior to use. Cultures were 
checked regularly to assess confluence or contamination using a phase-contrast 
microscope. 
 
2.1.2 Standard tissue culture medium 
 All cells were cultured in standard αMEM. Standard αMEM consists of α-Modified 
Eagle’s Medium (αMEM) supplemented with 10% foetal calf serum (FCS), 2 mM L-
Glutamine, 100 IU/ml Penicillin and 100IU/ml Streptomycin.  
 
2.1.3 Cell lines 
 Human breast cancer cell lines MDA-MB-231 and MCF7, human prostate cancer cell 
line PC3, mouse breast cancer cell line 4T1, mouse MC3T3-E1 pre-osteoblasts and mouse 
osteosarcoma cell line MC57G cell lines were purchased from ATCC (Manassas, VA, USA). 
Cells were cultured in 75 cm2 flasks and passaged every 48-72 hours at a ratio of 1:5 
(MCF7), 1:10 (MDA-MB-231, MC3T3, PC3, MC57G) or 1:20 (4T1). Briefly, culture medium 
was removed, cells washed in PBS and detatched by treatment with trypsin. Standard 
αMEM was added to inactivate the trypsin and cells were then transferred to a fresh sterile 
15 ml tube which was then centrifuged at 1200 rpm for 3 minutes. The supernatant was 
discarded and cells resuspended in 1 ml standard αMEM before a percentage of the 





2.1.4 Viability assay 
 The Alamar Blue assay was used to measure cell viability (389). This assay assesses 
cell viability using an oxidation/reduction (redox) reaction. The amount of the redox 
indicator that present in the AlamarBlue solution changes from oxidised (non-fluorescent, 
blue) to a reduced form (fluorescent, violet) is directly proportional to the number of viable 
and active cells. Briefly, 10% (v/v) of AlamarBlueTM reagent was added to each culture well 
and cultures were then incubated at 37˚C for 2-4 hours under standard tissue culture 
conditions. A plate reader (Bio-Tek Synergy HT) was then used to read the fluorescence of 
the wells (excitation wavelength 540 nm – emission wavelength 590 nm). Control wells of 
standard αMEM plus 10% v/v AlamarBlue solution were used to correct the data for 
background fluorescence.    
 
2.1.5 Bone marrow isolation and cultures 
 C57B6 mice aged 8-12 weeks were sacrificed by surgical dislocation and their long 
bones (tibia and femur) removed and transported to a sterile laminar flow hood. Long 
bones were then placed into a glass petri-dish, the soft tissue removed using a scapel and 
the ends of each bone cut off to reveal the bone marrow. To extract bone marrow (BM) 
cells from the isolated bones a 5 ml syringe filled with standard αMEM and with a 25 gauge 
(G) needle attached was inserted into the bone marrow cavity and used to flush out the 
bone marrow into a fresh 60 mm petri-dish. To homogenise the cell suspension the bone 
marrow cells in standard αMEM were passed through a series of needles of increasing 
gauge (19G to 25G). This cell suspension was then placed into a 15 ml tube and centrifuged 
at 1200 rpm for 3 minutes. The pellet was resuspended in 10 ml standard αMEM plus 100 
ng/ml M-CSF and plated into a fresh 100 mm petri-dish. Bone marrow cultures were left in 
standard conditions for 72 hours by which point adhered cells were considered to be M-CSF 







2.1.6 Osteoclast and macrophage cultures 
 Adherent M-CSF generated osteoclast precursors were scraped from the surface of 
their petri-dish, counted using a haemocytometer, and plated into 96 well plates at an 
initial seeding density of 12 x 103 cells per well in 150 l standard αMEM containing M-CSF 
(25 ng/ml) and, for osteoclast cultures, RANKL (100 ng/ml).  50% of the medium was 
refreshed after 24 hours with the addition of any desired test compounds. Medium and 
treatments were again refreshed after a further 48 hours and the cultured terminated 24-
48 hours after that. Viability of macrophage was assessed using the Alamar Blue assay, 
while osteoclast number was assessed by manual counting following TRAcP staining. 
 
 
2.1.7 TRAcP Staining 
 Osteoclast cultures were fixed in 4% (v/v) para-formaldehyde in PBS. Osteoclasts 
were then identified by TRAcP staining as described in van’t Hof et al (390). Briefly, 100 μl 
of TRAcP staining solution (See Appendix 2) was added to each well and plates incubated at 
37˚C for 45-60 minutes. The TRAcP staining solution was then removed and cells rinsed 
twice with PBS. 200 l of 70% (v/v) ethanol was added to each well and plates wrapped in 
cling-film and stored at 4˚C. To assess osteoclast cell number, TRAcP positive cells with 3 or 
more nuclei were considered to be osteoclasts and manually counted on a Zeiss Axiovert 






2.1.8 Resorption assay  
Osteoclasts cultures were generated on Corning® Osteo Assay Surface multiple well plates 
(Corning, USA). Following culture period, adherent osteoclasts were incubated in 50% 
bleach (Clorox-Ultra, USA) for 10 minutes and plates were rinsed 4 times with PBS. 200 l of 
70% (v/v) ethanol was added to each well and plates wrapped in cling-film and stored at 
4˚C. Resorption pits were visualised by phase contrast microscopy on an Olympus ScanR 
microscope using a 10x objective lens and area resorbed was quantified by Image Analysis 
using ImageJ software.  
 
2.1.9 Calvarial osteoblast cultures 
 Primary osteoblasts were isolated from the calvarial bones of 2-day-old mice 
sacrificed by decapitation. Calvariae were dissected out, washed in Hank’s Balanced Salt 
Solution (HBSS) and transferred to a sterile 15 ml tube containing 2 ml of collagenase type I 
in PBS (1 mg/ml). Calvariae were incubated at 37˚C in a shaking water-bath for 10 minutes, 
the supernatant discarded and a further 4 ml of collagenase in PBS (1 mg/ml) added to the 
15 ml tubes. After 30 minutes, additional incubation at 37˚C in a shaking water-bath the 
supernatant was removed and transferred to a sterile 15 ml tube containing 4 ml standard 
αMEM (fraction 1). The calvaria were then decalcified by incubation with 
ethylenediaminetetraacetic acid (EDTA) (4 mM) in PBS at 37˚C in a shaking water-bath for 
10 minutes. The supernatant was removed and transferred to a sterile 15 ml tube 
containing 4 ml standard αMEM (fraction 2). To obtain fraction 3 the remaining tissues 
were incubated in 4 ml of collagenase type I (1 mg/ml) in PBS for 30 minutes in a shaking 
water bath at 37˚C. The supernatant was again removed and added to 4 ml standard αMEM 
(fraction 3).  
 All three fractions were transferred into 15 ml tubes and centrifuged at 1200 rpm 
for 3 minutes. The supernatant was discarded and cell pellets resuspended in 1 ml standard 
αMEM. Two 75cm2 flasks containing 11 ml standard αMEM had 50% of each fraction added 
to them. These were then cultured under standard conditions, with the medium being 
changed after 24 hours, to remove any non-adherent cells, and every 48 hours after that 




 Once the 75 cm2 flasks of osteoblasts were confluent, medium was removed and 
the monolayer washed in PBS before being detached using trypsin treatment. Standard 
αMEM was added to the flask to deactivate the trypsin and the now detached cells were 
transferred to a fresh 15 ml tube. This was centrifuged at 1200 rpm for three minutes and 
the supernatant discarded. Cells were resuspended in 1 ml standard αMEM and manually 








2.1.10 Osteoblast viability 
 For studies of viability alone osteoblasts were plated in 96-well plates at a seeding 
density of 5 x 103 cells/well in 100 μl of standard αMEM. After 24 hours 50% of the medium 
was refreshed and desired treatments added. Cultures were left for 48 or 72 hours in 
standard culture conditions and cell viability at the end analysed using the Alamar Blue 
assay. 
 
2.1.11 Mineralisation cultures 
 To study mineralisation and osteoblast differentiation osteoblasts were plated in 12 
well plates at a seeding density of 100 x 103 cells/well in 1 ml standard αMEM and medium 
changed every 48 hours until the cultures were 100% confluent. The medium was then 
removed and replaced with standard αMEM supplemented with 50 μg/ml Vitamin C and 3 
mM beta-glycerophosphate (osteogenic medium) in the presence and absence of desired 
treatments. Cultures were then left for 3 weeks under standard conditions with medium 
2 days old C57/B6
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Extract calvaria Digest calvaria Osteoblasts
Figure 2.2 A diagram describing the method behind primary osteoblast cultures. 




and treatments refreshed every 48-72 hours. To terminate cultures cells were fixed in 70% 
(v/v) ethanol.  
 
2.1.12 Alazarin red assay 
 At the end of mineralisation cultures, Alizarin Red S staining was used to detect any 
mineralised bone nodules produced by the osteoblasts. Alizarin red interacts with the 
calcium deposits found in mineralised tissue and bone nodules. It binds to the calcium to 
form a complex that causes calcium ions to precipitate and form brick red deposits. 
 Alizarin Red was dissolved in dH2O at a concentration of 40 mM and the pH 
adjusted to 4.2 with 10% ammonium hydroxide. Fixed osteoblast cultures were washed 5 
times in dH2O before 500 μl of the alizarin red solution was added to each well and the 
plate incubated on a rocker for 20 minutes at room temperature. The staining solution was 
removed, cultures rinsed 3 times in dH2O, and the plates left to air dry overnight.  
A flatbed scanner was used to take images of the alizarin red stained cultures. In 
order to quantify the amount of bone nodules formed, cultures were de-stained by adding 
a solution of 10% (w/v) cetylpyridinium chloride in 10 mM sodium phosphate (pH 7.0) and 
placed on a rocker at room temperature for 30 minutes. Absorbance of the extracted stain 
was then measured at 562 nm using a Biotek Synergy HT plate reader and compared to an 
Alizarin Red standard curve. The values were normalised to cell number as determined by 
the AlamarBlue assay (391). 
 
2.1.13 Alkaline phosphatase assay 
 To measure osteoblast differentiation the Alkaline Phosphatase assay was used. 
This is based on the conversion of p-nitrophenyl phosphate to p-nitrophenol by the alkaline 
phosphatase enzyme highly expressed in osteoblasts. This conversion changes the solution 
from colourless to a yellow colour, allowing the amount of alkaline phosphase present to be 




 At the end of the culture period, osteoblasts were homogenised in 500 μl alkaline 
phosphatase lysis buffer (Appendix 2) for 20 minutes and cell lysates collected and stored at 
-20˚C. To calculate the  alkaline phosphate activity in each sample, cell lysates were mixed 
with an equal volume of paranitrophenyl-phosphate at a concentration of 20 mM in lysis 
buffer and absorbance measured 414 nm at 37°C in relation to a standard curve of p-
Nitrophenol known concentrations. Absorbance was then measured at 562 nm using a 
Biotek Synergy HT plate reader and compared to p-Nitrophenol standards. Alkaline 
Phosphatase activity was normalised to cell number as determined by the AlamarBlue assay 
(391).  
 
2.1.14 AlamarBlue assay 
AlamarBlue assay was used to measure cell number (391). At the end of culture period 
AlamarBlue reagent (10%, v/v) was added to each well. The cells were then incubated for a 
further 3 hours and fluorescence measured (excitation, 530 nm, emission 590 nm) using a 
Biotek Synergy HT plate reader.  
 
2.1.15 Bone cell – cancer cell co-cultures 
 Bone marrow cells were isolated and generated as described above. For bone 
marrow – cancer cell co-cultures, BM cells were plated into 96 well plates and cultured for 
24 hours to allow attachment of BM cells prior to the addition of cancer cells. For 
osteoblast-cancer cell co-cultures osteoblasts were allowed to reach confluence before the 
addition of cancer cells. Cancer cells were passaged, counted and then cells added to the 
bone cell cultures at initial seeding densities ranging from 10 to 5000 cells depending on 
cell types and culture conditions. All cultures were then allowed to proceed as described for 
BM cell culture experiments described above. Drug treatments were added 6 hours after 
the addition of cancer cells in order to avoid these compounds affecting cancer cell 






2.1.16 Conditioned medium assays 
 Conditioned medium from cancer cells was obtained by culturing cancer cells in 75 
cm2 flasks as described above.  They were allowed to grow to 80% confluence in standard 
αMEM. Then standard αMEM was removed and replaced with serum free αMEM (αMEM 
supplemented with 2 mM L-Glutamine, 100 IU/ml Penicillin and 100 IU/ml Streptomycin). 
Cells were then cultured for a further 24 hours and the now conditioned medium was then 
removed and filtered through a 0.2 μm filter. Control conditioned medium was created 
from serum free αMEM cultured in the same way as cancer conditioned medium, but in a 
sterile flask with no cancer cells added. 
 
 
2.1.17 Cancer cell adherence and spreading 
 The Xcelligence assay was used to measure cancer cell adherence and spreading. 
The Xcelligence system is a real-time, label free, cellular analysis system (Roche) which uses 
specialised culture plates with interdigitated gold-micro-electrode coated on the bottom. 
This allows the quantitative measurement of electrical impedance caused by the presence 




changes in cell number, viability, morphology, movement as well as various other aspects.  
The Xcelligence machine was placed into a incubator at 37˚C, 5% CO2 and linked to a laptop 
running the RTCA Xcelligence monitoring software (Roche). 
 Standard αMEM containing test compounds was added to Xcelligence plates and 
the plate read on the Xcelligence machine to establish a base reading for normalisation. 
Cells were then added to the Xcelligence plate, the plate placed onto the Xcelligence 
machine and monitoring of electrical impedance started. For cancer cell studies readings 
were taken as follows:   
 1 reading per minute for 1 hour 
 1 reading every 10 minutes for 7 hours 
 1 reading every 30 minutes for 40 hours 
For osteoclast studies, M-CSF generated macrophages were added to the Xcelligence plate 
and left in standard αMEM plus 25 ng/ml M-CSF for 24 hours prior to addition of 100 ng/ml 
RANKL and test compounds for a further 48 hours. Readings were taken after every 
medium refresh as follows: 
 1 reading per minute for 1 hour 
 1 reading every 10 minutes for 7 hours 
 1 reading every 30 minutes for 40 hours 
 
2.1.18 Wound healing assay 
 The wound healing assay was used to measure the migration rate of MC3T3 cells as 
previously described (392). MC3T3 cells were plated at 500 x 103 cells per well in 12 well 
plates and allowed to grow until confluent. Cultures were then scored with a fine pipette 
tip to produce a gap in the cell layer and treated with vehicle or test compounds for 24 
hours. The migration of cells into the wound was visualised and monitored using phase-
contrast light microscopy on an Olympus ScanR microscope. This system was automated to 




The rate of wound closure was calculated using the wound assay image analysis program 
Tscratch (393). These values were normalised to average starting size of the initial vehicle 
treated wounds. Graphs of wound size versus time were plotted for each experiment and 
the speed of wound closure calculated from the linear portion of the graph.  
 
2.2 Western blot 
 
 Western blot was used to study cell signalling in bone and cancer cells as previously 
described (394). 
 
2.2.1 Preparation of cell lysates 
 Cells were plated into 6 well plates at 250 x 103 cells/well in 2.5 ml of standard 
αMEM until they reached 80% confluence or in the case of osteoclast cultures, until a 
significant number of osteoclasts appeared. Medium was replaced with serum free medium 
and the cells incubated for 24 hours or in the case of osteoclasts for 2 hours. Test 
compounds were then added for appropriate lengths of time until the termination of the 
cultures. Cultures were terminated by removing medium, washing with PBS, and then lysing 
cells by gentle scraping in RIPA lysis buffer (Appendix 2), with 2% (v/v) protease inhibitor 
cocktail and 0.4% (v/v) phosphatase inhibitor cocktail. Plates were left on ice for 10 minutes 
before lysates were transferred to fresh Eppendorfs and centrifuged at 12000 g for 10 










2.2.2 Measuring protein concentration 
 The Pierce protein assay using bicinchoninic acid (BCA) was used to calculate 
protein concentrations. Bovine serum albumin (BSA) was used to create a standard curve of 
protein concentrations (0-2000 μg/μl). 10 μl of these and test protein samples were 
pipetted into a fresh 96-well plate in duplicate. 200 μl of copper (II) sulphate in BCA (1:50) 
was added to each well and plates were then incubated at 37oC for 15 minutes. Absorbance 
was measured at 562 nm using a Biotek Synergy HT plate reader and compared to BSA 
standards.  
 
2.2.3 Gel electrophoresis 
 Protein samples (30 - 50 μg) were mixed with appropriate volumes of 5x protein 
loading buffer and heated at 95˚C for 5 minutes in order to denature proteins. Samples 
were then loaded into wells of a CriterionTM XT BioRad (12% Bis-Tris) pre-cast 
polyacrylamide gel in an electrophoresis tank filled with electrophoresis running buffer 
(Appendix 2.4, page 272). A mix of Kaleidoscope pre-stained standard and a Magic Marker 
XP western standard were added to a separate well to allow identification of molecular 
weights. Gels were then run for 40 minutes at a constant voltage of 200V.  
 
2.2.4 Electrophoretic transfer 
 Proteins were transferred from the polyacrylamide gel to a polyvinylidene 
difluoride (PVDF) membrane (Hybond-P membrane, Amersham). Briefly, the gel was 
removed from the gel cassette and placed into transfer buffer (appendix 2) for 5 minutes. 
The PVDF membrane was cut to the size of the polyacrylamide gel and immersed in 100% 
methanol for 30 seconds before being placed into transfer buffer for 5 minutes. A blotting 
sandwich was prepared by arranging successive layers of three pads pre-soaked in transfer 
buffer, nitrocellulose or PVDF membrane, SDS polyacrylamide gel, three pre-soaked pads 
(Figure 2.4). The sandwich was orientated so that when an electrical current was applied 
the negatively charged proteins would move out of the polyacrylamide gel and transferred 







2.2.5 Immunostaining and antibody detection 
 Once transfer was complete the PVDF membrane was washed three times in Tris 
buffer saline (TBS) supplemented with 0.1% (v/v) Tween 20 (TBST) and then placed into 
blocking solution (Appendix 2) for 1 hour on a rocker at room temperature. This blocks any 
non-specific binding sites on the membrane and so reduces false positives and background 
staining. The membrane was then washed 3 times in TBST, each wash lasting 10 minutes on 
a rocker at room temperature. Then, the membrane was incubated with the appropriate 
primary antibody overnight (1:2000 in 3% BSA). The next day the membrane was removed 
and washed a further 3 times in TBST, 10 minutes each wash, before being incubated with 
the appropriate secondary anti-body solution (1:5000 in blocking solution (Appendix 2)) for 
1 hour at room temperature on a rocker. A final three 10 minute washes in TBST followed, 
before the immunoreactivity of the membrane was visualised using the Pierce SuperSignal® 
West Dura Extended Duration chemiluminescent detection system on a Syngene 





 To probe for other proteins on the same membrane, membranes were incubated in 
stripping buffer (Appendix 2) at 50˚C for 10 minutes, or until no bands were observed upon 
re-visualisation of the membrane. Membranes were then washed three times in TBST (5 
minutes per wash) and re-blocked for 1 hour in blocking solution (Appendix 2). Three 
washes in TBST (10 minutes per wash) followed before membranes were left overnight at 
4˚C on a rocker in 3% BSA in TBST containing the new relevant primary antibody. All steps 
then followed as before. 
 
2.3 Quantitative PCR 
 
2.3.1 RNA extraction 
 Cells were cultured in 6 well plates in standard αMEM under standard conditions 
until confluence, or in the case of osteoclasts a significant number of osteoclasts were 
formed. Following culture period, medium was removed and adherent cells were washed 
with 1 ml ice cold PBS and then lysed in 1 ml of Total RNA Isolation (Trizol®) reagent. 
Lysates were transferred to Pyrocarbonate (DEPC)–treated 1.5 ml Eppendorf tubes and 
stored at -80˚C. 
 To extract the RNA from Trizol, samples were defrosted and incubated at room 
temperature for 5-10 minutes. 200 μl of chloroform was then added to each lysate and 
they were mixed by shaking. Samples were incubated for a further 3 minutes at room 
temperature before being centrifuged at 12000 g for 15 minutes at 4oC. The aqueous phase 
of each sample was transferred into a fresh DEPC-treated 1.5 ml Eppendorf tube containing 
500 μl isopropanol. This was then mixed by inverting the Eppendorf tubes, incubated for 10 
minutes at room temperature and then centrifuged at 12000 g for 10 minutes at 4oC. 
Supernatant was discarded and 1 ml 75% (v/v) ethanol added to the RNA pellet. Samples 
were centrifuged at 7500 g for 5 minutes at 4oC and the supernatant removed. Samples 
were then air-dried for 5 minutes to remove the last ethanol and 20-30 μl of DEPC treated 
water added to each sample. The RNA pellet was allowed to dissolve in DEPC water on ice 
for 10 minutes before samples were heated at 65oC for 5 minutes to ensure all RNA had 





2.3.2 Measuring RNA concentration 
 RNA concentrations were measured using a Nanodrop 1000 spectrophotometer 
(Thermo Scientific). 1 μl of a sample was added to the nanodrop reader and the absorbance 
read at 230, 260 and 280 nm. Absorbance at 260 nm was used to calculate the 
concentration of RNA in ng/μl, while the ratios of absorbance at 260 nm and 280 nm, and 
230 nm and 260 nm were used to judge the purity of the RNA. If the 260:280 ratio was 
below ~2.0 or the 260:230 ratio was not between 1.8 and 2.2, then the RNA sample was 
considered to contain too many phenol contaminants to be of use and was not used any 
further. 
  
2.3.3 Reverse Transcription 
 The RNA samples were reverse transcribed to produce cDNA. An equal 
concentration of RNA (10 pg – 5 μg) was diluted in DEPC treated water to a total volume of 
13 μl and placed in a nuclease free microcentrifuge tube with the following reagents: 
 1 μl of oligo(dT)20 (50 μM) 
 1 μl of 10 mM dNTP mix (10 mM each)  
The microcentrifuge tubes were then heated to 65oC for 5 minutes and then incubated on 
ice for at least 1 minute. The samples were briefly centrifuged and the following reagents 
were then added: 
 4 μl of 5X first-strand buffer 
 1 μl of 0.1M DTT 
 1 μl of RNaseOut Recombinant RNase Inhibitor (40 U/μl) 
 1μl of SuperScript III Reverse Transcriptase (200 U/μl) 
 The microcentrifuge tubes were mixed by gentle flicking and briefly centrifuged. 
Samples were then incubated at 50oC for 60 minutes in a MJ Research thermocycler and 




2.3.4 qPCR amplification  
 Quantative polymerase chain reactions (PCR) were performed on the cDNA 
produced by reverse transcription using primers and TaqMan probes specific to the genes 
being studied (see Appendix 3). These were designed using the Roche Universal Probe 
Library (UPL) Assay Design Center (http://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). The TaqMan probes have two labels, 
one that fluoresces, and one that quenchers that fluorescence. During the extension phase 
of the PCR reaction the Taq polymerase cleaves the probe from its target sequence causing 
the fluorescent reporter label to be separated from the quencher label and thereby 
allowing it to fluoresce. Fluorescence was quantified using a MJ Research Chromo 4 Real 
Time PCR thermocycler and MJ OpticonMonitor 3.1 analysis software.  
For each gene to be studied a test sample was used to create a cDNA standard of known 
concentration. To do this, PCR reactions were set up as follows: 
 Volume of Reagent     Final concentration 
 5 μl of cDNA     → Varied 
 25 μl of 2X SensiMix(dT) Taq polymerase → 1X 
 0.5 μl of Universal ProbeLibrary Probe (10 μM) → 100 nM 
 0.5 μl of Forward Primer (20 μM)    → 200 nM 
 0.5 μl of Reverse Primer (20 μM)  → 200 nM 
 1 μl of MgCl2 (50 mM)    → 4 mM 
 17.5 μl of RNase-free H2O   → N/A 
Total volume = 50 μl  
The thermal cycler protocol for the PCR reactions was as follows: 
1. 95oC  for 10 minutes 




3. 60oC for 30 seconds 
4. 72oC  for 15 seconds 
5. Repeat steps 2 to 4 for 45 cycles 
 qPCR products were purified using the QIAquick PCR Purification Kit and 5 μl loaded 
onto a 1% agarose gel containing sybersafe. The gel was run at 100V for 1 hour and 
visualized under UV light on Genesnap software. The concentration of these target 
products was quantified using the Nanodrop 1000 spectrophotometer as described above. 
 Standard curves were generated by serial 10-fold dilutions of the quantified cDNA 
standard products. qPCR was performed on both samples and standards and fluorescence 
was then measured using a the MJ OpticonMonitor 3.1 analysis software. The 
concentration of the target gene in the sample was measured by comparing fluorescence 
intensity of samples to those of standard curve.  
 
2.3.5 Normalisation 
To ensure all samples had equivalent amounts of starting cDNA, in addition to nanodrop 
measurement, the expression levels of the housekeeping genes GAPDH and 18S ribosomal 
RNA were calculated for each sample as described above. For GAPDH the PCR reactions 
were run as for every other gene, but for 18S the PCR reaction was instead set up as 
follows: 
 5 μl of cDNA 
 25 μl of 2X SensiMix(dT) Taq polymerase     
 2.5 μl of TaqMan® Gene Expression Assay Mix for 18S ribosomal RNA  
 1 μl of MgCl2         
 16.5 μl of RNase-free H2O 




All other steps were run as described above. All results were then adjusted to account for 
18S and GAPDH expression levels. 
 
2.4 Ex Vivo Cultures 
 
2.4.1 Adapted calvarial organ culture 
A cancer cell – mouse calvaria organ culture system developed by Dr Aymen Idris was used 
as previously described in Frantzias et al 2011. 14 day old C57B6 mice were culled by 
surgical dislocation and the calvaria was removed as described above. Calvaria were then 
divided into equal halves along the median sagittal suture. The separated half-calvariae 
were explanted onto surfaces of stainless steel rafts in 48-well plates containing standard 
αMEM with either no cells or 3 x 103 MDA-MB-231 cells per well seeded 24 hours in 
advance. Medium was removed and replaced with fresh standard αMEM containing either 
vehicle or test compounds. Medium was at a level that partially covered the calvarial half, 
leaving a significant portion of the topside exposed. Cultures were maintained for 7 days 
with medium and treatments being refreshed every 48 hours. Calvaria were then fixed in 
4% para-formaldehyde in PBS overnight and then transferred to 70% ethanol and stored at 
4˚C. They were analyzed by micro-computed tomography (μCT) as described below. The 
viability of MDA-MB-231 cells in the calvarial organ culture were analysed using the Alamar 
Blue assay as described above. 
 
2.4.2 Adapted Femoral organ culture 
 10 week old C57B6 mice were culled by surgical dislocation and femurs were 
isolated as described above. They were then either fixed in 4% para-formaldehyde in PBS 
overnight and then transferred to 70% ethanol, or placed into 6 well plates containing 
standard αMEM. Test compounds were added with standard αMEM and the volume of 
medium adjusted so that the femurs were approximately 80% covered. Femurs were 
cultured for 14 days, with medium and treatments refreshed every 48-72 hours. Following 




transferred to 70% ethanol. Femurs were then analyzed by micro computed tomography 
(μCT) as described below. 
 
2.5 Animal work 
 
 All experimental protocols were approved by the Ethics Committee at the 
University of Edinburgh and were conducted in accordance with the UK Home Office 
regulations (personal licence number 60/12005, project licence number 60/3981). 
 
2.5.1 Animals 
 C57BL/6, Balb/C and Balb/C Nude mice were housed in a designated animal facility. 
Rooms were pathogen-free and maintained at a constant temperature with 12 hours 
light/12 hours dark cycles. All animals had free access to water and standard commercial 
rodent feed pellets (SDS, Special Diets Service). 
 
2.5.2 Intraosseous implantation 
  Balb/C and Balb/C nude mice were anesthetised by inhalation (isoflurane 5% in 
100% oxygen in an induction chamber until anesthetised then maintained at isoflurane 2%) 
and their hind limbs were scanned using an in vivo μCT scanner (SkyScan) at a resolution of 
9 microns. Human MDA-MB-231 or mouse 4T1 breast cancer cells were passaged using 
trypsin and manually counted using a haemocytometer. MDA-MB-231 or 4T1 cells (10 x 102, 
5 x 103 or 10 x 103) were suspended in 20 μl of warm sterile PBS and transported to the 
animal facility. Mice were anesthetised by inhalation of isoflurane (as above) and the tibia 
was exposed using a sterile scalpel. It was important that the bone marrow cavity was 
visible before implantation was commenced as this reduced the chance of an off target 
injection. A 27 gauge needle with the point bent to a 45° angle was then used to drill two 
small holes through the cortex of the tibia and into the bone marrow cavity. These holes 
were located roughly 2 mm and 4 mm below the growth plate of the tibia. This location 
avoids damaging the majority of the trabecular bone present in the tibia. A sterile syringe 




was used to flush through the lower hole, causing bone marrow to be expelled out of the 
upper hole. A second syringe attached to a third 27 gauge needle was then used to inject 20 
μl of the PBS containing cancer cells into this newly created cavity in the bone marrow. 
Both openings were quickly sealed with dental wax to prevent leakage into the surrounding 
tissue environment. The site is then flushed with sterile water and wound was sutured. 
Mice are then left to recover for 7 days with analgesics added to their water supply. 
 After the sutures have been removed (7 days post injection) mice were 
anesthetised and their hind limbs were scanned using an in vivo μCT scanner (SkyScan) 
every three days for the duration of the experiment. Treatment with test compound was 
begun on week 2 after this second in vivo μCT scan. Damage to the injected tibia of mice 
was monitored by μCT scans and by checking the injected limbs for excessive swelling or 
loss of movement. Mice received an injection of calcein (10 mg/kg) 5 days and 1 day prior 
to culling. Experiments were terminated by cervical dislocation after 8 weeks for MDA-MB-
231 cell implantations or 3 weeks for 4T1 cell implantations. The hind limbs were isolated 
and fixed in 4% formalin overnight followed by transfer into 70% ethanol for storage at 4°C.
  
2.5.3 PINP and CTX serum assays 
 Serum was extracted from mice to allow analysis of serum bone formation and 
bone resorption markers, specifically type I procollagen (PINP) (bone formation) and C-
terminal telopeptide fragments of type I collagen (CTX)(bone resorption). Briefly, 400 – 
1000 μl of blood was collected by cardiac puncture and transferred to fresh sterile 
Eppendorf tubes on ice. Serum was obtained by centrifugation of the whole blood at 3000 
rpm for 10 minutes at 4oC and removing the top clear layer into a fresh sterile Eppendorf 
tubes. Serum samples were stored at -20oC until further use. 
 Both the PINP and CTX serum assays are enzyme immunoassays that allow 
quantitative determination of their respective proteins. PINP is released during collagen 
synthesis and so is considered to be a specific marker of bone formation (395), while CTX is 
released from the bone matrix and into serum during bone resorption (395). CTX is 
therefore considered a marker of bone resorption, although it is also used as a marker of 
the rate of bone remodelling in general. PINP and CTX assays were carried out according to 




2.5.3 Micro computed tomography (μCT) 
 Micro computed tomography (μCT) was used to assess bone mass and architecture. 
For intratibial injection studies, the hind limbs of the mice were scanned using an in vivo 
μCT scanner (Skyscan) throughout the course of the experiment as described above, and ex 
vivo using an ex vivo μCT scanner (Skyscan). For ex vivo calvarial co-cultures, calvarial halves 
were fixed in 4% (v/v) parafolmadehyde in PBS and stored in 70% (v/v) ethanol. They were 
loosely wrapped in parafilm to prevent desiccation and placed in an ex vivo μCT scanner 
(SkyScan) in an upright position in a 2 ml syringe with both ends cut. This was placed into 
the ex vivo μCT scanner (SkyScan), fixed in an upright position on a platform within the 
scanner and processed in the same way as with the legs described below. 
 For both types of scan, SkyScan software was used to set the x-ray radiation 
source to 60kV and 150μA. A 0.5 mm aluminium filter was added for a 180˚ scan with a 
rotation step of 0.6 degrees. The pixel size was set at 9 μm for scanning mouse legs and 5 
μm for scanning calvarial halves. In the in vivo scanner the camera is rotated around the 
fixed in place mouse/legs to provide pictures from all 180˚, while on the ex vivo scanner the 
samples are rotated and the camera fixed. NRecon software (Skyscan) was used to produce 
3D image stacks by reconstructing the data from the rotation image projections. The top of 
the tibia on each leg was used as a reference line, and the 1000 frames below that were 
chosen for reconstruction. The entireties of calvarial halves were chosen for analysis. The 
parameters for reconstruction are shown in Table 2.1. 
 
Table 2.1 Reconstruction parameters used in NRecon software 
Parameter Description Setting 
Smoothing Smoothes image and 
removes noise 
Width of 1 pixel 
Beam Hardening Factor 
Correction 
Corrects for the absorbance 
of low energy x-ray on the 
outside of the specimen 
9% 
Ring correction level 
Corrects for the non-linear 







 Using CTAn software (SkyScan) the reconstructed images were analysed by 
selecting the region of interest. For tibias, this was from the region just below the growth 
plate where the calcified cartilage ridges of growth plate fuse together and extended 60 
frames. This area was used for analysis as it is the most trabecular rich area. For calvaria the 
whole calvarial half was analysed. The region of interest was selected using a free-hand 
drawing tool to highlight the area required for analysis, this was repeated at intervals of 10 
frames for legs and 50 frames for calvaria. The CTAn software used auto-interpolation to 
determine the region of interest at every other level.  
 The selected regions of interest were subject to a total bone analysis and analysed 
by 3D-reconstruction using the CTAn software. The parameters for 3D-reconstruction are 
shown in Table 2.2. 
Table 2.2 3D Reconstruction parameters used in CTAn software 
Parameter Description Setting 
Smoothing 
Smoothes images and 
removes noise 
Medium filter; 2D space, 
radius 1 
Threshold 
Segments the foreground 
from background to binary 
images 
Global; low level 100, high 
level 255 
Despeckle 
Removes speckles from 
binary 
Images 
Image; remove white 
speckles <150 voxels 
3D-Model 
Creates a 3D surface from 
binary images 
Adaptive rendering; file saved 
as .p3g 
3D-Analysis 
Calculates 3D parameters of 
binary images 
Requested for basic values, 
trabecular thickness, number 
and separation 
 
 The parameters that were obtained for each scan of tibia are listed in Table 2.3. For 
calvarial halves only total bone volume and 3D images were analysed. SkyScan CTVol 





Table 2.3 3D Trabecular bone parameters calculated by µCT analysis 
Parameter Abbreviation (unit) 
Trabecular bone volume BV/TV (%) 
Trabecular Thickness Tb.Th ( m) 
Trabecular Separation Tb.Sp ( m) 
Trabecular Number Tb.N (1/mm) 
Trabecular Pattern factor Tb.Pf (1/mm) 
 
2.5.4 Bone histomorphometric analysis 
 After μCT analysis of legs was complete they were processed for bone 
histomorphometric analysis as follows. The proximal tibia of each leg was dissected out and 
placed into an embedding basket in a Leica automatic tissue processor at room 
temperature for 28 hours. An 8 stages protocol of dehydration in ethanol dilutions and 
tissue clearing in xylene. The protocol used is as follows: 
1. PBS  45 minutes 
2. 50% Ethanol 2 hours 
3. 70% Ethanol 2 hours 
4. 80% Ethanol 2 Hours 
5. 96% Ethanol 2 Hours 
6. 100% Ethanol 3 hours 
7. 100% Ethanol 3 hours 
8. Xylene  1 hour 
9. Xylene  12 hours  
 Following this processing, tibia were then placed into fresh methyl methacrylate 
(MMA) infiltration solution (Appendix 2) and kept in an air tight vaccum desiccator for 1 
week at 4˚C. Now infiltrated, tibia were removed from vacuum and placed into individual 
block embedding moulds which were then filled with the same MMA solution as for 
infiltration, which had also been stored at 4˚C for a week. Moulds were shut and sealed 




solid resin blocks were mounted on embedding rings using a fast-hardening mounting 
medium consisting of two thirds dibenzoylperoxide and one third N,N-dimethyl-p-toluidine. 
 Blocks were sectioned on a low speed microtome using a steel edge. They were 
trimmed until reaching the sagittal plane of the tibia, and multiple 5 μm thick sections then 
cut and placed onto microscope slides covered in 96% ethanol. The ethanol allowed 
smoothing of the sections to ensure they were flat on the slide. A removable plastic 
coverslip (Kisol foil) was placed onto each slide, and the slide left to dry under pressure at 
37oC for 24-48 hours. Then the resin was removed by immersing the slides in 2-
Methoxyethyl acetate (MEA) for 60 minutes split into 3 x 20 minute washes. The slides 
were then rehydrated using the following program of washes. 
1. Xylene  10 minutes 
2. Xylene  10 minutes 
3. 100% Ethanol 1 minute 
4. 100% Ethanol 1 minute 
5. 96% Ethanol 1 minute 
6. 80% Ethanol 1 minute 
7. 70% Ethanol 1 minute 
8. 50% Ethanol 1 minute 
9. dH2O  1 minute 
 
 Slides were stained with Von Kossa and paragon staining for bone 
histomorphometric analysis. Briefly, sections were then immersed in 1.5% (v/v) aqueous 
silver nitrate and incubated in the dark for 5 minutes and rinsed 3 times in dH2O before 
being immersed in 0.5% (w/v) aqueous hydroquinone for 2 minutes. 3 further washes in 
dH2O followed.  Following Von Kossa staining, the slides were counterstained using Paragon 
stain. This is a 1:5 mixture of Paragon solution with Borax buffer solution (Appendix 2). They 




then air dried in a fume hood, briefly dipped in xylene and covered with DPX mounting 
medium. 
 Bone histomorphometry analysis was performed on the Von Kossa stained sections, 
and on blank sections for calcein labelling analysis as follows. The tibial proximal 
metaphysis distal to the epiphysial growth plate were visualised using a Zeiss Axio Imager 
microscope fitted with a QImaging Retiga 4000R camera. Custom software developed by 
Dr. Rob J. van’t Hof using the Aphelion Image Analysis tool kit (Adcis SA, Hérouville-Saint-
Clair, France) was used to perform static and dynamic bone histomorphometry (396). 
Parameters defined by this were calculated according to the ASBMR Histomorphometry 
Nomenclature Committee (397) and are shown in Table 2.4. 
Table 2.4 ASBMR Histomorphometry Nomenclature Committee Bone histomorphometry 
parameters  
Parameter Abbreviation (unit) Calculation/Expression 
Bone Volume per Total 
Volume 
BV/TV (%) Value x 100 
Active resorption area per 
Bone Surface 
Oc.S/BS (%) Value x 100 
Osteoclast Number per 
Bone Surface 
Oc.N/BS 
(# of cells/mm) 
Osteoclast number/Bone 
surface 
Osteoblast Number per 
Bone Surface 
Ob.N/BS 
(# of cells/mm) 
Osteoblast number/Bone 
surface 
Osteoclast Number per total 
section area 
Oc.N/T.Ar 
(# of cells/mm2) 
Osteoclast number/Section 
area 
Osteoblast Number per total 
section area 
Ob.N/T.Ar 
(# of cells/mm2) 
Osteoblast number/Section 
area 
Single Labelled Surface sLS (μm) Calculated by software 
Double Labelled Surface dLS (μm) Calculated by software 
Bone Surface BS (μm) 
sLS + dLS + 
unlabelled surface 
Labelled Width L.Wi (μm) Calculated by software 
Mineral Apposition Rate MAR (μm/day) L.Wi /# of days 
Mineralising Surface per 
Bone Surface 
MS/BS (ratio) (dLS + sLS/2)/BS 
Bone Formation Rate (at 
bone surface level) 
BFR (μm2/day) MAR*(MS/BS) 
 
Slides were stained with TRAcP and aniline blue staining for osteoclast 




hours at 37˚C or until the red stain had begun to develop. They were the washed 3 times in 
dH2O, before being placed into aniline blue counter stain (Appendix 2) for 20 minutes. 
Sections were then air dried in a fume hood and then briefly dipped in xylene. Sections 
were then air dried in a fume hood, briefly dipped in xylene and covered with DPX 
mounting medium. TRAcP and Aniline blue stained slides were used for image purposes 
only. 
 
2.6 Statistical Analysis 
Student’s t test was performed to determine the significance level of differences between 
two sets of results. Where appropriate comparison between groups was done by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test using SPSS for Windows version 11. 
A p-value value of 0.05 or below was considered statistically significant, and a p-value of 














Models to study cancer-induced  






Bone metastases in breast cancer patients generally cause osteolytic lesions as the 
invading tumour cells release a variety of factors that up regulate bone remodelling in a 
manner that favours bone resorption. The main aim of this chapter was to develop in vitro 
models to study this cancer-induced osteolysis. Given the limitations of cancer cell lines as 
models for the study of cancer, a number of mouse and human cancer cell lines were 
chosen for this purpose.  
Human MDA-MB-231, human MCF7, mouse 4T1, and mouse MC57G breast cancer 
cells significantly enhanced RANKL and M-CSF-stimulated osteoclast formation, size and 
nuclearity in cancer cell - bone marrow (BM) co-cultures regardless of number of cancer 
cells seeded. In the absence of RANKL, human and mouse breast cancer cells failed to 
induce osteoclast formation regardless of number of cancer cells seeded. This 
demonstrates that breast cancer cells alone are incapable of stimulating osteoclast 
formation.  
To study the role of breast cancer derived factors in the absence of the cancer cells 
themselves, conditioned medium derived from human and mouse breast cancer cells was 
used. Conditioned medium derived from human MDA-MB-231, human MCF7, mouse 4T1, 
and mouse MC57G increased osteoclast formation, size and nuclearity. Functional studies 
with conditioned medium showed that MDA-MB-231 stimulated osteoclast signalling and 
increased the RANKL/OPG ratio in osteoblasts. Treatment of M-CSF dependant osteoclast 
precursors with conditioned medium from human and mouse enhanced the adhesion and 
spreading of these cells without affecting cell viability. In contrast, conditioned medium 
from human and mouse reduced osteoblast differentiation without affecting cell viability. 
 Overall, this chapter describes an in vitro model to study cancer-induced bone cell 
differentiation, survival and activity. These models will be utilised to test the effects of 







 The bone microenvironment is the most common metastasis site for the three 
most common human cancers; breast, prostate and lung (182). Bone metastases are 
apparent in more than 80% of advanced stage breast cancer patients (181). Our 
understanding of the precise mechanisms behind the development and pathophysiology of 
bone metastases is currently limited. Research is needed to elucidate the complex 
interactions between bone and tumour cells, identifying new drug targets and testing novel 
therapeutic agents. 
 Bone metastases observed in breast cancer patients are generally osteolytic as the 
invading tumour cells release a variety of factors that up regulate bone remodelling in a 
manner that favours bone resorption. In this chapter I will be discussing the development 
of models to aid studies into the effects of tumour cells on the three key bone cell types; 
osteoclasts, osteoblasts and bone marrow derived osteoclast precursors. I will present 
studies showing the effect of co-cultures with tumour cells, as well as the effect of 
conditioned medium from tumour cells. 
 In vitro techniques for culturing a variety of cancer cell lines are well established as 
are cultures of primary bone cells including macrophage, osteoclasts (398) and osteoblasts 
(399), and various immortalised bone cell lines such as RAW 264.7 cells (400) and MC3T3 
cells (401). However there are far fewer recent examples of successful direct co-cultures 
containing combinations of both bone and cancer cells. This is a useful and currently under-
used tool for studying the interactions between cancer and bone cells in vitro.  
 One technique that has been successfully utilised by various groups is the use of 
conditioned medium from tumour cells as a treatment to be applied to various bone cell 
types. Here I will demonstrate a range of different analyses that can be applied using 





3.3 Aim  
The aim of this chapter was to design and set up co-culture and conditioned medium 
in vitro models of the interactions and cross-talk between osteolytic breast cancer cells and 
three bone cell types; osteoclasts, osteoclast pre-cursors and osteoblasts. The models 
would then be used to investigate the effect of the tumour cells on the bone cell 
differentiation and activity in this chapter and the modulating action various therapeutic 







3.4.1 Breast cancer cells? 
 The most important factor in designing any co-culture system is the cell types that 
will be used. In this study, osteoclasts, osteoblasts and M-CSF generated bone marrow 
macrophage cultures were used as these are the most important bone cell types. This 
leaves the vital question of which tumour cells to use. The two most common cancers to 
metastasise to bone in humans are breast and prostate cancers (402). These two cancers 
are classically thought to have distinct pathologies within the bone microenvironment; 
breast cancers causing osteolytic lesions and prostate cancers causing osteoblastic lesions. 
While this does typically hold true, in reality the situation is more complex and either 
cancer can cause either type of lesion, and lesions can display both osteolytic and 
osteoblastic characteristics. Mindful of the limitations of cancer cell lines as models for 
studying cancer, a number of mouse and human cancer cell lines were chosen. Table 3.1 







Cell Line Species Cancer Type Notes 
MDA-MB-231 Human Breast Cancer One of the two most commonly used breast cancer cell lines. Triple negative (ER, PR and 
Her2/neu negative), highly metastatic, and has undergone EMT. Fast growing in culture 
(403-405). 
MCF7 Human Breast Cancer One of the two most commonly used breast cancer cell lines. ER and PR positive and 
Her2/neu negative, non-metastatic and has not undergone EMT. Slow growing in 
culture (406, 407). 
4T1 Mouse Breast Cancer Balb/c derived cell line. ER positive, highly metastatic, has not undergone EMT. 
Extremely fast growing in culture (408-410).  
MC57G Mouse Fibrosarcoma C57B6 derived cell line. Moderately quick growth in culture (411). 
PC3 Human Prostate One of the two ‘classical’ prostate cancer cell lines. Highly metastatic and androgen 
independent. Relatively slow growing in culture (412, 413). 






3.4.2    Cancer induced osteoclastogenesis 
3.4.2.1 Breast cancer cells enhance RANKL and M-CSF-induced osteoclast 
formation and bone resorption 
 Cultures of RANKL and M-CSF stimulated mouse osteoclasts were used to study 
breast cancer-induced osteoclast formation and resorption. Mouse M-CSF generated 
osteoclast precursor cells were cultured in the presence of RANKL (100 ng/ml) and M-CSF 
(25 ng/ml) before the addition of human MDA-MB-231 cells (75 - 1200 cells/well) for 48 
hours. Osteoclasts were visualised using TRAcP staining. Figure 3.1 panel A shows that the 
presence of MDA-MB-231 cells significantly increased the number of osteoclasts by 100-
150% (p<0.01) at all initial MDA-MB-231 seeding densities. These effects were most evident 
in the cultures with the lowest seeding densities of MDA-MB-231 cells. This was in contrast 
to the cultures with higher concentrations of MDA-MB-231 cells which had smaller, less 
nucleated osteoclasts (Figure 3.1, panel C). The reason for this difference seems to be the 
human MDA-MB-231 cells expanding and competing with the mature osteoclasts and their 
precursors for space within the cultures. This reduces the space available for osteoclasts 
thereby inhibiting the fusion of osteoclast precursors and preventing the formation of the 
very large osteoclasts seen when MDA-MB-231 cell numbers are very limited. This effect is 
clearly evident in Figure 3.2, which shows that if the cultures are left for longer the MDA-
MB-231 cells continue to expand and by 96 hours at the higher seeding densities they have 









Figure 3.1. MDA-MB-231 human breast cancer cells stimulate osteoclast formation, size and nuclearity. Osteoclast 
precursor macrophages were seeded in the presence of M-CSF (25 ng/ml) and RANKL (100 ng/ml) and allowed to attach 
overnight. MDA-MB-231 cells (75-1200 initial seeding number) were then added and the co-culture allowed to proceed for 72 
hrs. Multi-nucleated osteoclasts were visualised and counted following TRAcP staining. Osteoclast number is expressed as a 
percentage of the control well. The graphs show the number of osteoclasts when only those with 3 (A) or 10 (B) nuclei were 
included. C shows representative photomicrographs of the cultures. Data is from three independent experiments (N=3) 








Figure 3.2. MDA-MB-231 human breast cancer cells out compete osteoclasts after 96 hours. Osteoclast precursor 
macrophages were seeded in the presence of M-CSF (25 ng/ml) and RANKL (100 ng/ml) and allowed to attach overnight. MDA-
MB-231 cells (75-1200 initial seeding number) were then added and the co-culture allowed to proceed for 96 hrs. Multi-
nucleated osteoclasts were visualised and counted following TRAcP staining. Osteoclast number is expressed as a percentage of 
the control well. The graphs show the number of osteoclasts when only those with 3 (A) or 10 (B) nuclei were included. C shows 
representative photomicrographs of the cultures. Data is from three independent experiments (N=3) performed in quintuplicate 





 Cultures of RANKL and M-CSF stimulated osteoclasts were also used to study breast 
cancer-induced bone resorption. RANKL and M-CSF-generated osteoclasts cultures were 
generated as described above on Corning® Osteo Assay Surface multiple well plates 
(Corning, USA). Once mature osteoclasts were formed, human MDA-MB-231 breast cancer 
cells (300 cells / well) were added to the culture and left for 96 hours. Adherent osteoclasts 
were removed by adding 50% bleach (Clorox-Ultra, USA) for 10 minutes. The resorption pits 
were then visualised by phase contrast microscopy and the area resorbed quantified by 
image analysis using ImageJ. Figure 3.3 panel A shows that the presence of MDA-MB-231 
cells significantly increased the area resorbed by over 700% (p<0.01). A small decrease 
(25% loss, p<0.05) in the number of osteoclasts was observed at the termination of the 
culture (Figure 3.3 panel B). This was probably due to the 96 hour length of the culture 
allowing MDA-MB-231 cell to out compete osteoclasts as discussed above. Alternatively, it 
could also be explained by the significant increase in osteoclast size resulting in a reduced 





Figure 3.3. MDA-MB-231 human breast cancer cells enhance bone resorption. Osteoclast 
precursor macrophages were seeded onto Corning® Osteo Assay Surface multiple well plates (Corning, 
USA) in the presence of RANKL (100 ng/ml). Once mature osteoclasts had formed the culture was 
allowed to proceed for 96 hrs as before (control) or with the addition of MDA-MB-231 cells (300 initial 
seeding number). Multi-nucleated osteoclasts were visualised and counted following TRAcP staining. 
The graphs show resorbed area (A) and the number of osteoclasts when only those with 3 nuclei were 
included (B). Data is from three independent experiments (N=3) performed in quintuplicate and error 





Mindful of the limitations of cancer cell lines as models for studying cancer, three 
further cell lines were chosen to determine if the effects observed above were general or 
specific to the MDA-MB-231 cell line. These cell lines were human MCF7 breast cancer cells, 
mouse (Balb/C) 4T1 breast cancer cells and mouse (C57B6) MC57G fibrosarcoma cells 
(Table 3.1). All these cells have been shown to cause osteolytic bone metastases in vivo 
(414-416).  M-CSF generated osteoclast pre-cursors were plated into 96 well plates with M-
CSF (25ng/ml) and RANKL (100ng/ml), and left to adhere overnight. MDA-MB-231, MCF7, 
4T1 or MC57G cells were then added at an initial seeding density of 300 cells per well. 
Photographs of these cultures are shown in Figure 3.4.  
Figure 3.4 panel A shows that, in a similar fashion to MDA-MB-231 cells, the 
addition of MCF7, 4T1 or MC57G to RANKL and M-CSF stimulated BM cultures increased 
osteoclast number, size and nuclearity. MCF7, 4T1 and MC57G increased osteoclast 
number by 83%, 81% and 67%, respectively. However, the increase in osteoclast size and 
nuclearity was not consistent across all cell types. For example, smaller osteoclasts were 
observed in MC57G-osteoclast co-cultures. This difference was quantified when cultures 
were reanalysed counting only those osteoclasts with ten or more nuclei. In this count 
increases over control were now 375% by MDA-MB-231 cells, 294% by MCF7 cells, 319% by 






Figure 3.4 Osteolytic cancer cells stimulate osteoclast formation, size and nuclearity. Osteoclast precursor macrophages were 
seeded in the presence of RANKL (100 ng/ml) and allowed to attach overnight. MDA-MB-231, MCF7, 4T1 and MC57G cells were then added at 
an initial seeding density of 300 cells and the co-culture allowed to proceed for 72 hrs. Multi-nucleated osteoclasts were visualised and 
counted following TRAcP staining. Osteoclast number is expressed as a percentage of the control well which did not have any cancer cells 
added. The graphs show the number of osteoclasts when only those with 3 (A) or 10 (B) nuclei were included. C shows representative 
photomicrographs of the cultures. Data is from three independent experiments (N=3) performed in quintuplicate and error bars represent +/- 




3.4.2.2 Breast cancer derived factors enhance RANKL and M-CSF-induced osteoclast 
formation  
To study the effects of cancer-induced osteoclastogenesis in the absence of cancer 
cells I decided to create tumour cell conditioned medium and then use this as a treatment 
for our various bone cell cultures. This had the added advantage of allowing us to 
determine whether the effects we had already seen were determined by secreted factors 
or purely through cell-cell contact. 
Cultures of RANKL and M-CSF generated mouse osteoclasts were used to study the 
effects of cancer cell derived factors on osteoclast formation. M-CSF generated BM 
macrophage were plated into 96 well plates and allowed to adhere overnight in the 
presence of RANKL (100 ng/ml). MDA-MB-231 conditioned medium and control 
conditioned medium were created and used to treat these osteoclast cultures at 
concentrations of 5, 10, 20, 50 or 100%. MDA-MB-231 cells (300 cells / well) were also 
added to provide a positive control for comparison. Media, and conditioned medium 
treatments were refreshed after 48 hours, and the culture stopped after 96 hours of 
treatment. Osteoclasts were identified by TRAcP staining. In initial tests when osteoclast 
cultures were treated with 50 or 100% (v/v) conditioned medium strong inhibition of 
osteoclast formation was seen and so no further work was done at these concentrations. 
Increases in osteoclast number were seen in all the cultures treated with MDA-MB-231 
conditioned medium at 5, 10 or 20% (v/v). Figure 3.5 A shows that the increase in 
osteoclast number was fairly consistent between different treatments and when compared 
to the MDA-MB-231 cell co-culture; between 46% and 56% (p<0.05). However, the size of 
osteoclasts formed is clearly different in the photomicrographs shown in Figure 3.5 C and 
this observed difference is born out when only osteoclasts with 10 or more nuclei are 
counted (Figure 3.5 B). In this count, treatment with conditioned medium at 5% did not 
significantly increase osteoclast number, compared to significant increases of 73% and 
110% with conditioned medium at 10 and 20% respectively (p<0.05). The MDA-MB-231 cell 
treatment shows the starkest difference with an increase in osteoclasts with 10 or more 







Figure 3.5 Conditioned medium from MDA-MB-231 human breast cancer cells stimulate osteoclast formation, size and nuclearity. 
Osteoclast precursor macrophage were seeded in the presence of RANKL (100 ng/ml) and allowed to attach overnight. MDA-MB-231 cells (300 
cells) or conditioned medium (5-20%) from MDA-MB-231 flasks or from control flasks was then added and the cultures allowed to proceed for 72 
hrs. Multi-nucleated osteoclasts were visualised and counted following TRAcP staining. Osteoclast number is expressed as a percentage of the 
control well. The graphs show the number of osteoclasts when only those with 3 (A) or 10 (B) nuclei were included. C shows representative 
photomicrographs of the cultures. Data is from three independent experiments (N=3) performed in quintuplicate and error bars represent +/- 




As with the osteoclast co-cultures a variety of other osteolytic bone metastasis cell 
lines were tested to examine whether or not the effects of MDA-MB-231 conditioned 
medium on osteoclasts was specific to that cell line. Again, 3 further cell lines were used 
MCF7 human breast cancer cells, 4T1 mouse breast cancer cells and MC57G mouse 
fibrosarcoma cells (Table 1). M-CSF generated osteoclast precursors were allowed to attach 
overnight in the presence of RANKL before treatment with conditioned medium from the 4 
cell types at a concentration of 10%. In each case the conditioned medium treatment 
increased the osteoclast number, size and number of nuclei as seen in Figure 3.6. 
 
 
Figure 3.6 Conditioned medium from osteolytic cancer cells stimulate osteoclast 
formation, size and nuclearity. Osteoclast precursor macrophages were seeded in the 
presence of RANKL (100 ng/ml) and allowed to attach overnight. MDA-MB-231, MCF7, 4T1 and 
MC57G conditioned medium (10%) was then added and the co-culture allowed to proceed for 
72 hrs. Multi-nucleated osteoclasts were visualised following TRAcP staining. Representative 
photomicrographs of the cultures are shown. Data is from three independent experiments (N=3) 




3.4.2.3 Breast cancer cells do not produce RANK ligand in M-CSF stimulated bone marrow 
cultures 
 To establish whether breast cancer cells produce the osteoclastic factor RANKL, we 
studied the effect of cancer cells on osteoclast formation in M-CSF generated mouse 
osteoclast precursor cultures in the absence of exogenous RANKL. M-CSF generated mouse 
osteoclast precursors were cultured in the presence of M-CSF (25 ng/ml) for 24 hours 
before the addition of human MDA-MB-231 cells (75 - 1200 cells/well) for 72 hours. 
Osteoclasts were visualised using TRAcP staining. Figure 3.7 shows that MDA-MB-231 (75 - 
1200 cells/well) failed to stimulate any osteoclast formation in the absence of RANKL (100 
ng /ml). Attempts were also made using AlamarBlue to measure the effect of the MDA-MB-
231 cells on the viability of the M-CSF generated bone marrow macrophages over 48 and 
72 hours, however it proved impossible to separate the two cell types once they were in co-




Figure 3.7 MDA-MB-231 human breast cancer cells do not induce osteoclastogenesis in the 
absence of RANKL Osteoclast precursor macrophages were seeded either in the presence or absence of 
RANKL (100 ng/ml) and allowed to attach overnight. MDA-MB-231 cells (75-1200 initial seeding number) 
were then added and the co-culture allowed to proceed for 96 hrs. Multi-nucleated osteoclasts were 
visualised following TRAcP staining. Representative photomicrographs of the cultures are shown. Data is 




 M-CSF generated BM macrophage cultures were generated and allowed to attach 
overnight in the absence of RANKL. They were then treated with MDA-MB-231 conditioned 
medium or control conditioned medium at a concentration of 10%. After 48 hours 
AlamarBlue was added to the cultures and they were then read in a plate reader to test the 
viability of the cells present. Figure 3.8 shows that both MDA-MB-231 and control 
conditioned medium produced a slight increase (~15%) in the number of viable cells, and 
while this was significantly different from the vehicle control, there was no difference 










Figure 3.8 Conditioned medium from MDA-MB-231 cancer cells had no effect on 
macrophage viability. Osteoclast precursor macrophages were seeded and allowed to 
attach overnight. MDA-MB-231 or Control conditioned medium (10%) was then added and 
the culture allowed to proceed for 48 hrs. AlamarBlue was then added to each well at a 
concentration of 10% and after 4 hours the plate read in a plate reader. Data is from three 
independent experiments (N=3) performed in quintuplicate and error bars represent +/- 




3.4.2.4 Breast cancer derived factors enhance RANKL and M-CSF-induced osteoclast 
motility and spreading 
 The motility and proliferation of osteoclast precursors was measured using the real-
time Xcelligence system in the presence and absence of M-CSF, RANKL and/or MDA-MB-
231 conditioned medium. M-CSF generated BM macrophages (8000 cells/well) were 
allowed to attach for 24 hours in the presence of 25 ng/ml M-CSF before 50% of medium 
was refreshed and cells treated with either M-CSF 25 ng/ml alone in 10% (v/v) control 
conditioned medium, or with M-CSF 25 ng/ml and RANKL 100 ng/ml in 10% (v/v) control or 
MDA-MB-231 conditioned medium. Impedance readings were then taken on the 
Xcelligence every minute for 1 hour, then every ten minutes for 8 hours, and finally every 
30 minutes until treatments were refreshed after 48 hours and the reading system 
repeated. After treatments were refreshed, cells were left for a further 24 hours before the 
culture was stopped. This treatment regime was used to keep treatments and conditions as 
close as possible to those used for the osteoclast formation experiments described above 
(Section 3.4.2.2, page 109). 
 The Xcelligence system uses the impedance readings to produce what is known as a 
cell index value. Changes in this value can represent a number of different features of cells 
depending on the study type and time frame. In this project long-term increases in cell-
index were taken to represent proliferation rates, while immediate and short-term changes 
represent changes in cell-shape and spreading. 
 In Figure 3.9 cell index values were normalised to the last time point before the 
first treatment and long-term changes monitored to investigate changes in cell 
proliferation. As expected, continuation of M-CSF treatment alone caused no change in the 
cell proliferation rate with an average cell doubling time of 32.5 hours observed, though 
this rate did increase sharply when the treatment was refreshed. Cells treated with RANKL 
in addition to M-CSF did not proliferate as quickly, only having a doubling time of 87.1 
(p<0.05) hours after the addition of RANKL. The addition of MDA-MB-231 conditioned 
medium as well as M-CSF, and RANKL caused cells to return to proliferation rates not 
significantly different to those of cells treated with M-CSF alone. However, the overall cell-




increase in the first two hours after treatment that is unlikely to represent changes in 
proliferation; this is shown in Figure 3.10. 
 To investigate changes in cell shape and spreading, changes in cell index value in 
the first two hours after treatments were investigated in detail. Figure 3.10 shows that after 
the first treatment no difference between M-CSF alone and M-CSF and RANKL treated cells 
was observed.  Both treatments caused a transient increase in cell index values, doubling 
times of 4.1 and 3.4 hours respectively, before settling to their long-term proliferation 
rates. This increase likely represents the changes in cell movement and morphology in 
response to fresh cytokines.  In contrast, cells treated with conditioned medium in addition 
to RANKL and M-CSF showed a very different pattern of changes in cell index values. A 
short sharp increase was followed by a prolonged drop, these are likely to represent 
changes in cell morphology. There is then a prolonged rapid rise, likely representing a rapid 
increase in cell movement, with a doubling time of 0.74 hours, significantly faster than the 
other treatments (p<0.01). 
 Figure 3.11 shows the results after they were normalised to the last time point 
before the second treatment point. This shows that when the treatment was changed there 
was initially no difference between treatments; all increase at a doubling rate of around 1 
hour. The only difference is that the conditioned medium treated cells cell index continue 
to increase for a prolonged period of time, as opposed to the other two treatments where 










Figure 3.9 Conditioned medium from MDA-MB-231 human breast cancer cells increased osteoclast proliferation. M-CSF generated macrophages were 
seeded into Xcelligence plates and allowed to grow for 24 hours in M-CSF (25 ng/ml). Cells were then treated with M-CSF (25 ng/ml) alone or with the addition of RANKL 
(100ng/ml) plus either 10% control conditioned medium or MDA-MB-231 conditioned medium. Treatment was refreshed after 48 hours. A) shows a representative graph 
of the cell index values (derived from their electrical impedance) over 96 hours and normalized to the last time point before treatment. B) A graph showing the average 












Figure 3.10 Conditioned medium from MDA-MB-231 human breast cancer cells caused a quick increase in osteoclast impedance values in Xcelligence 
analysis after treatment. M-CSF generated macrophages were seeded into Xcelligence plates and allowed to grow for 24 hours in M-CSF (25ng/ml). Cells were then 
treated with M-CSF (25 ng/ml) alone or with the addition of RANKL (100 ng/ml) plus either 10% control conditioned medium or MDA-MB-231 conditioned medium. 
Treatment was refreshed after 48 hours. A) shows a representative graph of the Cell index values (derived from their electrical impedance) between hours 23 and 27 of 
the experiment and normalized to the last time point before treatment. B) A graph showing the average doubling time (hours) of cells at the linear part of the curves 










Figure 3.11 Conditioned medium from MDA-MB-231 human breast cancer cells caused a prolonged increase in osteoclast impedance values in 
Xcelligence analysis after treatment was refreshed. M-CSF generated macrophage were seeded into xcelligence plates and allowed to grow for 24 hours in M-
CSF (25 ng/ml). Cells were then treated with M-CSF (25 ng/ml) alone or with the addition of RANKL (100 ng/ml) plus either 10% control conditioned medium or MDA-
MB-231 conditioned medium. Treatment was refreshed after 48 hours. A) shows a representative graph of the cell index values (derived from their electrical 
impedance) between hours 70 and 75 of the experiment and normalized to the last time point before treatment was refreshed. B) A graph showing the average 






3.4.2.5 Breast cancer derived factors stimulate PI3K/Akt, MAPK and NFB activation in 
osteoclasts 
 The effects of breast cancer derived factors on key signalling pathways in 
osteoclasts were investigated using western blot. As shown in Figure 3.12 – 3.14, RANKL 
and M-CSF generated mouse osteoclasts were treated with either standard medium or 
conditioned medium from human MDA-MB-231 breast cancer cells (5%, 10% or 20% v/v) 
for 5, 15 or 30 minutes. The PI3K/Akt signalling pathway is known to be a vital pathway for 
osteoclast differentiation, survival and function and is known to be stimulated by the 
osteoclastic factors RANKL and M-CSF (417, 418). Figure 3.12 shows that conditioned 
medium from human MDA-MB-231 breast cancer cells stimulated the phosphorylation of 
AKT at serine (Ser) 473 in a dose dependent manner. While stimulation was equally strong 
after 5 or 15 minutes, the difference compared to the negative control was most apparent 
at 15 minutes. 30 minutes after treatment phosphorylation of AKT began to decline and 
only at 20% was any increase over control apparent. Interestingly no stimulation of AKT 






Figure 3.12 Conditioned medium from MDA-MB-231 human breast cancer cells 
stimulates PI3Kinase signalling in osteoclasts Osteoclast precursor macrophage were 
seeded in 12 well plates and treated with M-CSF (100 ng/ml) and RANKL (100 ng/ml) until a 
significant numbers of osteoclasts had formed. Cells were then starved for 2 hours before 
stimulation with MDA-MB-231 conditioned medium (5-20%) or control conditioned medium 
(20%) for 5, 15 or 30 minutes. Cells were then lysed, total protein extracted and 50µg run on a 
western blot.  Blots were exposed to antibodies for A) β-Actin, Total AKT or pAKT Serine 473, 
pAKT Threonine 308. All antibodies are from Cell Signalling (UK) except β-Actin (Sigma-Aldrich, 






 The MAPK signalling pathway is essential for osteoclast differentiation and is known 
to be stimulated by the osteoclastic factors RANKL and M-CSF (419, 420). The effects of 
conditioned medium from human MDA-MB-231 breast cancer cells on ERK1/2 and 
JNK/SAPK MAP phosphorylation is shown in Figures 3.13. Strong stimulation of ERK1/2 
phosphorylation was observed at all three time points, but this was strongest at 15 and 30 
minutes, while only weak stimulation was seen after 5 minutes treatment. No JNK/SAPK 
phosphorylation was observed with any treatment at any time point. 
 
  
Figure 3.13 Conditioned medium from MDA-MB-231 human breast cancer cells stimulates 
MAPKinase signalling in osteoclasts Osteoclast precursor macrophages were seeded in 12 well plates 
and treated with M-CSF (100 ng/ml) and RANKL (100 ng/ml) until a significant numbers of osteoclasts had 
formed. Cells were then starved for 2 hours before stimulation with MDA-MB-231 conditioned medium 
(5-20%) or control conditioned medium (20%) for 5, 15 or 30 minutes. Cells were then lysed, total protein 
extracted and 50mg run on a western blot.  Blots were exposed to antibodies for total ERK1/2, pERK, total 
JNK/SAPK and pJNK/SAPK. All antibodies are from Cell Signalling (UK) except β-Actin (Sigma-Aldrich, UK). 





The NFκβ signalling pathway is a vital pathway for osteoclast differentiation and is 
known to be stimulated by the vital osteoclastic factor RANKL. Figure 3.14 shows that MDA-
MB-231 conditioned medium strongly stimulated phosphorylation of IKBα at all 
concentrations after 5 minutes, but only very weakly at any other time point. Weak 
activation of IKKα/β was observed after exposure to conditioned medium from MDA-MB-






Figure 3.14 Conditioned medium from MDA-MB-231 human breast cancer cells stimulate 
NFκB signalling in osteoclasts Osteoclast precursor macrophages were seeded in 12 well plates and 
treated with M-CSF (100 ng/ml) and RANKL (100 ng/ml) until a significant numbers of osteoclasts had 
formed. Cells were then starved for 2 hours before stimulation with MDA-MB-231 conditioned medium 
(5-20%) or control conditioned medium (20%) for 5, 15 or 30 minutes. Cells were then lysed, total 
protein extracted and 50mg run on a western blot.  Blots were exposed to antibodies total IKBα, pIKBα, 
total IKKα/β and pIKKα/β. All antibodies are from Cell Signalling (UK). The results shown are 





3.4.3 Cancer induced osteoblastogenesis 
3.4.3.1 Cancer derive factors inhibit osteoblast differentiation and bone nodule formation 
 Osteoblasts were isolated from the calvaria of 2-day old c57B6 mice and plated in 
12-well plates. Once the osteoblasts had reached confluence BGP and vitamin C were 
added to the culture media to induce mineralisation. At this point human MDA-MB-231 
breast cancer cells and human PC3 prostate cancer cells were added at initial seeding 
densities of 10 cells per well and the cultures were allowed to grow under standard 
conditions. However by the end of week 1 the MDA-MB-231 cells had grown to confluence 
and completely covered the osteoblast layer making any analysis of mineralisation 
impossible. In contrast, by the end of week 1 PC3 cells were growing in small colonies on 
top of the osteoblast layer, but by the end of week 3 they too had taken over the culture, 
see Figure 3.15.  
 
Figure 3.15 Cancer cells out compete osteoblasts in vitro Osteoblasts were seeded into 12 well plates and 
allowed to grow to confluence. Media was then supplemented with 10 mM β glycerophosphate (BGP) and 50 
ug/ml L-ascorbic acid and PC3 cells were added at an initial seeding density of 10 cells. Cultures were fixed after 
21 days. Representative photomicrographs of the cultures are shown. Data is from three independent 




 To study the effects of cancer derived factors on osteoblastogenesis, osteoblasts 
were cultured in osteogenic media and treated with standard or conditioned medium from 
MDA-MB-231 at concentrations of 1, 5, 10 or 20% (v/v). Medium and treatments were 
changed every 48 hours for 21 days, or until significant mineralisation had occurred in the 
control treated cultures. Osteoblast viability, differentiation and bone nodule formation 
were measured using AlamarBlue, alkaline phosphatase and alazarin red assays, 
respectively.   
 Figure 3.16 A shows that MDA-MB-231 conditioned medium had no effects on 
osteoblast viability at 1 and 5% (v/v). At 10% (v/v) there seems to be a modest reduction in 
viability of around 5% but this is not statistically significant. When treated with 20% (v/v) 
MDA-MB-231 conditioned medium osteoblast viability was significantly reduced by 10% 
(p<0.05). 
 Figure 3.16 B shows that MDA-MB-231 conditioned medium caused a dose 
dependent inhibition of alkaline phosphate production in osteoblast cultures, although this 
reduction was only statistically significant at 10 and 20%. At 5% the results were highly 
variable with an average reduction of 24%, while the reduction was more consistent with 
treatments of 10 and 20% conditioned medium resulting in reductions of 35% and 45% 
respectively (p<0.05). 
 Bone nodule formation was also measured in osteoblast cultures treated with 5, 10 
or 20% MDA-MB-231 conditioned medium (Figure 3.16 C). All three concentrations showed 
a reduction in bone nodule formation when compared to standard media treatment; 
however at 5 and 10% the reduction was minor and not statistically significant. At 20% the 
conditioned medium reduced the amount of mineralisation by 30%, indicating a strong 








Figure 3.16 Conditioned medium from MDA-MB-231 human breast cancer cells inhibits osteoblast differentiation and mineralisation 
Osteoblasts were seeded into 12 well plates and allowed to grow to confluence. Media was then supplemented with 3 mM β glycerophosphate (BGP) 
and 50 ug/ml L-ascorbic acid. MDA-MB-231 conditioned medium (1-20%) was added and media and treatment refreshed every 48 hours. After 21 days 
10% AlamarBlue was added to each well and after 4 hours the plate read on a plate reader. Each weel was washed and then either either lysed for 
alkaline phosphatase measurement or stained with alazarin red. Graphs show cell viability (A) as measured by alamar blue, differentiation as measured 
by alkaline phosphatase production (B), and mineralisation as measured by destaining of alazarin red (C).  Representative photomicrographs of the 
cultures prior to staining are shown in D. Data is from three independent experiments (N=3) performed in triplicate and error bars represent +/- one 




3.4.3.2 Breast cancer derived factors stimulate PI3K/Akt and MAPK activation in 
osteoblasts 
 The effect of MDA-MB-231 conditioned medium on key signalling pathways in 
osteoblasts was also tested. PI3K/Akt and ERK1/2 signalling pathways play an important 
role in osteoblast differentiation and are known to be activated by a number of osteoblast 
stimulating factors including PTH, IGF1 and PGE2. As shown in Figures 3.17, MDA-MB-231 
conditioned medium induced the phosphorylation of AKT at both Thr and Ser sites. 
Phosphorylation of ERK1/2 was also observed, however this occurred with both the MDA-
MB-231 and control conditioned medium treatments and so was not considered significant. 
Figure 3.17 Conditioned medium from MDA-MB-231 human breast cancer cells stimulate 
PI3Kinase signalling in osteoblasts Osteoblasts were seeded in 12 well plates and left until 
confluent. Cells were then starved overnight before stimulation with nothing, MDA-MB-231 
conditioned medium (10%) or control conditioned medium (10%) for 15 minutes. Cells were then 
lysed, total protein extracted and 50mg run on a western blot.  Cells were then lysed, total protein 
extracted and 50mg run on a western blot.  Blots were exposed to antibodies total IKBα, pIKBα, total 
IKKα/β and pIKKα/β. All antibodies are from Cell Signalling (UK). The results shown are representative 






3.4.3.3 Breast cancer derived factors stimulate RANKL/OPG ratio in osteoblasts 
 The effect of osteoblast support for osteoclastogenesis was studied by measuring 
RANKL and OPG expression in calvarial osteoblasts in the presence and absence of breast 
cancer derived factors. Osteoblasts were treated with 10% (v/v) standard or MDA-MB-231 
conditioned medium for 16 hours and mRNA expression of RANKL and OPG in osteoblasts 
was measured using qPCR. Figure 3.16 shows that MDA-MB-231 conditioned medium 
stimulated both OPG and RANKL expression increasing OPG production by 2.5-fold and 
RANKL production 13-fold. This increased the RANK/OPG ratio by almost 10 fold (992% 
increase ± 167, p<0.05 
  
FIGURE 3.18 Conditioned medium from MDA-MB-231 human breast cancer cells increases 
osteoblast RANKL and OPG expression. Osteoblasts were seeded into 12 well plates and allowed to 
grow to confluence. They were then treated for 16 hours with either control or MDA-MB-231 conditioned 
medium (10%) before being lysed in Trizol. mRNA was then extracted and analysed using qPCR analysis. All 
results were adjusted to account for expression of 18S and GAPDH housekeeping genes. Graphs show the 
average mRNA expression levels of OPG (A) or RANKL (B) relative to control.  Data is from three 
independent experiments (N=3) performed in triplicate and error bars represent +/- one standard 







 It has long been known that crosstalk from the bone metastases of diverse cancers 
effect bone cells in various ways leading to imbalances in the bone remodelling cycle. 
Breast cancer metastases are known to generally cause osteolytic bone lesions. This is 
thought to occur via the direct and indirect stimulation of osteoclast differentiation and 
activity rather than through the tumour cells themselves degrading bone (421, 422), but 
the molecular mechanisms involved in this process are still uncertain. The aim of this 
chapter was to model the effect of osteolytic tumour cells, particularly breast cancer cells, 
on the key bone cell types osteoclasts, macrophages, and osteoblasts. 
 This chapter demonstrates that a general property of breast cancer cells that cause 
osteolytic metastases in vivo is that they strongly stimulate osteoclast formation, fusion and 
activity when co-cultured with bone marrow cells in the presence of RANKL and M-CSF in 
vitro. This occurs even when the tumour cells are seeded at very low initial seeding 
densities and in fact the osteoclasts formed in these cultures are larger at the lowest 
tumour cell seeding densities. This effect seems to be due to competition for space 
between the tumour cells and osteoclasts and their precursors. There have been very few 
co-culture experiments published since the discovery of RANKL as the key osteoclast 
differentiation factor and these have generally studied other facets of the tumour-bone cell 
interactions.  Nicolin et al (2008) demonstrated that MCF7 human breast cancer cells 
induce the differentiation of RAW 264.7 murine monocyte-macrophage cells into 
osteoclasts when in co-culture through the direct production of RANKL (423). Ramnaraine 
et al (2006) co-cultured 4T1 cells with RAW 264.7 cells but did not look at the effect on 
osteoclast differentiation (424). While Ohshiba et al (2003) found that adding MDA-MB-231 
cells to a co-culture of mouse bone marrow cells and osteoblasts greatly induced osteoclast 
formation and concluded that cell-cell interaction was vital for MDA-MB-231 induced 
osteoclast formation (425). The results of this present study confirm the hypothesis that 
osteolytic tumour cells directly enhance osteoclast formation and activity. 
 There is some disagreement in the literature over the ability of tumour cells to 
induce osteoclast formation in the absence of RANKL. MDA-MB-231 cells are known not to 
produce RANKL (203) as are the majority of osteolytic tumour cells previously tested (426, 




produce both soluble and membrane bound forms of RANKL (423). This result, however, 
contrasts with previous works that found no production of RANKL by MCF7 cells (203, 426, 
427).  In the present study, MDA-MB-231 failed to induce the formation of TRAcP positive 
cells in M-CSF generated BM macrophage cultures. A result that disagrees with Lau et al ( 
2006) who found that MDA-MB-231 cells caused osteogenesis via a RANKL independent 
pathway, but agrees with Thomas et al (1999). The reason for this may be that Lau et al 
were studying Tumour associated macrophages (TAMs) rather than the murine bone 
marrow used by Thomas et al or M-CSF generated macrophage used here. Other 
explanations include MDA-MB-231 cell line clonal differences, and the contamination of the 
cultures of Lau et al with RANKL-producing stromal cells. 
 This chapter demonstrated that factors derived from osteolytic breast cancer cells 
had a variety of effects on the three different bone cell types studied. In osteoclasts MDA-
MB-231 conditioned medium induced dose-dependent increases in the differentiation and 
fusion of osteoclasts from M-CSF-generated BM macrophage in the presence of RANKL. 
This increase was not as effective as that seen when cells were directly co-cultured with the 
osteoclasts, but was still substantial. Generally there were similar increases in osteoclast 
number, but not similar increases in osteoclast size and nuclearity. No increase in cell 
viability was seen when MDA-MB-231 conditioned medium was applied to osteoclast 
precursors in the absence of RANKL. This result could be explained in two ways. Firstly, this 
could be due to the constant supply of breast cancer derived factors when the cells were 
present, as opposed to the discreet treatment regime used in conditioned medium 
treatments. The other explanation is that part of the increase observed could be due to 
cell-cell interactions between the cancer cells and mature osteoclasts and their precursors. 
The lesser effect seen when using conditioned medium is then explained as the cell-cell 
contact mediated effects are absent. There are conflicting reports in previous work on the 
effects of conditioned medium from both MDA-MB-231 and other osteolytic cell types 
when applied to osteoclasts and their macrophage precursors. Bendre et al (2005) found 
that MDA-MB-231 conditioned medium did not stimulate osteoclast formation in human 
PBMCs (304), while Tumber et al (2001), Grano et al (2000) and Guo et al (2008) all found 
that MDA-MB-231 conditioned medium stimulated osteoclast formation in bone marrow 
cultures, bone explants and RAW 264.7 cells respectively (428-430). An explanation for the 




concentration of conditioned medium used. Guo et al showed that MDA-MB-231 
conditioned medium was most effective at 10% with a dose dependent drop in effect at 
higher concentrations leading to negligible effect at 50%. In addition, in preliminary work to 
the results presented here osteoclast cultures were treated with MDA-MB-231 conditioned 
medium at 50% and a negative effect on osteoclast formation noted. Presumably due to 
both the reduction in the concentration of FCS present in these cultures and the excess of 
toxic factors in the conditioned medium. Notably, Rucci et al (2004) found that conditioned 
medium from MCF7 cells was able to induce osteoclast formation in the absence of 
exogenous RANKL, suggesting a confirmation of the results reported by Nicolin et al (2008) 
mentioned above (414). However Rucci et al used bone marrow cultures with osteoblast 
and stromal cells still present, which could have provided the required RANKL. 
 The effect of MDA-MB-231 conditioned medium on osteoblasts was such that there 
was no statistically significant effect on osteoblast viability, but a slight trend towards a 
reduction at higher concentrations of conditioned medium. There was however a 
significant reduction in osteoblast differentiation as measured by alkaline phosphatase 
activity at all concentrations of conditioned medium except 5% and at 20% a reduction in 
bone nodule formation. The reason for this is likely to be factors produced by the MDA-MB-
231 cells inhibiting osteoblast differentiation. This is in agreement with previous work by 
Mercer et al (2004) who showed that MDA-MB-231 conditioned medium (50% v/v) 
inhibited the differentiation and mineralisation of the osteoblast like cell line MC3T3-E1 by 
a mechanism dependant on the presence of TGFβ production (431). 
 The use of conditioned medium to study the effects of cancer-induced bone cell 
activity allowed us to explore a range of other techniques including western blot, qPCR and 
Xcelligence analysis. Western blot showed that factors secreted by the osteolytic breast 
cancer cell line MDA-MB-231 stimulated 3 key pathways involved in the differentiation, 
function and survival of osteoclasts. In particular, stimulation of the NFκB pathway is vital 
for osteoclast differentiation (432, 433). This provides a potential mechanism for the 
increases in osteoclast number, size and nuclearity observed in previous experiments. In 
osteoblasts stimulation of both the PI3K/Akt and MAPkinase signalling pathways was 
observed. This is again a potential mechanism behind the increases in both RANKL and OPG 




conditioned medium. However, as these are key survival pathways in osteoblasts it seems 
unlikely that this stimulation could explain the decrease in osteoblast differentiation and 
function noted (19, 23, 24, 322). 
 The increase in RANKL/OPG ratio in osteoblasts by MDA-MB-231 conditioned 
medium is an important finding as it suggests that tumour cells enhance osteoclastogenesis 
indirectly by increasing osteoblast support for osteoclast formation, survival and activity. 
OPG is a decoy receptor for RANKL, so any relative increase in levels of RANKL compared to 
OPG leads to higher amounts of RANKL free to bind RANK contribute to osteoclastagenesis.  
The fact that the increase in RANKL expression was a 13-fold increase compared to only a 
2.5-fold increase of OPG production suggests that in the metastatic bone 
microenvironment this effect would lead to a sharp increase in osteoclast formation even in 
the absence of any direct effect of the tumour cells on the osteoclasts or their precursors. 
 Finally, the Xcelligence results revealed the complexity of the crosstalk between the 
tumour cells and osteoclasts. For example, for the moment excluding the conditioned 
medium effects, the Xcelligence analysis show that RANKL inhibits proliferation of M-CSF 
derived bone marrow cultures. This is most likely explained by changes in cell motility and 
spreading in M-CSF-generated BM macrophage in response to RANKL, switching from a 
proliferative state to one where they are migrating and searching for cells to fuse with and 
form osteoclasts. The overall effect of the conditioned medium was two-fold. Firstly it 
returned the rate of proliferation in RANKL treated cells to the same level as that seen in 
the M-CSF only treated cells. Secondly it caused a large and extremely rapid increase in 
impedance within the first two hours of treatment. I hypothesise that these two effects are 
caused by two different factors or sets of factors. A transit acting set of factors that causes 
the initial effects and a slow acting set that causes the long-term increased rate of increase 
in cell index value representing proliferation. However, further work using complementary 
techniques is needed to examine this hypothesis. 
 Focusing on the transit acting set of factors, upon initial treatment with breast 
cancer conditioned medium a small rise in cell index was observed followed by a prolonged 
drop and then a sharp rise. This could be explained by the transit factors in the conditioned 
medium causing the macrophage to change to a more elongated morphology as they 




explained as the cells bunch up before elongating; this would slightly increase impedance 
before reducing it. This would also explain why this pattern was not repeated when the 
treatments were refreshed, the cells had already changed morphology and so could not do 
so again. The sharp increase is unlikely to be proliferation as it is far too rapid, and is more 
likely explained by increased spreading and fusion of the cells increasing impedance values. 
The long term increase in cell index values could then be explained by increased 
proliferation; however, no change in cell viability was noted in alamarblue studies of 
macrophages. This means that either the alamarblue was not sufficiently sensitive to detect 
any changes, or the conditioned medium only affects the viability and proliferative rate of 
macrophages that have been exposed to RANKL, or the increase is due to some other factor 
such as cell fusion. The last explanation seems most likely given the results seen in the 
osteoclast formation experiments.  Overall, the Xcelligence analysis shows that the MDA-
MB-231 conditioned medium has a wide range of effects on the developing osteoclasts and 
greatly changes not just their number and size but also the way in which they develop. 
More work is needed to elucidate exactly how this occurs. Potential candidates for the 
cancer produced factors causing these effects are RANKL, M-CSF, IGF-1, PTHrP, TGFβ and 
others which are discussed in detail in chapter 5. 
 In summary, the results reported in this chapter demonstrate that cancer derived 
factors from osteolytic human breast cancer cell lines enhance RANKL and M-CSF 
stimulated osteoclast formation but do not support osteoclast survival in the absence of 
RANKL and M-CSF. This occurs both directly, by acting on mature osteoclasts and their 
precursors and indirectly by increasing osteoblast support for osteoclast formation. In 
addition, osteoblast differentiation and bone nodule formation were also inhibited by 
MDA-MB-231 conditioned medium without effecting cell viability. This suggests that bone 
loss in osteolytic metastases may be compounded by a concurrent loss of osteoblast 
function. The aim of this chapter was to establish in vitro models of breast cancer-induced 
osteoclastic and osteoblastic changes that could be used for therapeutic intervention 
studies of osteolytic bone metastasis in later chapters (see chapter 7). This aim has been 
achieved as osteoclast-tumour cell co-cultures, and the use of tumour cell conditioned 









Models to study cancer-induced 






Bone metastases observed in breast cancer patients are mainly osteolytic in nature. 
The aim of this chapter was to design and test established models of breast cancer-induced 
osteolysis ex vivo and in vivo that could be used in later chapters to test novel therapeutic 
agents for the treatment of osteolytic bone metastasis. With this in mind, attempts were 
made to set up three different models, a calvarial organ culture, a femoral organ culture 
and an intratibial injection model. 
 The ex vivo cancer cell – mouse calvaria organ culture used in the present study 
was an adaptation of the standard calvarial organ culture. Briefly, each mouse calvaria was 
divided into equal halves along the median sagittal suture and each half was placed into 
culture on stainless steel rafts in 48-well plates containing standard media or MDA-MB-231 
(1 x 104 cells/well).  Osteolysis was assessed using μCT. The calvaria halves co-cultured with 
MDA-MB-231 cells lost significant amounts of bone, confirming that this is a working model 
of osteolytic bone destruction. Attempts to use the same methodology to study breast 
cancer-induced osteolysis using MDA-MB-231 - femoral bone organ cultures were less 
successful. No loss of either trabecular or cortical bone was seen by μCT analysis, and there 
may in fact have been a slight increase in bone mass, though this was not statistically 
significant.  
 The standard model of intraosseous injection was decided as the most appropriate 
in vivo model for a study of interactions between bone and tumour cells. This method 
allowed the control of tumour site, and ignored the mechanisms of metastasis itself. MDA-
MB-231 and a bone seeking variant failed to cause any osteolytic bone destruction when 
injected into the tibia of female Balb/c Nude mice despite being left for 8 weeks. This led to 
the use of 4T1 cells which were injected into the tibia of female Balb/c wild-type mice. After 
only 3 weeks experiments had to be stopped as all trabecular and most cortical bone had 
been destroyed in the injected legs.  
 Overall, this chapter was partially successful at creating usable models for ex vivo 
and in vivo studies of bone metastasis. The adapted calvarial organ culture and the 4T1 
intratibial injection model can now be utilised in therapeutic intervention studies. Further 






 While Chapter 3 showed that much can be learned from investigating tumour cell-
bone cell interactions in vitro, the overall impact of the observed effects cannot be deduced 
in so simplified an environment. To do this techniques that maintain the normal bone 
microenvironment are required. The overall effects of breast cancer cells on osteolysis can 
only be investigated using ex vivo and in vivo models of osteolytic bone disease. The aim of 
this chapter was to establish ex vivo and in vivo models that could later be used to test 
novel therapeutic agents for the treatment of osteolytic bone metastasis (see Chapter 8).  
  In this chapter, I will be discussing the development of several methods for 
investigating the influence of osteolytic tumour cells on osteolysis in both ex vivo and in 
vivo settings. I will demonstrate the effects of breast cancer cells on organ cultures, both 
calvarial and femoral, as well as what happens when these cells are placed directly into the 
bone microenvironment through intratibial injection. 
 Bone organ cultures are well established models that are routinely used to study 
bone turnover. This model provides a link between animal and cell culture studies while 
avoiding the complicating effects of systemic factors (434). Various different bones have 
been used including femora (435), metatarsals (436), and most commonly calvaria (434, 
436, 437). The use of organ cultures to study bone metastasis has rarely been done, so here 
I will present a novel use of a well established technique. 
 Various in vivo models of bone metastasis exist (reviewed in (438, 439)) using a 
variety of different cell lines and injection sites.  In this project, I am interested in the 
influence malignant tumour cells exert on bone cell differentiation, survival and activity 
once these cells are in the bone microenvironment and not the process of metastasis itself. 
Therefore, efforts were made to develop and adapt the existing intratibial injection based 









 The aim of this chapter was to use organ cultures and animal experiments to design 
and set up ex vivo and in vivo models to study the interactions and cross-talk between 
osteolytic breast cancer cells and bone. The models would then be used to investigate the 
effect of the tumour cells on osteolysis in this chapter and the modulating action various 






4.4.1 Human MDA-MB-231 breast cancer cells induce osteolysis in MDA-MB-231 – 
mouse calvaria organ culture 
 To allow the investigation of crosstalk between tumour cells and bone cells ex vivo, 
the breast cancer – mouse calvaria organ culture (see Figure 4.1) was used. This method is 
an adaptation of the standard mouse calvarial organ culture and it was originally developed 
by Dr. Aymen I. Idris (440).  Briefly, calvaria were removed from 7 day old mice and cut into 
halves along the median sagittal suture. Each half was then placed onto iron mesh 
platforms in 48 well plates in the presence or absence of human MDA-MB-231 breast 
cancer cells. Media was refreshed every 48 hours for a period of 1 week. Calvarial halves 
were then fixed and analysed by μCT analysis. 
 
  Figure 4.1 Diagram of the cancer cell – mouse calvaria 
organ culture 






Figure 4.2 shows that factors produced by the human MDA-MB-231 breast cancer cells 
caused a significant loss in bone volume when co-cultured with mouse calvaria for 7 days, 
indicative of osteolytic bone damage (Figure 4.2 panel A). The extent of bone loss was 
quantified by µCT analysis (Figure 4.2 panel B), this showed that the presence of MDA In 
the wells significantly reduced calvaria bone volume by 46% (p<0.01). Wells were inspected 
at the end of the experient and it was found that in wells with no MDA-MB-231 cells 
present a number of mouse cells of mixed origin can be seen (Data not shown).  
  Figure 4.2. MDA-MB-231 human breast cancer cells cause osteolytic destruction of bone in human 
MDA-MB-231 - mouse calvaria organ culture. Panel A shows the effect of MDA-MB-231 cells on a mouse 
calvarial organ culture. Calvarial bones were isolated from 7 day-old mice, washed thoroughly in Hank’s 
balanced salt solution (HBSS) and divided into equal halves along the median sagittal suture. The separated 
half-calvariae were explanted onto surfaces of stainless steel rafts in 48-well plates containing αMEM with 
either nothing or 3 x 10
3
 MDA-MB-231 cells per well, seeded for 24 hours in advance. Media was refreshed 
every 48 hours for 7 days. Panel A shows representative microCT images of half-calvariae from the same 
mouse co-cultured with or without MDA-MB-231 cells. Panel B shows quantification of the bone volume in the 
calvaria halves by µCT analysis. Values in the graphs are means ± SD and are obtained from 4 independent 





4.4.2 Conditioned medium from MDA-MB-231 human breast cancer cells failed to 
induce osteolysis in femoral organ culture 
 Calvaria organ cultures allowed us to investigate the effect of tumour cells on flat 
bones; however long bones are a far more common site of metastasis. To investigate breast 
cancer-induced osteolysis in long bones ex vivo, an adaptation of the standard femoral 
organ culture was used. Femurs were extracted from 10 week old C57B6 mice and exposed 
to one of two different treatment sets. Either one femur was fixed straight away and the 
other left in αMEM, or both were placed into αMEM and one supplemented with 20% 
control conditioned medium and the other with 20% MDA-MB-231 conditioned medium. 
The media was refreshed every 48 hours and cultures were incubated for 2 weeks. 
Osteolysis was then analysed by μCT analysis. 
 





 Figure 4.4 shows that conditioned medium from MDA-MB-231 did not cause any 
significant change in either trabecular or cortical bone mass. Surprisingly, a minor and 
statistically non-significant increase in trabecular bone mass was observed in samples 
treated with MDA-MB-231 conditioned medium treatment. There was also no change in 
trabecular number, spacing, thickness or pattern factor (data not shown). 
 
Figure 4.4 Conditioned medium from MDA-MB-231 human breast cancer cells failed to induce 
osteolysis in femoral organ culture. Panels A and B show the effect of MDA-MB-231 cells on a mouse femoral 
organ culture. Both femurs bones were isolated from 12 week-old mice, washed thoroughly in PBS and explanted 
to 6-well plates before being divided into two treatment regimes. In the first regime one of the two femurs was 
fixed straight away, and the other placed in αMEM for 2 weeks. In the second regime both femurs were placed in 
αMEM for 2 weeks and treated with either 20% Control or MDA-MB-231 conditioned medium. Media was 
refreshed every 48 hours for 14 days. Panel A shows representative microCT images of femurs from two mice, 
one following treatment regimen 1, and the other regimen 2. Panels B and C show percent bone volume of 
cortical bone (B) or trabecular bone (C) determined by μCT analysis. Values in the graphs are means ± SD and are 






4.4.3 Human MDA-MB-231 breast cancer cells failed to induce osteolysis following 
intratibial injection in humanised Balb/c mice 
 Cancer-induced osteolytic bone damage associated with human breast cancer cells 
was investigated in humanised mice using an intratibial injection model. Initial plans 
involved using the same MDA-MB-231 cells that had been used for much of the in vitro 
work. Either 10,000 or 100,000 cells were injected into the right tibia of three 6 week old 
female Balb/c Nude mice. These mice were monitored for any discomfort in the injected leg 
and analysed by in vivo μCT analysis once a week for 8 weeks. To avoid analysing the bone 
physically damaged by the act of injection only the first 30 sections below the tibial growth 
plate were analysed. This experiment was designed to give us an overview of how the 
MDA-MB-231 cells would grow in the tibia, the rough level of bone destruction they would 
cause and to help decide a timeframe for any therapeutic treatment in future work. 
 Figure 4.5 A shows that over the course of the 8 weeks of the experiment there was 
no obvious damage to either the cortical or trabecular bone caused by the MDA-MB-231 
cells regardless of the number of cells injected. Using μCT analysis to compare the injected 
leg to the uninjected leg over the course of the experiment show that at no point is there 
any significant difference in trabecular bone volume (Figure 4.5 B and C), number, 
separation or trabecular pattern factor (data not shown). The only possible difference was 
actually a slight, and not significant, increase in bone mass when compared to the 
uninjected leg. 
 As the MDA-MB-231 cells had failed to cause any osteolytic bone destruction I 
decided to change the cell line used. The next cell line tested was an MDA-MB-231 variant 
cell line previously determined to metastasis to bone (441). Again this MDA-MB-231-BS cell 
line was injected into the right tibia of three 6 week old female Balb/c nude mice and two 
seeding densities used; 10,000 cells or 100,000 cells per mouse. Mice were again monitored 
and scanned by in vivo μCT once a week for 8 weeks; unfortunately due to a technical error 
data collected in week 1 was not usable. Figure 4.6 A shows that after 8 weeks there was 
again no obvious visual bone damage. Using detailed μCT analysis showed there was no 
difference between the injected or uninjected legs in bone volume (Figure 4.6 B and C), or 
any of the trabecular attributes measured (data not shown) and if anything a slight gain in 






Figure 4.5 MDA-MB-231 cells did not cause osteolytic lysis when intratibially injected. 6-week old female Balb/c nude mice received 




 MDA-MB-231 breast cancer cells into their right leg. Tibia were then analysed by in vivo microCT every 7 
days. Animals were sacrificed at week 8. Panel A shows representative microCT images of tibia throughout the study. Panels B and C show the 
percent bone volume of the tibia injected with 1x10
4
 (B) or 1x10
5 
(C) MDA-MB-231 cells as a percentage of the percent bone volume of the 







Figure 4.6 Bone seeking MDA-MB-231 cells did not cause osteolytic lysis when intratibially injected. 6-week old female Balb/c nude mice 




 bone seeking MDA-MB-231 breast cancer cells into their right leg. Tibia were then analysed by in vivo 
microCT every 7 days. Animals were sacrificed at week 8. Panel A shows representative microCT images of tibia throughout the study. Panels B and C 
show the percent bone volume of the tibia injected with 1x10
4
 (B) or 1x10
5 
(C) bone seeking MDA-MB-231 cells as a percentage of the percent bone 






4.4.3 Mouse 4T1 breast cancer cells caused osteolysis following intratibial injection in 
wild type Balb/c mice 
 The effect of cancer-induced osteolytic bone damage associated with breast cancer 
cells was investigated in wild type mice using the syngeneic mouse 4T1 cells.  An initial 
seeding density of 5000 4T1 cells was chosen before cells were injected into the right tibia 
of three female 6 week old Balb/c wildtype mice. Mice were analysed by in vivo μCT 
analysis twice a week. This was planned to last 8 weeks, however after 3 weeks many of the 
mice were found to have lost the use of their right hind limbs and so all were culled. 
 Figure 4.7 shows that extensive osteolysis occurred in the injected legs over the 
course of the experiment. Visually, this appears to start at week 2 and leads to almost total 
loss of both trabecular and cortical bone in the injected legs by the end of week 3. μCT 
analysis showed that while no bone loss had occurred after one and half weeks, by week 2 
4T1 injected legs had 43% less bone (p<0.05) than the uninjected control, this increased to 
76% (p<0.01) and 80% (p<0.01) bone loss by weeks 2.5 and 3 respectively. As expected, 
trabecular number fell in line with the overall loss of bone. At week 1.5 there were 6% less 
trabeculi in the injected legs, falling further to 44% (p<0.05), 73% (p<0.01) and 79% 
(p<0.01) less after 2, 2.5 and 3 weeks. Trabecular thickness did not change at first 
remaining roughly equal in injected and uninjected legs until week 2.5 when it had 
decreased by 16% (p<0.05) in the 4T1 injected tibia, and by week 3 it had fallen by 35% 
(p<0.01). Trabecular pattern factor increased rapidly and by the end of the experiment had 
reached close to 500% (p<0.01) of the value of the pattern factor in the uninjected legs, 
indicative of significant loss of trabecular connectivity. 
 Figure 4.7 F and G show detailed ex vivo μCT modelling of representative injected 
and uninjected legs from the 4T1 experiment. The uninjected leg shows typical bone 
architecture for a 9 week old female Balb/c mouse. On the other hand, the leg injected with 
4T1 cells shows not just a loss of bone, but also of general bone architecture, with large 
areas where bone seems to have been pulled or pushed away from the tibia. The sectioned 
view shows the normal contingent of trabeculi within the uninjected leg, while the 4T1 




Figure 4.7 4T1 cells cause osteolytic lysis when intratibially injected. 6-week old female Balb/c mice 
received intratibial injections of 5x10
4
 4T1 mouse breast cancer cells into their right leg. Tibia were then analysed by 
in vivo μCT every 7 days. Animals were sacrificed at week 3. Panel A shows representative μCT images of tibia 
throughout the study. Percent bone volume of the 4T1 injected tibia is shown in Panel B, trabecular number in 
panel C, trabecular thickness in panel D and trabecular pattern factor in panel E. All are shown as a percentage of 
the same feature in the uninjected tibia through the course of the experiment. Panels F and G show representative 
images from detailed ex vivo μCT analysis of the tibia, either whole (F) or artificially cut to reveal trabecular bone 







 Osteolytic tumour cells are known to disrupt the bone remodelling cycle leading to 
imbalances that cause an overall loss of bone. The aim of this chapter was to create ex vivo 
and in vivo models to be used for the modelling of interactions between breast cancer and 
bone cells. Unlike chapter three, the aim was not to look at specific bone cell types, but 
instead to see the overall effects the tumour cells would have on bone mass, integrity and 
architecture. 
 This chapter demonstrates that while it was a general property of osteolytic tumour 
cells and conditioned medium to cause increases in osteoclast numbers in vitro (see 
chapter 3), this did not necessarily translate to ex vivo or in vivo settings. While adaptations 
to calvarial organ cultures were successful, it proved far trickier to fashion good models 
using either femoral organ cultures or in vivo intratibial models. 
 Bone explant cultures have been used since the 1920s (442) and in particular 
calvarial organ cultures and long bone organ cultures have been in use since the 1970s 
(443, 444) and 1980’s (445), as well as more recently by Mundy et al at the turn of the 
century (446, 447). While many groups have in the past used organ cultures to study bone, 
very few groups have used these models to assess breast cancer-induced osteolysis or used 
cancer cells - organ co-culture systems combined with microCT analysis. This had made it 
difficult to see how our results fit with the existing literature. Some groups however have 
used conditioned medium to treat organ cultures. Of particular interest was Tabuenca et al 
(1995) who looked at the effect of conditioned medium from 5 breast cancer cell lines, 
including MDA-MB-231 and MCF7 cells, on 3 day old mouse calvaria (448). They found that 
the breast cancer cell conditioned medium led to an increase in bone resorption measured 
by release of 45Ca. This is in broad agreement with our finding that culturing MDA-MB-231 
cells below mouse calvaria leads to a loss of bone and osteolytic lesions. 
 There are two possible explanations for the bone loss observed in calvaria when 
they are cultured with human MDA-MB-231 breast cancer cells. The most likely is that in a 
similar way to that seen in the in vitro results of Chapter 3, the bone loss is caused by 
factors released by the MDA-MB-231 cells effecting bone cells. This means not only an 




environments in the early weeks after birth, the effects on osteoblasts may also be 
particularly important. MDA-MB-231 conditioned medium inhibited osteoblast 
differentiation and function while at the same time stimulating RANKL production. The 
overall effect of this is that in the co-cultured calvaria half MDA-MB-231 cells stimulate 
osteoclast formation, while inhibiting osteoblast differentiation and function and at the 
same time causing osteoblasts to further increase osteoclastogenesis through an increase 
in RANKL production. Future histological analysis of the calvarial bone from these 
experiments is needed to conclusively establish whether enhanced bone resorption or 
inhibition of bone formation (or both) is the mechanism behind the osteolysis observed. An 
alternative explanation for the bone loss seen is that changes in pH are caused by the 
tumour cells and this leads to a more acidic environment and it is this that causes an 
increase in osteoclast number. It is less likely that this could fully explain the extent of bone 
loss observed, and even if it does play a part this is an effect that would also occur with 
osteolytic bone metastases in vivo and so could be seen as a positive point for this model. 
 The fact that MDA-MB-231 conditioned medium failed to cause any bone loss in 
the femoral organ culture model was disappointing. This could be due to a variety of 
confounding factors. The most plausible explanation is the rate of turnover in the femur is 
significantly slower than that generally observed in the calvarial bone. Secondly, it may be 
that the factors in the conditioned medium were simply not reaching the bone cells either 
through the culture not keeping the cells in the organ alive, or through them being unable 
to penetrate the organ. This is countered by the fact that the legs appeared to be healthy 
through the course of the experiment, and that a variety of cell types were seen growing in 
the wells; though its possible they were from external connective tissue. Another 
explanation is that the concentrations of factors were simply not high enough or the lack of 
active production from cells meant that they did not have any great effect. It may be that 
using conditioned medium is not an appropriate technique for organ cultures, although 
both Tabuenca et al (1995) and Yi et al (2002) have successfully used it in studies of the 
more easily accessible calvaria (448, 449). Further work using a similar co-culture to that 
used with calvaria above would determine if this is true. The final explanation would be 
that the factors produced by the MDA-MB-231 cells used in this study have a different 
overall effect in long bones and particularly long-bone derived osteoblasts. Instead of 




osteoclastogenesis; this would then possibly explain why there is a non-significant growth 
in both trabecular and cortical bone mass. However, this seems unlikely given the results 
seen in chapter three and any increase is most likely due to variation and/or technical error. 
 There are many and varied in vivo models of bone metastasis, from autochthonous 
models, either naturally occurring or in GM mice (450), to mammary fat pad (451), 
intracardiac (452), or tail vein injections (453) and of course intraosseous injection models 
(454, 455).  As we were not interested in the mechanisms of metastasis and wanted to 
ensure we had a 100% metastasis rate within a controlled location we chose to use an 
intraosseous model, in this case by intratibial injection. We were expecting MDA-MB-231 
cells to proliferate within the bone marrow and cause osteolytic bone destruction following 
injection at the two injection densities chosen. This is an established effect within the 
literature, for example, Jones et al 2010 injected 100,000 MDA-MB-231 cells into the tibia 
of 6 week old female SCID mice (454). They demonstrated osteolysis noticeable on a 
radiograph by day 21 and severe loss of bone when mice were terminated at day 49. 
Gordon et al 2005 demonstrated similar results injecting 10,000 MDA-MB-231 cells into 
Balb/c nude mice and achieving extensive osteolytic lesions by day 28 (456), as have a 
variety of other groups (457-460). In many cases these groups have used identical protocols 
to ours and obviously it was disappointing not to be able to replicate these effects. 
However, Bendre et al 2005 also found that when MDA-MB-231 cells were injected into the 
tibia of nude mice they did not proliferate or cause bone destruction (304). Therefore it 
seems possible that some clones of the MDA-MB-231 cell line are unable to grow within the 
bone microenvironment and this may explain why our own line did not cause any bone 
destruction. 
 It was thought that using a bone seeking variant of the MDA-MB-231 cell line (441) 
should overcome this problem. Unfortunately that too did not cause any visible osteolysis 
over the course of our experiment. While it is possible that these cells could only grow in 
bone after intracardiac injection, as was done by Kang et al 2003, this seems unlikely. When 
combined with the failure of our own MDA-MB-231 intratibial injections, the most probable 
explanation is that something in our protocol causes the MDA-MB-231 cells, and their sub 
types, to undergo apoptosis either prior to or during the Intratibial injection. The most 




immune response in our nude mice. Another possible explanation is that the low resolution 
of our in vivo μCT analysis masked any bone loss, as it proved difficult to see trabecular 
bone using 18micron scans. This also seems unlikely as by the end of 8 weeks extensive 
cortical bone loss should also have occurred.  Additionally, in a parallel experiment by 
another member of the group mice injected with another MDA-MB-231 variant cell line 
were left for 14 weeks with no visible bone destruction occurring (data not shown). 
Whether or not MDA-MB-231 cells proliferate in the bone could be determined by 
histological analysis, but it was decided that time could be used more productively. It is 
unfortunate that MDA-MB-231 cells proved unworkable for intratibial injection as that 
would have provided a more direct link between much of the in vitro and ex vivo work and 
our eventual in vivo model.  
 Mouse 4T1 breast cancer cells were chosen as the next best alternative. They had 
several advantages over other choices, firstly 4T1 enhanced RANKL and M-CSF-induced 
osteoclast formation in 4T1 - BM derived macrophage co-cultures (see Chapter 3). 
Secondly, they are also an established cell line for bone metastasis studies (415, 461) and 
lastly, as a mouse derived cell line they allowed the use of wild type Balb/C mice which is 
advantageous for several reasons. Nude mice do not have competent immune systems and 
as bone homeostasis is in some part regulated by immune cells (including the T-cells nude 
mice specifically lack) (462). This means that they do not have a normal bone remodelling 
cycle or bone mass. In fact in a separate study I showed that nude mice had 30-50% lower 
trabecular bone mass compared to their wild type counterparts (see Figure 4.8). Figure 4.7 
shows that intratibial injection of 4T1 cells caused extensive bone destruction and in just 3 
weeks an initial injection of only 5000 cells had removed most bone. In agreement with 
these findings, Thiolloy et al 2009 found that 10,000 4T1 cells began to breach cortical bone 
after 9 days (463). This is a far greater level of destruction than is practical for our use. By 
three weeks there was no trabecular bone left and even most of the cortical bone was 
absent. To remedy this lower initial cell numbers were considered for future work, but it 
was decided that 5000 cells was the lowest usable initial cell number before variation in 
counting or injecting could cause too much variability in results. It was therefore 
determined that the 4T1 intratibial injection model, while not perfect, could be used as it 
was, but with any experiments terminated by day 14. This would ensure that there would 




therapeutic treatment can be started in our animals until they have healed from the 
intratibial injection (day 7), which leaves only 7 days for any therapeutic intervention 

















In conclusion, while there is still further work needed to set up more advanced ex 
vivo and in vivo models for our use, in this study I successfully developed models that were 
usable for work presented later in this thesis. Ex vivo we have the fully functional adapted 
calvarial organ culture, where the results of any therapeutic studies can be measured both 
by μCT analysis of the bone, histology, and by measurement of the viability of the MDA-
Figure 4.8 CD1 Nude mice have less trabecular bone than 
corresponding CD1 WT mice.  Tibia were dissected out of twelve week old 
CD1 WT or Nude mice and submitted for μCT analysis. Panel A shows 
representative three-dimensional reconstructions of the trabecular bone of 
CD1 WT and nude tibia. Percent bone volume of the CD1 WT and CD1 nude 
tibia are shown in Panel B. Values are means ± standard deviation. 3 mice per 




MB-231 cells. In vivo, a 4T1 intratibial injection model is fully functional with extensive 
osteolytic destruction demonstrated, and a timeframe for any therapeutic intervention 
treatments determined. In the future, work should be done to establish both a working ex 


















 RANKL and M-CSF play important roles in osteoclast formation, survival and 
acitivity. This chapter aimed to examine the role of exogenous and breast cancer derived 
M-CSF and RANKL in cancer-induced osteoclastogenesis in vitro. First, qPCR studies in this 
chapter showed that human MDA-MB-231 breast cancer cells express M-CSF mRNA, but 
not RANKL mRNA. In contrast, mRNA expression of RANK receptor was detected, as was 
low expression of the M-CSF receptor C-FMS. 
 Co-culture and conditioned medium experiments were carried out to determine 
whether or not the presence of MDA-MB-231 cells was sufficient to support osteoclast 
formation and survival in the absence of the key osteoclastic cytokines M-CSF or RANKL. 
Confirming the results shown Chapter 3, these experiments showed that when RANKL was 
absent in MDA-MB-231 – BM derived macrophage co-cultures no osteoclasts were formed 
and all existing osteoclasts would undergo apoptosis. When M-CSF was absent the vast 
majority of cells underwent apoptosis, regardless of whether or not the experiment was 
investigating osteoclast formation or survival. This demonstrated that human MDA-MB-231 
breast cancer cells do not produce a sufficient amount of RANKL or M-CSF to support 
osteoclast formation and survival in our model. 
 Through the use of conditioned medium it was found that treating MDA-MB-231 
cells with M-CSF and/or RANKL enhanced their ability to stimulate osteoclast formation. 
This was particularly profound when MDA-MB-231 cells were treated with RANKL, greatly 
enhancing the size and nuclearity of the osteoclasts subsequently produced. This confirms 
our finding that the human MDA-MB-231 breast cancer cells used in this study express 
RANK and C-FMS. This also implies that RANK and M-CSF-mediated signalling in breast 
cancer cells may play an important positive feedback role in breast cancer-induced 
osteoclastogenesis.  
 MDA-MB-231 produced M-CSF and RANKL were not sufficient to explain the 
osteoclast stimulating effects previously observed. Therefore qPCR was used to look for 
other osteolytic factors produced by the tumour cells. A range of different cytokines and 
growth factors were produced by MDA-MB-231 cells including TGFβ, PTHrP, IL-1 and IGF-1. 




unlikely to be the key factors responsible for the breast cancer-induced osteoclastogenesis 
observed in our models. However, signalling pathways downstream of RANK and M-CSF 
within tumour cells themselves merits further investigation in a future project. A range of 
factors known to enhance osteoclastogenesis are produced by the osteolytic cancer cells 






 Accumulating evidence suggests that a wide range of cytokines and growth factors 
are produced by tumour cells resulting in osteolytic bone metastasis (175, 180, 197, 464). 
These paracrine signals have a complex and multi-faceted effect on bone cells, and no one 
factor is likely to be the overall single cause of cancer induced osteolysis. 
RANK ligand and M-CSF play important roles in osteoclast formation, survival and 
activity (237, 238).  M-CSF is expressed by osteoblasts and binds to the transmembrane 
receptor c-FMS found on both osteoclast precursors and mature osteoclasts (465). This 
stimulates both osteoclast precursor differentiation and osteoclast survival. RANKL is a 
membrane bound cytokine from the TNF family expressed mainly on the surface of 
osteoblasts, osteocytes, mammary gland epithelial cells, T-cells and various other stromal 
cells (433). It is also less commonly found in a secreted soluble form (466, 467). It binds to 
the RANK receptor expressed by osteoclast precursors initiating their differentiation and 
fusion into mature multi-nucleated osteoclasts (209, 224). 
 As Chapters 3 and 4 demonstrated, osteolytic tumour cells strongly enhance the 
formation, and function of osteoclasts. The most obvious possible way in which this effect 
could be mediated would be through the production of either M-CSF and/or RANKL by 
tumour cells. While Chapter 3 showed that in the absence of RANKL MDA-MB-231 cells 
could not support osteoclast formation, various tumour cells have been shown to produce 
these factors in previous studies, and both have been linked to the osteolytic effect of bone 
metastases (228-231, 244). MDA-MB-231 human breast cancer cells strongly enhanced 
osteoclast activity both in vitro and in vivo, so here we explored RANKL and M-CSF 
expression by these cells, and whether this effects osteoclast formation and survival. 
 In addition to the ligands, the receptors themselves RANK and C-FMS, have been 
linked to the metastasis of breast cancer and other cancers to bone (232, 233). In 
particular, RANK expression has been linked to shorter survival times and accelerated 
metastasis to bone (234). Here we investigate whether signalling through these receptors 







 The aim of this chapter was first to investigate whether MDA-MB-231 cells produce 
M-CSF and to determine if this could support osteoclast formation and survival in our in 
vitro model. Chapter 3 showed that MDA-MB-231 cells could not support osteoclast 
formation in the absence of RANKL, but RANKL expression was not investigated. So here I 
also aim to confirm this result, to investigate RANKL expression by MDA-MB-231 cells and 
wheather or not it can support osteoclast survival. The Second aim of this chapter was to 
determine if RANK and C-FMS receptors were expressed by MDA-MB-231 cells, and if 
signalling through these receptors could modulate the ability of these cancer cells to 
enhance osteoclast formation. Finally, this chapter aimed to determine if other candidate 
factors were being produced by MDA-MB-231 cells. These will then be investigated further 

















5.4.1 Human MDA-MB-231 breast cancer cells express M-CSF but not RANKL 
 To determine if the MDA-MB-231 cells used in this study express RANKL and M-CSF 
we performed qPCR.  Human PBMC mRNA was used as a positive control. Figure 5.1 shows 
human MDA-MB-231 breast cancer cells express very low RANKL mRNA (0.04% of PBMC 
expression). In contrast, M-CSF was detected and at the strikingly high level of 19.7% of the 
level seen in the PBMC positive control.  
 
Figure 5.1 MDA-MB-231 cells express M-CSF but not RANKL. Panels 
A and B show the expression of M-CSF (A) and RANKL (B) in MDA-MB-231 
cells and PBMCs as measured by quantitative rt-PCR followed by qPCR. 
Transcript numbers are corrected for expression of 18s RNA and displayed 
as a percentage of PBMC expression. Values in the graphs are mean ± SD 





5.4.2 Human MDA-MB-231 breast cancer cells express C-FMS and RANK receptors 
 To determine whether or not the MDA-MB-231 cells used in this study may 
themselves respond to RANKL and M-CSF treatment we performed qPCR. Human PBMC 
mRNA was used as a positive control. As shown in Figure 5.2, both receptors were detected 
in the human MDA-MB-231 breast cancer cells, but at levels far lower than those seen in 
the PBMC positive control. RANK was relatively high at 20.6% of the PBMC mRNA, while C-
FMS was found at only 0.0001% of the PBMC mRNA. C-FMS while extremely low was 
however clearly above blank negative controls and so is taken to represent a positive result.  
Figure 5.2 MDA-MB-231 cells express M-CSF ligand and RANK 
receptor Panels A and B show the expression of M-CSF receptor C-FMS 
(A) and RANK (B) in MDA-MB-231 cells and PBMCs as measured by 
quantitative rt-PCR followed by qPCR. Transcript numbers are corrected 
for expression of 18s RNA and displayed as a percentage of PBMC 
expression. Values in the graphs are mean ± SD and are obtained from 





5.4.3 Addition of MDA-MB-231 cells or conditioned medium to BM cultures is not 
sufficient to support osteoclast formation 
 We wished to determine if the M-CSF and/or RANKL, produced by the MDA-MB-
231 cells was sufficient to support the formation of osteoclasts in cultures of BM derived 
macrophages.  To achieve this we cultured M-CSF generated macrophages either in a co-
culture with or without 300 MDA-MB-231 cells or treated with 10% control or MDA-MB-
231 conditioned medium. These cultures were then exposed to RANKL (100 ng/ml) and M-
CSF (25 ng/ml), RANKL alone, M-CSF alone or nothing for 72 hours. Figure 5.3 shows that 
when both RANKL and M-CSF are present MDA-MB-231 cells or conditioned medium 
increased osteoclast formation, as confirmed in Chapter 3. Also as shown in Chapter 3 
figure 3.7, when RANKL was absent from the culture, only a very few mono-nucleated 
TRAcP positive cells and no osteoclasts were observed in the presence or absence of human 
MDA-MB-231 cells or conditioned medium. No change in the number of these TRAcP 
stained cells was present.  In the absence of M-CSF, by the end of the culture the majority 
of cells have undergone apoptosis. Many of the remaining cells are TRAcP positive but all 
are mono-nucleated cells, with no mature osteoclast present. There is no difference in the 
number of TRAcP positive cells between the two cultures; however there does appear to be 
more macrophages present in the MDA-MB-231 treated cultures. Though, it is difficult to 
be sure due to the presence of the MDA-MB-231 cells, which cannot be distinguished from 
macrophages by phase contrast microscopy without the aid of specific markers. When 
neither RANKL nor M-CSF are present, very few macrophages and no TRAcP positive mono- 




Figure 5.3 Addition of MDA-MB-231 cells or conditioned medium to BM cultures is not 
sufficient to support osteoclast formation. Osteoclast precursor macrophages were seeded and 
allowed to attach overnight. Cultures then had 300 MDA-MB-231 cells, MDA-MB-231 conditioned 
medium (10%), control conditioned medium 10% or nothing added.  Cultures were untreated, or had 
M-CSF (25 ng/ml), RANKL (100 ng/ml), or both added. Media was refreshed after 48 hours and 
cultures fixed after 72 hours. Multi-nucleated osteoclasts were visualised following TRAcP staining. 
Representative photomicrographs of the cultures are shown. Data is from three independent 




5.4.4 Addition of MDA-MB-231 cells or conditioned medium to osteoclast cultures is 
not sufficient to support osteoclast survival  
 To determine the effect of breast cancer derived factors on osteoclast survival, 
RANKL and M-CSF-stimulated osteoclasts were generated and then were exposed to MDA-
MB-231 cells or conditioned medium from these cells in the presence and absence of 
RANKL or M-CSF for 48 hours. Osteoclasts were identified using TRAcP staining. Figure 5.4 
shows that MDA-MB-231 cells and conditioned medium increased the number of 
osteoclasts in the presence of both RANKL and M-CSF. When mature osteoclasts were 
treated with only M-CSF the vast majority of osteoclasts underwent cell death. There are 
clearly many TRAcP stained cells still present but all of the large multi-nucleated osteoclasts 
have gone, as have most of the smaller osteoclasts, exact numbers were not counted. The 
MDA-MB-231 cell and conditioned medium treatments did not affect either the number of 
osteoclasts remaining or the number of TRAcP stained cells present. In the cultures where 
only RANKL treatment was present, many of the cells, osteoclast and macrophage, have 
undergone cell death. Numerous remaining cells were TRAcP positive but no osteoclasts 
were present. The presence of MDA-MB-231 cells or conditioned medium had no effects on 
osteoclast survival or the number of TRAcP positive cells in these cultures. Cultures where 





Figure 5.4 Addition of MDA-MB-231 cells or conditioned medium to BM cultures is not 
sufficient to support osteoclast survival. Osteoclast precursor macrophages were seeded and 
allowed to attach overnight in the presence of RANKL (100 ng/ml) and M-CSF (25 ng/ml). Cultures 
were allowed to develop for 96 hours or until a significant number of osteoclasts had formed. All 
media was then removed, cells washed in PBS and then 300 MDA-MB-231 cells, MDA-MB-231 
conditioned medium (10%), control conditioned medium 10% or nothing added. Cultures were 
either left untreated, or had M-CSF (25 ng/ml), RANKL (100 ng/ml), or both added. Cultures were 
fixed after a further 48 hours. Multi-nucleated osteoclasts were visualised following TRAcP staining. 
Representative photomicrographs of the cultures are shown. Data is from three independent 




5.4.5 Exposure to RANKL and M-CSF enhances the ability of MDA-MB-231 human 
breast cancer cells to stimulate osteoclast formation 
 As MDA-MB-231 cells expressed mRNA for both RANK and C-FMS, we wished to 
establish if pre-exposure of these cells to RANKL or M-CSF affected their ability to influence 
osteoclast formation. We treated MDA-MB-231 cells with RANKL (100 ng/ml), M-CSF (25 
ng/ml) or both for 48 hours and then collected the conditioned medium. Osteoclast 
cultures were then treated with these various conditioned medium at a concentration of 
10% for 72 hours. Osteoclasts were then identified using TRAcP staining. Figure 5.5 shows 
that conditioned medium from untreated MDA-MB-231 cells led to the formation of more 
and larger osteoclasts when compared to either the control conditioned medium 
treatment, or the untreated osteoclast cultures. This effect was augmented when the 
conditioned medium came from MDA-MB-231 cells treated with M-CSF, RANKL or both. 
Though an increase was also noted when control conditioned medium from an M-CSF 
treated flask was used. MDA-MB-231 conditioned medium from cells treated with M-CSF 
provided only a minor boost over that from the untreated cells, while cells treated with 
RANKL, or both provided a far greater increase. In fact when conditioned medium came 
from cells treated with both M-CSF and RANKL cultures started to look comparable to MDA-
MB-231 – osteoclast co-cultures. There was a particularly marked increase in the size and 






Figure 5.5 Exposure of MDA-MB-231 to RANKL and M-CSF enhanced their ability to stimulate osteoclast formation. 
Osteoclast precursor macrophages were seeded and allowed to attach overnight in the presence of RANKL (100 ng/ml) and M-CSF 
(25 ng/ml). Cultures were then untreated, had 300 MDA-MB-231 cells added, or had control or MDA-MB-231 conditioned medium 
(10%) added. This conditioned medium came from control or MDA-MB-231 cultures untreated or treated with M-CSF (25 ng/ml), 
RANKL (100 ng/ml), or both. Media was refreshed ever 48 hours and cultures fixed after 72hours. Multi-nucleated osteoclasts were 
visualised following TRAcP staining. Representative photomicrographs of the cultures are shown. Data is from three independent 




5.4.6 Expression of osteolytic factors by human MDA-MB-231 breast cancer cells is 
unaffected by RANKL or M-CSF 
To investigate other potential tumour produced factors that may be involved in 
MDA-MB-231 induced osteolysis I measured the mRNA expression of a number of known 
osteolytic factors. As shown in Figure 5.6, TGF, PTHrP, IL1, uPA and IGF-1 were expressed 





As Figure 5.5 had suggested that RANKL and M-CSF treatment of MDA-MB-231 cell 
may increase their capacity to induce osteoclast formation, we studied the effect RANKL 
and M-CSF had on the production of tumour derived osteolytic factors. The mRNA 
expression of TGF, PTHrP, IL1, uPA and IGF-1 was measured in the presence and absence 
of RANKL and M-CSF. Figure 5.7 shows that RANKL (100 ng/ml) and M-CSF (25 ng/ml) had 
no significant effects on the mRNA expression of these factors after 16 hours of continuous 
treatment. 
Figure 5.6 MDA-MB-231 cells express a range of pro-osteolytic factors. The 
expression of TGFβ, TNFα, PTHrP, IL1β, MMP9, uPA and IGF-1 in MDA-MB-231 cells as 
measured by quantitative rt-PCR followed by qPCR. Transcript numbers are corrected for 
expression of 18s RNA and displayed as ng/ul mRNA. Values in the graphs are mean ± SD and 







Figure 5.7 Pro-osteolytic factors produced by MDA-MB-231 cells are not affected by RANKL and M-CSF treatment. The expression of IL1β  
(A), TGFβ (B), PTHrP (C), and IGF-1 (D) in MDA-MB-231 cells untreated or treated with RANKL (100 ng/ml) and M-CSF(25 ng/ml) as measured by 
quantitative rt-PCR followed by qPCR. Transcript numbers are corrected for expression of 18s RNA and displayed as ng/ul mRNA. Values in the graphs 






 RANKL and M-CSF are known to be the key factors behind the regulation of 
osteoclast formation and survival (433, 465). As bone metastases from a variety of tumours 
cause osteolysis, it was hypothesised that tumour derived RANKL and M-CSF may play an 
important role in cancer-induced osteoclastogenesis. The aim of this chapter was to 
establish whether RANKL and M-CSF were secreted by the human MDA-MB-231 breast 
cancer cells used in this study, and to determine if tumour derived RANKL and M-CSF play a 
significant role in cancer-induced osteoclastogenesis. 
 The data presented in this chapter demonstrates that while MDA-MB-231 express 
M-CSF mRNA, these cells do not produce RANKL. In osteoclast cultures, MDA-MB-231 cells 
were not sufficient to replace either RANKL or M-CSF and in their absence could not 
support osteoclast formation or survival. In contrast, the receptor RANK was highly 
expressed in MDA-MB-231 cells and they responded to RANKL treatment by increasing 
conditioned media effect on osteoclastogenesis, most likely through an increase in the 
production of unkown osteolytic factors. 
 Several groups have previously hypothesised that RANKL and/or M-CSF production 
from tumour cells contributes to osteolytic bone metastases. Some have even looked 
specifically at MDA-MB-231 cells with mixed results. Mancino et al (2001), Park et al (2003) 
and Ohshiba et al (2003) found similar results to that presented here, that MDA-MB-231 
cells do not express or secrete RANKL (244, 425, 468). In contrast, Nicolin and Narducci 
(2010) report that they found basal levels of RANKL from MDA-MB-231 cells (469). As for 
M-CSF, we found a significant amount was produced, as did Mancino et al (2001), Gallet et 
al (2004), and Pederson et al (1999) (228, 244, 464). This suggests that M-CSF may play a 
significant role in breast cancer induced osteolysis. 
 While the production of M-CSF by MDA-MB-231 cells is confirmed, whether it is 
actively secreted by these cells in the metastatic bone environment is another matter. 
Work presented here shows that MDA-MB-231 cells could not replace the cytokine itself in 
osteoclast cultures. Neither co-culture nor conditioned medium were able to support the 
formation of osteoclasts in the absence of M-CSF. This is the opposite result of that found 




cells allowed the formation of osteoclasts upon the addition of RANKL. As my work involved 
the use of M-CSF generated bone marrow macrophage, two possible reasons for this 
discrepancy are possible. Firstly, it may be that our M-CSF generated bone marrow 
macrophages are more sensitive to the presence of M-CSF as they have been cultured in 
high concentrations (100 ng/ml) for 2 -3 days, and so the relatively small amount produced 
by the MDA-MB-231 cells is not sufficient for their survival. The other possibility is that 
MDA-MB-231 cells do not secrete M-CSF, and Mancino et al’s results are explained by the 
presence of a variety of other bone cells such as bone marrow stromal cells that are known 
to produce M-CSF. Work by Pederson et al (1999) suggests that M-CSF was present in MDA-
MB-231 conditioned medium and so it seems likely that the first explanation is true. 
 Osteoclast survival was also unaffected by the presence of MDA-MB-231 cells or 
conditioned medium when M-CSF was absent. Once M-CSF is removed from the cultures 
the vast majority of mono- and multi-nucleated cells seem to have undergone cell death, 
both in the MDA-MB-231 treated and untreated cultures. No difference in the number of 
surviving cells, let alone osteoclasts was noted. Again this suggests either that the M-CSF 
present in the MDA-MB-231 cells is not secreted, or is not sufficient to permit the survival 
of these M-CSF dependent cells. In the survival experiments, when both M-CSF and RANKL 
were absent cultures were identical to those where only M-CSF was absent. This supports 
the hypothesis that M-CSF is vital for these cells survival, as the absence of the key 
osteoclast survival factor (RANKL) made no further difference to the cultures.  
 When RANKL alone is absent from either the osteoclast formation or survival 
experiments there was again no difference between the MDA-MB-231 treated and 
untreated cultures. This was expected since no expression of RANKL was detected in MDA-
MB-231 cells. However Lau et al (2006) have suggested that MDA-MB-231 cells are capable 
of inducing RANKL independent osteoclast formation (426), we observed no evidence to 
support this. As for survival, while there were a very few small osteoclasts apparent in the 
MDA-MB-231 treated cultures, this was also true for the untreated cultures with no 
differences noticed. This shows that MDA-MB-231 cells do not support osteoclast 
formation or survival either through RANKL dependent or independent mechanisms. 
 We next explored the possibility that RANKL and M-CSF in the bone 




studies have shown that RANK expression is associated with bone metastasis development, 
tumour migration and poor survival rate in breast cancer patients (232, 234). Here we show 
that exposure of MDA-MB-231 cells to RANKL prior to addition to BM cultures enhances the 
ability of these cells to increase osteoclast formation and size. This RANKL stimulated 
conditioned medium also leads to larger and more nucleated osteoclasts, in a similar 
fashion to osteoclast–MDA-MB-231 co-cultures; this was also, to a lesser extent, true for M-
CSF. This suggests that one reason cells are more efficient than conditioned medium 
treatment at increasing osteoclast formation is that the MDA-MB-231 cells are also 
exposed to RANKL and M-CSF. However as MDA-MB-231 cells only produce trace levels of 
C-FMS and control conditioned medium also appeared to respond to M-CSF, this may be a 
false positive. The most successful conditioned medium when it comes to increasing 
osteoclast formation was from cells treated with both RANKL and M-CSF, and there was no 
response to control conditioned medium in this case.  It therefore seems possible that 
MDA-MB-231 cells may contain an alternative M-CSF receptor such as V-FMS, and M-CSF 
signalling can enhance the production of osteolytic factors.  
While M-CSF and RANKL signalling in MDA-MB-231 cells is important and will be 
thoroughly investigated in another project, other factors produced by the MDA-MB-231 
cells are of more interest to this thesis. qPCR was used to determine the expression levels 
of a range of potential candidate genes, as well as whether or not any of them were 
enhanced if they came from cells treated with RANKL and M-CSF. Expression was found for 
5 of the 7 genes, with no TNFα or MMP-9 found, but none were affected by RANKL and M-
CSF treatment. The genes with the highest expression levels were TGFβ, PTHrP and IL-1β. 
IGF-1 and uPA showed far lower but still significant expression levels. This suggests that 
multiple growth factors and cytokines produced by MDA-MB-231 cells are likely to cause 
the effects seen in this chapter as well as Chapters 3 and 4. This is in broad agreement with 
Pedersen et al (1999) who found that a number of different factors produced by MDA-MB-
231 cells could enhance osteoclast activity, and that the complex nature of their 
interactions with osteoclasts meant that it was difficult to single out any specific factors as 
being the most important (464). The three most highly expressed genes have been 
extensively studied in both bone, and bone metastasis, and as I had access to a novel 
specific IGF-1 receptor inhibitor, I will test our osteolytic bone metastasis models by 




 In conclusion, I found that MDA-MB-231 cells express M-CSF but not RANKL. 
However, MDA-MB-231 cells were unable to support osteclast formation or survival in the 
absence of M-CSF and/or RANKL in BM derived macrophage cultures. This suggests that 
tumour derived M-CSF is not sufficient to support osteoclast formation and survival in my 
model. On the other hand, both RANK and C-FMS were expressed by the MDA-MB-231 
cells. Moreover, MDA-MB-231 cells were found to produce conditioned medium that 
significantly further enhanced osteoclast formation when pre-incubated with RANKL and 
M-CSF. Finally, a range of osteoclastic factors were shown to be produced by MDA-MB-231 
cells, suggesting any effects are likely to be due to a combination of effects from multiple 










The effects of the novel kinase inhibitor 
of IGF-1 receptor PQIP on bone cell 





 IGF-1 is the most abundant growth factor in the bone microenvironment and is 
known to be involved in the regulation of both bone formation and resorption. In Chapter 5 
it was shown that the MDA-MB-231 tumour cells that enhanced osteoclast formation and 
function expressed IGF-1. Due to this and the fact that I had access to a novel inhibitor of 
IGF-1 receptor, called PQIP, I decided to test the effect of IGF-1 receptor inhibition on bone 
cell differentiation and activity in vitro prior to studying its effects on tumour cell – bone 
cell cross talk. 
 The relative expression levels of IGF-1 and its receptor in the different bone cell 
types was investigated using qPCR. It was found that osteoblasts expressed the highest 
levels of IGF-1 receptor while osteoclasts and macrophages produced more of the IGF-1 
ligand. This is in agreement with the hypothesis that IGF-1 can act as an 
autocrine/paracrine regulator in the bone microenvironment. Western blot analysis 
established that IGF-1 induced signalling through the PI3K/Akt pathway in osteoblasts and 
osteoclasts but not in BM osteoclast precursors. PQIP treatment prevented this IGF-1 
induced effect in all cell types studied. 
 In osteoblasts, IGF-1 treatment increased cell function, migration and RANKL 
production. No effects on either cell viability or differentiation were observed. Pre-
treatment with PQIP reduced both IGF-1 induced and basal levels of bone nodule 
formation, osteoblast differentiation, cell migration and RANKL production, again without 
affecting cell viability. 
 Studies in osteoclasts and BM osteoclast precursor cells showed that PQIP inhibited 
basal and IGF-1 induced increases in early osteoclast formation, but that neither IGF-1 nor 
PQIP treatment effected mature osteoclast survival until micromolar concentration caused 
toxic effects. Potential direct effects of PQIP on RANKL or M-CSF signalling were eliminated 
as western blot analysis showed that it failed to inhibit signalling induced by either ligand. 
 Overall, this chapter showed that IGF-1 signalling plays an important role in the 
regulation of both osteoblasts and osteoclasts, as well as the interactions between the two 




suppressing both osteoblast and osteoclast activity, suggesting it may be of use as a 
treatment for the excess bone turnover associated with diseases such as bone metastasis.  





 IGF-1 is a polypeptide systemic hormone with 40-50% sequence homology to 
insulin (470-472). It binds to a tetrameric transmembrane receptor tyrosine kinase, IGF-1R, 
which has high homology to insulin receptor (IR) particularly in the β subunit (473). IGF-1R  
is widely expressed in human tissues including bone and various common tumours 
including breast sarcoma (471, 474). It is activated by IGF-1, IGF-2, and to a lesser extent by 
insulin (474). The binding of these ligands to the IGF-1R results in activation of its kinase 
domain leading to the initiation of various intracellular signalling pathways including the 
PI3K/Akt, JAK/STAT and MAPKinase pathways (474, 475). 
 IGF-1 is known to play a vital role in the regulation of bone remodelling in health 
and in disease (Reviewed in (287)). It is the most abundant growth factor in the bone 
microenvironment (273) and has been shown to regulate various aspects of both osteoblast 
(287-290) and osteoclast (291-293) growth, differentiation and function in vitro and in vivo. 
Specifically, IGF-1 is known to induce Osx expression in osteoblasts, enhancing osteoblast 
differentiation, migration and function in vitro (287-289, 476), while genetic inactivation of 
IGF-1 receptors in osteoblasts in vivo leads to suppressed bone formation and reduced 
bone mass. This was due not to a reduced number of osteoblasts, but due to a lack of 
mineralisation as the osteoblasts are unable to properly mineralise the bone matrix (290, 
477), suggesting that IGF-1 plays an important role in osteoblast differentiation and 
function (290). Other studies show that IGF-1 also stimulates osteoclast formation and 
bone resorption (291-293).  IGF-1 null mice have increased trabecular bone density and 
connectivity. This is partly due to a direct inhibition of osteoclastagenesis in the absence of 
IGF-1 and partly an indirect effect due to severely reduced RANKL expression in osteoblasts 
(293, 478, 479).  In addition, genetic inactivation of IGF-1 or its receptor prevents 
ovariectomy induced bone loss through the inhibition of osteoclast formation and function 
(294).  
 In recent years there has also been increasing interest in the role of IGF-1 in tumour 
development and metastases (277, 471, 475, 480, 481). These findings have encouraged 
the development of therapeutic agents for the treatment of various cancers based on 
targeting the IGF-1R. One such agent is PQIP (cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-




molecule inhibitor of the human IGF-1R, and to a far lesser extent the insulin receptor, 
which shows minimal activity against a wide panel of other protein kinases (482, 483). PQIP 
inhibits tumour proliferation and induces apoptosis in a variety of colon, breast and 
pancreatic tumour cells in vitro, and showed significant in vivo efficacy in tumour 
xenografts, in particular against tumours whose progression is dependent on an IGF/IGF-1R 







The aim of this chapter was to test the effects of the IGF-1 receptor kinase inhibitor PQIP on 








6.4.1 IGF-1 receptors are highly expressed in osteoblasts  
 Quantitative PCR was used to determine the relative IGF-1R mRNA expression in 
macrophages, osteoclasts, and osteoblasts. As shown in Figure 6.1 A, osteoblasts express 
the highest level of IGF-1R, 10-fold higher than both osteoclasts and M-CSF dependent 
osteoclast precursors (p < 0.05). Expression of IGF-1 itself was also detected in all three 
bone cell types; with the highest mRNA level observed in M-CSF dependent osteoclast 
precursor cells (Figure 6.1 B). Osteoclasts expressed IGF-1 at a level 2-fold lower than M-
CSF dependent osteoclast precursors and osteoblasts at a level 3-fold lower than those of 
osteoclasts (Figure 6.1 B). 
  
Figure 6.1 IGF-1 receptor is highly expressed in osteoblasts Panels A and 
B show the expression of IGF-1 (panel B) and its receptor IGF-1R (panel A) in 
bone cells as measured by quantitative rt-PCR followed by qPCR. Transcript 
numbers are corrected for expression of 18s RNA. Values in the graphs are 
mean ± SD and are obtained from three independent experiments. * p < 0.05 






6.4.2 Effects of pharmacological inhibition of IGF-1R kinase activity on 
osteoblastogenesis in vitro 
6.4.2.1 The IGF-1 receptor kinase inhibitor PQIP inhibits osteoblast differentiation and 
bone nodule formation without affecting cell viability 
 As osteoblasts expressed the highest amount of IGF-1R mRNA we first investigated 
the effects of IGF-1 and the IGF-1R specific inhibitor PQIP on various properties of primary 
calvarial osteoblasts. Osteoblast viability, differentiation and bone nodule formation were 
assessed by AlamarBlue, alkaline phosphatase and alazarin red assays, respectively. Figure 
6.2 shows that after 21 days of continuous treatment neither IGF-1 nor PQIP had any 
significant effect on primary calvarial osteoblast viability. The images in Figure 6.2A and C 
clearly demonstrate that both IGF-1 and PQIP effected bone nodule formation in a dose-
dependent manner; IGF-1 increasing mineralisation and PQIP significantly reducing it. 
Unfortunately mistakes in the destaining and alkaline phosphatase assays mean quantative 
data on osteoblast formation and differentiation was not obtained from this experiment.  
 Figure 6.2 The IGF-1 receptor kinase inhibitor PQIP inhibits osteoblast function without affecting 
long-term cell viability in calvarial osteoblast cultures. Mouse calvarial osteoblasts were cultured in 
osteogenic medium containing 3 mM -glycerol phosphate and 50 ng/ml L-ascorbic acid for 21 days in the 
presence and absence of IGF-1 (0-100 ng/ml) or PQIP (0-200 nM). Representative photomicrographs from 
cultures are shown in panels A and C. Cell number was measured by AlamarBlue assay and is shown in graphs B 




 To measure the effects of PQIP on IGF-1 induced osteoblast differentiation and 
bone nodule formation, bone nodule cultures were repeated. In these experiments 
osteoblasts were either untreated, or treated with IGF-1 100 ng/ml, PQIP 200 nM or both. 
Figure 6.3B shows that again after 21 days there was no significant change in osteoblast 
viability with any treatment. Destaining of the alazarin red demonstrated that IGF-1 caused 
a 25% increase in bone nodule formation (p < 0.05) after 21 days of continuous treatment. 
PQIP reduced mineralisation to 60% of vehicle in both the presence and absence of IGF-1 
treatment (p < 0.05). As a measure of osteoblast differentiation, alkaline phosphatase 
activity was measured in all cultures. PQIP reduced alkaline phosphatase activity by 55% in 
both IGF-1 treated and untreated cultures (p < 0.05), while IGF-1 itself had no significant 
effect at the concentration found to be stimulatory to osteoblast function. 
 
 
Figure 6.3 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 induced osteoblast 
differentiation and function without affecting long-term cell viability in calvarial osteoblast 
cultures. Mouse calvarial osteoblasts were cultured in osteogenic medium containing 3mM b-glycerol 
phosphate and 50ng/ml L-ascorbic acid for 21 days in vehicle (0.1% DMSO) or IGF-1 (100ng/ml) in the 
presence or absence of PQIP (100-200nM). Quantitation of nodule formation and osteoblast differentiation 
were carried out using Alazarin red (C) and alkaline phosphatase (D) assays respectively, and corrected for 
cell number as measured by AlamarBlue assay (B). Representative photomicrographs from cultures are 
shown in panels A. Values in the graphs are mean ± SD and are obtained from three independent 





6.4.2.2 The IGF-1 receptor kinase inhibitor PQIP suppresses IGF-1 induced AKT activation 
in primary osteoblasts  
 IGF-1 is known to activate PI3K/Akt signalling in a variety of cell types including 
osteoblasts (484). Here, the effect of IGF-1 and PQIP treatment on the phosphorylation 
state of AKT was investigated by western blot. Figure 6.4 shows that IGF-1 (100 ng/ml) 
strongly induced AKT phosphorylation at serine 437 (Ser437) and threonine 308 (Thr308), 
indicative of PI3K/AKT activation. Treatment of osteoblasts with PQIP (50 – 500 nM) for 1 
hour prior to stimulation with IGF-1 (100 ng/ml) caused a significant and dose-dependent 
inhibition of AKT phosphorylation at both phosphorylation sites, abolishing all AKT 




Figure 6.4 IGF-1 receptor kinase inhibitor PQIP prevents AKT activation in 
osteoblasts. Mouse calvarial osteoblasts were exposed to vehicle (0.1% DMSO) or PQIP (50 – 
500 nM) prepared in serum free αMEM media for 1 hour prior stimulation with IGF-1 (100 
ng/ml) for 15 minutes. Total cellular protein was subjected to western blot analysis (50µg/lane) 
using rabbit anti-phospho-AKT (Ser473), anti-phospho-AKT (Thr308), anti-AKT (Cell Signalling 
Biotechnology, USA) or anti-actin antibodies (Sigma-Aldrich, UK). Identical experiments have 








6.4.2.3 The IGF-1 receptor kinase inhibitor PQIP suppresses IGF-1 induced osteoblast 
migration  
 Recent studies have shown that IGF-1 acts as a chemotactic agent for osteoblasts 
and so stimulating osteoblast migration, which is essential for their recruitment to sites of 
bone formation (289). Here I used wound assays to study the effects of IGF-1 and PQIP on 
the migration of the osteoblast-like mouse cell line MC3T3-E1. Figure 6.5 shows that 
treatment with IGF-1 (100 ng/ml) resulted in a modest yet significant increase in the speed 
of wound closure when compared to vehicle (15%; p < 0.01). In contrast, PQIP (200 nM) 
significantly inhibited both basal and IGF-1 induced migration of MC3T3-E1 cells by 11% (p < 
0.05) and 14% (p < 0.05), respectively. Interestingly, though wound healing progressed 
faster in IGF-1 treated cultures, gaps were left in their healed wounds and cells appeared to 
lack the organisation of the vehicle and PQIP treated cultures. Instead cells continued to 
move rapidly in a disorganised fashion after the wound had healed; PQIP inhibited this 
effect. Figure 6.5 C shows that neither IGF-1 nor PQIP had a significant effect on MC3T3-E1 






Figure 6.5 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 induced MC3T3 migration without affecting long-term cell viability in calvarial 
osteoblast cultures. Panels A and B show the effect of PQIP on basal and IGF-1 induced migration of the osteoblast-like cells MC3T3-E1. MC3T3-E1 were exposed 
to vehicle (0.1% DMSO) or PQIP (200 nM) prepared in standard αMEM media for 1 hour prior stimulation with vehicle (0.1% BSA) or IGF-1 (100 ng/ml) for 20 hours. 
Representative photomicrographs from cultures are shown in panel A. MC3T3-E1 migration was assessed by wound healing assay and rates of wound closure were 
calculated using ScanR microscope and Tscratch image analysis program as described in materials and methods, the results are shown in panel B.  Cell number was 
measured by AlamarBlue assay (C). Values in the graphs are mean ± SD and are obtained from three independent experiments. *= p < 0.05 from vehicle treated 






6.4.2.4 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1-induced RANKL production 
in osteoblasts  
 Chapter 3 demonstrated that MDA-MB-231 conditioned medium increased the 
osteoblast production of the key osteoclastic factor RANKL. qPCR was used to determine 
the effect of IGF-1 and PQIP on this process. Figure 6.6 shows that IGF-1 (100 ng/ml) caused 
a significant increase in RANKL mRNA expression (19%), whereas PQIP strongly inhibited 
both basal and IGF-1 induced RANKL expression in osteoblasts, reducing it to less than 20% 
of the expression seen in untreated cells (p < 0.05). This suggests that IGF-1R kinase 
inhibition inhibits osteoblast support for osteoclast formation. 
 
Figure 6.6 IGF-1 receptor kinase inhibitor PQIP prevents basal and IGF-1 
induced RANKL expression in osteoblasts. Calvarial osteoblast cultures treated with 
vehicle (0.1% DMSO) or PQIP (200 nM) for 1 hour prior to stimulation with vehicle (0.1% 
BSA) or IGF-1 (100 ng/ml) for 16 hours. The mRNA expression of RANKL was measured by 
quantitative rt-PCR followed by qPCR and is displayed in the graph. Transcript numbers 
are corrected for expression of 18s RNA. Values in the graphs are mean ± SD and are 
obtained from three independent experiments. *= p < 0.05 from vehicle treated cultures, 







6.4.3 Effects of pharmacological inhibition of IGF-1R kinase activity on 
osteoclastogenesis in vitro 
6.4.3.1 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 induced osteoclast 
formation 
 As mature osteoclasts and their precursors were found to express IGF-1 receptors, 
we studied the effects of the IGF-1 receptor kinase inhibitor PQIP on IGF-1-induced 
osteoclast formation in RANKL and M-CSF generated osteoclast cultures. M-CSF generated 
macrophages were cultured in 96 well plates in the presence of M-CSF and RANKL and 
allowed them to grow for 24 hours. Cells were then treated with IGF-1 (50-100 ng/ml), PQIP 
(100-200 nM), or both for 72 hours. Figure 6.7 shows that IGF-1 increased osteoclast 
number in a dose dependent manner but only at 100 ng/ml was this significant (31% 
increase, p<0.01). Similarly, PQIP dose dependently inhibited osteoclast formation, but only 
at 200 nM was it statistically significant (40% reduction, p<0.01). The increase in osteoclast 
number caused by IGF-1 was completely prevented by PQIP, reducing the osteoclast 
number to similar values to those seen with PQIP treatment alone, 85% and 65% of vehicle 





Figure 6.7 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 induced osteoclast formation. 
Mouse bone marrow cells were cultured in the presence of M-CSF (100 ng/ml) for 3 days and then exposed to 
RANKL (100 ng/ml) and M-CSF (25 ng/ml) for 72 hours in the presence or absence vehicle (0.1% DMSO), IGF-1 
(100 ng/ml) and/or PQIP (200 nM). Osteoclast numbers were assessed by counting multinucleated TRAcP 
positive cells with three or more nuclei. Osteoclast numbers are shown in panels A and representative 
photomicrographs from the cultures in panels B. Values in the graph are mean ± SD and are obtained from 








6.4.3.2 The IGF-1 receptor kinase inhibitor PQIP inhibits osteoclast survival at micromolar 
concentrations 
 Here, we studied the effects of IGF-1 and the IGF-1 receptor kinase inhibitor PQIP 
on osteoclast survival in RANKL and M-CSF generated osteoclast cultures. This was achieved 
by treating cultures of M-CSF generated macrophage with M-CSF (25 ng/ml) and RANKL 
(100 ng/ml) for 96 hours prior to a further 48 hours treatment with the addition of IGF-1 (0-
300 ng/ml) or PQIP (0-5000 nM). Figure 6.8 shows that treatment with IGF-1 had no 
significant effect on osteoclast survival, though there was a dose dependent trend peaking 
at 100 ng/ml IGF-1 treatment (22% increase). Interestedly, the IGF-1 receptor kinase 
inhibitor PQIP did inhibit osteoclast survival but only at a concentration of 5000 nM (27% 
reduction, p < 0.05). 
 
Figure 6.8 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 induced osteoclast survival. Mouse bone 
marrow cells were cultured in the presence of M-CSF (100 ng/ml) for 3 days and then exposed to RANKL (100 ng/ml) 
and M-CSF (25 ng/ml) for 96 hours prior to 48 hours additional treatment with RANKL (100 ng/ml) and M-CSF (25 
ng/ml) in the presence or absence of IGF-1 (0-300 ng/ml) or PQIP (0-5000 nM). Osteoclast numbers were assessed by 
counting multinucleated TRAcP positive cells with three or more nuclei. Osteoclast numbers are shown in panels A 
and C and representative photomicrographs from the cultures are shown in panels B and D. Values in the graphs are 







6.4.3.3 The IGF-1 receptor kinase inhibitor PQIP prevents PI3K/AKT activation in 
osteoclasts 
 Western blot was used to investigate the signaling mechanisms by which the IGF-1 
receptor kinase inhibitor PQIP repressed IGF-1-induced osteoclast formation.  The effect of 
PQIP on PI3K/AKT activation in osteoclasts was investigated. As shown in Figure 6.9, PQIP 
(50 – 500 nM) caused a significant and dose-dependent inhibition of both basal and IGF-1 
induced AKT phosphorylation in osteoclast cultures at the serine site. No activation of the 
threonine site by IGF-1 was found.  
  
Figure 6.9 The IGF-1 receptor kinase inhibitor PQIP prevents IGF-1 induced AKT 
activation in osteoclasts. Mouse osteoclasts were treated with a range of PQIP concentrations 
(50 – 500 nM) for 1 hour prior to stimulation with IGF-1 (100 ng/ml) for 15 minutes. Total cellular 
protein was subjected to western blot analysis using anti-phospho-AKT (Thr308), anti-phospho-AKT 
(Ser473), anti-AKT antibodies or anti-actin antibodies. Abbreviations: M – molecular weight marker; 




































6.4.3.3 The IGF-1 receptor kinase inhibitor PQIP had no effects on RANKL and M-CSF-
induced signalling in osteoclasts 
 Western blot was used to eliminate the possibility that the IGF-1 receptor kinase 
inhibitor PQIP might have direct inhibitory effects on RANKL and M-CSF signalling in 
osteoclasts. As shown in Figure 6.10, PQIP did not inhibit RANKL induced IκB 
phosphorylation or M-CSF induced ERK1/2 phosphorylation in osteoclasts even at 
concentrations up to 500 nM. This indicates that at the concentrations that PQIP inhibited 
osteoclast formation, this compound did not interfere with signalling induced by the two 









































Figure 6.10 The IGF-1 receptor kinase inhibitor PQIP does not affect M-CSF induce ERK 
activation or RANKL induced IκB activation. Mouse osteoclasts were treated with a range of PQIP 
concentrations (200 and 500 nM) for 1 hour prior to stimulation with either RANKL (100 ng/ml; top 
panel) or M-CSF (25 ng/ml; bottom panel) for 5 minutes. Total cellular protein was subjected to 
western blot analysis using anti-phospho-IκBα and and anti-actin antibodies (A) or anti-phospho-
ERK1/2 and anti-ERK1/2 antibodies (B). Abbreviations: M – molecular weight marker; kD - kilo Dalton; 





6.4.4 Effects of pharmacological inhibition of IGF-1R kinase activity on osteoclast 
precursor viability and growth in vitro 
6.4.4.1 The IGF-1 receptor kinase inhibitor PQIP had no effects on the viability of M-CSF-
generated BM macrophages 
 To determine if the inhibitory effect of PQIP on osteoclastogenesis were due to a 
non-specific toxic effect of the compound on the viability of precursor cells, we examined 
the effects of IGF-1 and PQIP on the growth of M-CSF-dependent osteoclast precursors 
using the AlamarBlue assay. As shown in Figure 6.11 neither IGF-1 (100 ng/ml) nor PQIP 
(200 nM) showed any significant effects on macrophage cell viability, though IGF-1 





Figure 6.11 PQIP has no significant effect on M-CSF dependent osteoclast precursor viability at 
concentrations inhibitory to osteoclast formation. A, B, mouse bone marrow cells were cultured in 
the presence of M-CSF (25 ng/ml) for 3 days and then exposed to vehicle (0.1% DMSO) or IGF-1 (100 ng/ml) 
in the presence and absence of PQIP (200 nM). The number of M-CSF dependent osteoclast precursors was 
assessed by AlamarBlue assay (A). Values are mean ± S.D. and are obtained from three independent 







6.4.4.2 The IGF-1 receptor kinase inhibitor PQIP prevents PI3K/AKT activation in M-CSF-
generated BM macrophages 
 Western blot was used to investigate whether the IGF-1 receptor kinase inhibitor 
PQIP affect IGF-1-induced signaling in M-CSF-generated BM macrophages.  As shown in 
Figure 6.12, IGF-1 caused only minimal, if any, activation of AKT at the serine 
phosphorylation site.  PQIP (50 – 500 nM) caused a significant and dose-dependent 
inhibition of both basal and IGF-1 induced AKT phosphorylation in M-CSF-generated BM 





Figure 6.12 The IGF-1 receptor kinase inhibitor PQIP prevents PI3K/AKT activation in 
M-CSF-generated BM macrophages. M-CSF dependent osteoclast precursors treated with a 
range of PQIP concentrations (50 - 500 nM) for 1 hour prior to stimulation with IGF-1 
(100ng/ml) for 15 minutes. Total cellular protein was subjected to western blot analysis using 
anti-phospho-AKT (Ser473), anti-phospho-AKT (Thr308) anti-AKT, and anti-Actin antibodies. 
Abbreviations: M – molecular weight marker; kD - kilo Dalton; p – phosphorylated. Identical 









































6.4.4.3 The IGF-1 receptor kinase inhibitor PQIP has no effects on M-CSF-induced 
signalling in M-CSF-generated BM macrophages 
 Western blot was used to determine if the IGF-1 receptor kinase inhibitor PQIP 
would directly affect M-CSF-induced signaling in M-CSF-generated BM macrophages.  As 
shown in Figure 6.13, M-CSF activated both PI3K/AKT and ERK1/2 MAPkinase in M-CSF-






Figure 6.13 The IGF-1 receptor inhibitor PQIP does not inhibit M-CSF induced signalling in 
M-CSF dependent osteoclast precursors. Panel A and B show M-CSF dependent osteoclast 
precursors treated with a range of PQIP concentrations (100 and 200 nM) for 1 hour prior to 
stimulation with M-CSF (25 ng/ml) for 5 minutes. Total cellular protein was subjected to western blot 
analysis using anti-phospho-ERK1/2, anti-phospho-AKT (Ser473), anti-phospho-AKT (Thr308) anti-
ERK1/2, anti-AKT, and anti-Actin antibodies. Abbreviations: M – molecular weight marker; kD - kilo 

















































 The Insulin-like growth factor/insulin system of receptors and ligands are known to 
play a role in bone homeostasis. In particular, IGF-1 is the most abundant growth factor in 
the bone microenvironment (273) and is important for the differentiation and function of 
bone cells (287, 485). The balance between bone formation and resorption is tightly 
regulated and IGF-1 is thought to play an autocrine / paracrine role in these processes 
thereby affecting the actions of all bone cell types particularly cells of the osteoblast lineage 
(486, 487). In broad agreement with these findings, we found that IGF-1R mRNA expression 
was significantly higher in mature osteoblasts than in either osteoclasts or their M-CSF 
dependent precursors, while the reverse was true for IGF-1 mRNA expression. This is 
consistent with the notion that IGF-1 and its receptor play a role in osteoblast–osteoclast 
coupling. In particular IGF-1 is thought to regulate the expression of RANKL and OPG in 
osteoblasts which are key factors responsible for osteoclast formation, survival and 
function (488). In support of this, we demonstrated that the novel kinase inhibitor of IGF-1 
receptor PQIP inhibits both basal and IGF-1 induced mRNA expression of RANKL by 
osteoblasts indicating that IGF-1R blockage is likely to affect osteoblast support for 
osteoclastogenesis.  
 IGF-1 is known to play a key role in osteoblast survival, differentiation and function 
and in particular is known to enhance the expression of Osx in osteoblasts (288, 290, 476). 
Here, we showed that PQIP was also able to directly inhibit both IGF-1 induced osteoblast 
differentiation and bone nodule formation. Interestingly, IGF-1 treatment had no effect on 
osteoblast differentiation in our cultures. This may have been due to the long term nature 
of the assay saturating osteoblast differentiation and that in reality, as previously shown, 
IGF-1 does have a direct stimulatory effect on osteoblast differentiation and function. 
Recent reports have showed that IGF-1 also stimulates osteoblast migration which is 
required for the recruitment of osteoblasts to sites of bone formation. Here we showed 
that treatment with PQIP suppressed basal and IGF-1 induced migration of MC3T3-E1 
osteoblast like cells at concentrations inhibitory to bone nodule formation. Thus PQIP can 
directly affect osteoblast differentiation, migration and function. This raises the possibility 
that inhibition of IGF-1 signalling may also be effective in the prevention of enhanced 




IGF-1 regulates PI3K/AKT signalling and in this study treatment with IGF-1 
stimulated the phosphorylation of AKT in both osteoblasts and osteoclasts. In osteoblast 
cultures, IGF-1 induced signalling was completely abolished following PQIP treatment at 
concentrations that also inhibited bone nodule formation. Interestingly, PQIP had no effect 
on PTH induced ERK phosphorylation or BMP-2 induced SMAD-2 activation in osteoblasts 
(data not shown), indicating a specific effect on IGF-1 signalling.  
 Early treatment with PQIP at the start of osteoclast formation inhibited both IGF-1-
induced and basal osteoclast formation in RANKL and M-CSF stimulated BM cultures. 
However, late treatment with either IGF-1 or PQIP had no effect on osteoclast number, 
with the exception of 5000 nM PQIP which reduced numbers but was most likely due to a 
non-specific toxic effect. This implies that inhibition of IGF-1R by PQIP directly inhibits 
osteoclast formation but probably does not affect survival. However, as the effect of IGF-1R 
inhibition on osteoclast survival was not directly studied here this cannot be stated as 
certain. Notably, early PQIP treatment also resulted in a significant reduction in osteoclast 
size, raising the possibility that IGF-1R inhibition also affects the fusion of osteoclast 
precursors but further work is required to confirm this. Inhibition of basal levels is likely to 
be due to the presence of IGF-1 in FCS media serum. Unfortunately all attempts to remove 
or replace serum in experiments resulted in the failure of osteoclast formation (data not 
shown). 
  As stated above, IGF-1 is known to regulate PI3K/AKT signalling. In this study IGF-1 
stimulated the phosphorylation of AKT in all cell types studied with the exception of 
macrophages. In osteoblast cultures, IGF-1 induced signalling was completely reduced by 
PQIP in a dose-dependent manner and abolished following PQIP treatment at 
concentrations that also inhibited bone nodule formation. This provides a potential 
mechanism for these effects. PQIP also inhibited IGF-1 induced AKT phosphorylation in 
osteoclasts and importantly these effects were observed at concentrations similar to those 
that inhibited osteoclast formation and size. Recently it has been shown that TRAF6, the 
key adaptor molecule of RANK (489), is essential for AKT ubiquitination, membrane 
recruitment and phosphorylation (490). Activation of TRAF6 in osteoclasts plays an 
essential role in RANKL-mediated osteoclastogenesis (491). This suggests that AKT 




RANK. Therefore the inhibition of AKT phosphorylation observed may provide a potential 
mechanism for the inhibition of osteoclast formation found following PQIP treatment.  To 
exclude the involvement of RANKL and M-CSF signalling, we investigated the effects of PQIP 
on RANKL induced IκB phosphorylation and M-CSF induced ERK1/2 activation in osteoclasts. 
Our studies clearly showed that PQIP had no direct effect on either of these two key 
osteoclast signalling pathways. In keeping with this, PQIP also had no significant effect on 
cell viability of M-CSF generated osteoclast precursors, thereby excluding the possibility 
that PQIP’s inhibitory effect was mediated by a decreased number of precursor cells. In 
these cells PQIP did not inhibit activation of either the PI3K/AKT or MAPkinase pathways by 
M-CSF, again demonstrating the specificity of its action. Taken together, our current 
findings are consistent with a model whereby PQIP inhibits osteoblast differentiation, 
function and migration, and can inhibit osteoclast formation directly by suppressing 
PI3K/AKT activity or indirectly by inhibiting IGF-1 induced RANKL expression by osteoblasts.  
 In conclusion, the studies performed here demonstrate that preventing IGF-1 
signalling using the novel selective IGF-1R kinase inhibitor PQIP directly suppresses 
osteoblast and osteoclast differentiation, function and migration, and for the first time we 
have established that pharmacological inhibition of IGF-1R inhibits osteoblast support for 
osteoclastogenesis in vitro. Therefore, selective small molecule kinase inhibitors of IGF-1R 
such as PQIP and its analogue OSI-906, which is currently in advanced clinical development, 
may have clinical value in the reduction of excessive bone turnover associated with a 








The effects of the novel kinase inhibitor 
of IGF-1 receptor PQIP on breast cancer-






 IGF-1 is the most abundant growth factor in the bone microenvironment and is 
known to be involved in both bone homeostasis and the development and progression of 
bone metastases associated with various cancers, particularly breast cancers. IGF-1 was 
expressed in MDA-MB-231 tumour cells in Chapter 5. Due to this and the fact that we had 
access to the novel inhibitor of IGF-1 receptor PQIP, we decided to test the effect of IGF-1R 
kinase inhibition on bone - tumour cell crosstalk using the various in vitro techniques 
developed in Chapter 3. 
 PQIP prevented IGF-1 induced AKT phosphorylation in human MDA-MB-231 breast 
cancer cells in a dose dependant manner, indicating a consistent inhibition of PI3K/AKT 
signalling. In contrast, effects of PQIP on breast cancer cell viability was varied; human 
MCF7 cells were sensitive to PQIP treatment, while MDA-MB-231 and 4T1 cell viability was 
unaffected.  
 PQIP treatment significantly exacerbated the inhibitory effect of MDA-MB-231 
conditioned medium treatment on osteoblasts, leading to a marked reduction in osteoblast 
viability as well as differentiation and function. PQIP did however inhibit MDA-MB-231 
induced increases in RANKL production in osteoblast cultures, indicating a significant 
inhibition of osteoblast support for osteoclastogenesis. In co-cultures and conditioned 
medium treatments of RANKL and M-CSF-stimulated BM cultures, PQIP was able to 
successfully inhibit tumour induced increases in osteoclast number, and particularly size. 
This was true for all tumour cell lines studied. Xcelligence analysis demonstrated that IGF-1 
treatment of osteoclasts caused a similar change in cell index values to MDA-MB-231 
conditioned medium, albeit with a lower increase in values. This suggests that IGF-1 plays a 
role in tumour cell induced effects on osteoclasts. PQIP inhibited both the IGF-1 and 
conditioned medium effects. Interestingly, PQIP inhibited MDA-MB-231 induced PI3K/AKT 
signalling in osteoblasts and osteoclasts, without affecting MDA-MB-231-induced ERK1/2 
activation. This suggests that inhibition of tumour induced PI3K/AKT pathways downstream 
of IGF-1 may be responsible for the effects seen. 
 Overall, this chapter successfully demonstrated the effectiveness of the techniques 




cell – bone cell cross-talk in vitro. Preventing IGF-1 signalling using the novel selective IGF-
1R kinase inhibitor PQIP was found to suppress a variety of bone cell facets as well as 
interfering with tumour cell induced increases in osteoclast number and size. It is therefore, 
possible that PQIP, or more likely its analogue OSI-906, which is currently in advanced 
clinical development, may have clinical value in the treatment of osteolytic bone 






 In addition to its role in bone remodelling, in recent years there has also been 
increasing interest in the role of IGF-1 in both tumour development and metastasis (277, 
471, 475, 480, 481). Numerous studies have shown that IGF-1 stimulates proliferation, 
survival, transformation and invasiveness of tumour cells in vitro and in vivo (276, 277, 471, 
475). The elevated expression of IGF-1 and its receptor has been detected in a variety of 
tumours (275) and the increased circulating levels of IGF-1 and IGF-1 binding protein 3 have 
been linked to increased risks of breast and prostate cancer development (276-279).  
 IGF-1 appears to be of particular importance in bone metastasis and subsequent 
osteolysis associated with breast cancer. Many studies have reported that a variety of 
breast cancer cell lines express IGF-1 and IGF-1R, and elevated activity of IGF-1 and its 
receptor has been detected in a variety of primary breast cancer cells, breast cancer cell 
lines and the plasma of breast cancer patients (492-494).  Moreover IGF-1 has been linked 
to breast cancer metastasis and resistance to chemotherapy (495), and importantly cells 
with mutant IGF-1 receptors have reduced metastasis to and proliferation within the bone 
microenvironment (273, 496). Importantly, a bone seeking variant of MDA-MB-231 cells 
was shown to specifically migrate and proliferate in response to IGF-1 whilst MDA-MB-231 
cells that metastasised to other locations did not, suggesting that IGF-1 signalling may be of 
particular importance in the development of bone metastases from breast cancers (497).  
 As stated in Chapter 6, the linking of IGF-1 and its receptor to the progression of 
various cancers, including breast cancer, has led to the development of several novel drugs 
that target IGF-1 or the IGF-1 receptor. One of these is the selective novel small molecule 
inhibitor of IGF-1R called PQIP (cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-
quinolin-7-yl)-imidazol[1,5-a]pyrazin-8-ylamine) (482, 483). The inhibition of IGF-1R by PQIP 
has previously been shown to induces apoptosis and inhibit tumour growth and in a variety 
of breast, colon and pancreatic tumour cells in vitro, and in vivo (483). It is most effective in 
cells reliant on IGF/IGF-1R signaling for survival, and has proven effective enough for the 
analogue of PQIP called OSI-906 to reach stage 3 clinical trial for the treatment of 
adrenocortical carcinoma (498). The chapter presented here investigates the effect of PQIP 
on the cancer cells used previously in this thesis, and on their interactions with bone cells 





The aim of this chapter was to test the effect of the novel IGF-1 receptor kinase inhibitor 






7.4.1 Effects of pharmacological inhibition of IGF-1R kinase activity on breast cancer 
cell behaviour in vitro 
7.4.1.1 The IGF-1 receptor kinase inhibitor PQIP suppresses adhesion and spreading of 
human and mouse breast cancer cells in vitro 
 The adhesion and spreading of human and mouse breast cancer cells were assessed 
by using the real-time cell analyser Xcelligence (Roche Applied Science, UK). Mouse and 
human breast cancer cells were plated into specialised 16-well plates (Roche Applied 
Science, UK) containing standard αMEM supplemented with IGF-1 (100 ng/ml) in the 
presence and absence of PQIP (200 nM). Figure 7.1 shows the graphs of cell impedance 
over the first 4 hours and analysis of the slopes of the graphs during the linear part of the 
initial increase in cell index. Changes in cell index during this period are thought to 
represent changes in cell adhesion and spreading.  IGF-1 treatment did not significantly 
alter cell adhesion or spreading in any cell type studied. In contrast, PQIP treatment caused 
significant changes to the initial adhesion and spreading of both 4T1 and MCF7 cells. In 4T1 
cells this change was not obvious in the cell-index graphs (Figure 7.1C), but analysis of the 
rate of change in cell index value shows that PQIP treatment significantly reduced the rate 
of cell index increase by 28% (p<0.01). This effect was particularly prominent at the earliest 
time-point, so likely represents a reduction in the initial adhesion of 4T1 cells. MCF7 cell 
adhesion and spreading was clearly inhibited by PQIP treatment. Figure 7.1F shows that 
while PQIP treatment alone did not significantly change the rate of increase in cell index 
values compared to vehicle treated cells, when cells were treated with both IGF-1 and PQIP 
the rate of increase was reduced to only 23% (p<0.05) of that observed in the vehicle 
treated cells. This was also significantly lower than in cultures treated with IGF-1 alone. 






















 Figure 7.1 Xcelligence analysis demonstrates the short-term effects of IGF-1 and the IGF-1 receptor inhibitor on the adherence and spreading of various 
cancer cell lines. MDA-MB-231 (A,B), 4T1 (C,D), and MCF7 (E,F)) cells were seeded into xcelligence plates in the presence of vehicle (0.1% DMSO) or IGF-1 (100 ng/ml) in the 
presence or absence of PQIP (200 nM).  A, C, and E  shows a representative graph of the Cell index values (derived from their electrical impedance) over 4 hours. The 
treatments are represented as follows; Vehicle (RED), IGF-1 (GREEN), PQIP (BLUE), and IGF-1 and PQIP (PINK) B, D, and F show the average slope of the graphs at the initial 
linear portion of the graphs. N=4 experiments were performed. Values are mean ± S.D. and are obtained from three independent experiments. * p < 0.05 from vehicle treated 





7.4.1.2 The IGF-1 receptor kinase inhibitor PQIP had no effects on the viability of human 
and mouse breast cancer cells 
 To determine if the inhibitory effect of PQIP on osteoclast formation in MDA-MB-
231 – BM co-cultures was due to inhibition of the growth of breast cancer cells in these 
cultures, we examined the effects of IGF-1 and PQIP on the viability of MDA-MB-231. MDA-
MB-231 cells were treated with IGF-1 (0-300 ng/ml) or PQIP (0-500 nM) for 48 or 72 hours, 
and cell viability measured by the AlamarBlue assay. Figure 7.2 shows that neither 
treatment had any significant effect on cell number, though following treatment with 100 
ng/ml IGF-1 for 72 hours there was a modest but not significant increase in MDA-MB-231 
growth.  
Figure 7.2 IGF-1 and the IGF-1 receptor inhibitor PQIP do not affect MDA-MB-231 human breast 
cancer cell viability. MDA-MB-231 cells were seeded and allowed to attach over night prior to treatment 
with a range of PQIP concentrations (200 and 500 nM)(A) or IGF-1 (100 and 300 ng/ml) (B) and cell number 










 The effect of PQIP on the viability of other osteolytic tumour cells used for co-
culture experiments in Chapter 3 was tested. Mouse 4T1, mouse MC57G and human MCF7 
cells were cultured in the presence or absence of PQIP (0-1500 nM) for 72 hours and cell 
viability measured by the AlamarBlue assay. Figure 7.3 shows that PQIP had no effect on 
the growth of mouse 4T1 and MC57G at concentrations up to 1500 nM. In contrast, 
treatment of MCF7 with PQIP reduced cell viability in a dose dependant manner. Even at 
the lowest concentrations of PQIP (200 nM) we observed a significant drop in viability of 
33%. The highest concentration of 1500 nM caused reduction in cell numbers to increase to 
45%. 
 
Figure 7.3 The IGF-1 receptor inhibitor PQIP did not affect 4T1 or MC57G mouse cancer cell 
viability, but does inhibit MCF7 human breast cancer cell viability. 4T1 (A), MC57G (B), or MCF7 (C) 
cells were seeded and allowed to attach over night prior to treatment with a range of PQIP concentrations 
(200 -1500 nM). Cell number was assessed by AlamarBlue after 72 hours. Values are mean ± S.D. and are 






The long term effects of PQIP on the proliferation of human and mouse breast 
cancer cells was also assessed by using the real-time cell analyser Xcelligence (Roche 
Applied Science, UK). Figure 7.4 shows graphs of the cell index values from cultures of 
human MDA-MB-231 and MCF7 cells or mouse 4T1 cells treated with IGF-1 (100 ng/ml), 
PQIP (200 nM) or both over a period of 48 hours. In this case the increases in cell index 
values represent the rates of cell proliferation. No significant effect on MDA-MB-231 or 4T1 
cell proliferation was observed in these cultures, however both these cell types did have a 
trend of increased proliferation with IGF-1 treatment, and inhibition of this trend by PQIP 
treatment. Quantitive measurements of the graph slopes shown in Figure 7.4 B and D 
demonstrate that, in both MDA-MB-231 and 4T1 cell IGF-1 treatment had only minimal 
effect on proliferation and that this was not a statistically significant. In contrast, the 
proliferation rate of MCF7 cells was clearly affected by both IGF-1 and PQIP treatment. 
Measurement of the slopes shown in Figure 7.4E shows that IGF-1 treatment significantly 
increased cell proliferation by an average of 33% (p<0.05), while PQIP reduced proliferation 
rates of both vehicle and IGF-1 treated cultures respectively to 41% (p<0.05) and 29% 


















Figure 7.4 Xcelligence analysis demonstrates the long-term effects of IGF-1 and the IGF-1 receptor inhibitor on various cancer cell viabilities. MDA-MB-231 (A,B), 
4T1 (C,D), MCF7 (E,F)), and MC3T3 (G,H)) cells were seeded into xcelligence plates in the presence of vehicle (0.1% DMSO) or IGF-1 (100ng/ml) in the presence or absence of PQIP 
(200nM).  A, C, E and G shows a representative graph of the Cell index values (derived from their electrical impedance) over 48 hours. The treatments are represented as follows; 
Vehicle (RED), IGF-1 (GREEN), PQIP (BLUE), and IGF-1 and PQIP (PINK) B, D, F, and H are show the average slope of the graphs between hours 16 and 24. N=4 experiments were 





7.4.1.3 The IGF-1 receptor kinase inhibitor PQIP inhibits PI3K/AKT activation in human 
MDA-MB-231 breast cancer cells 
 Western blot was used to investigate whether the IGF-1 receptor kinase inhibitor 
PQIP affects IGF-1-induced signaling in human breast cancer cells.  As shown in Figure 7.5, 
PQIP (50 – 500 nM) caused a significant and dose-dependent inhibition of both basal and 
IGF-1-induced AKT phosphorylation in human MDA-MB-231 breast cancer cells at both 











Figure 7.5 The IGF-1 receptor inhibitor PQIP inhibits IGF-1 induced AKT signalling in MDA-MB-
231 human breast cancer cells. MDA-MB-231 cells were treated with a range of PQIP concentrations (50 
– 500 nM) for 1 hour prior to stimulation with vehicle (0.1% BSA) or IGF-1 (100 ng/ml) for 15 minutes. Total 
cellular protein was subjected to western blot analysis using anti-phospho-AKT (Ser473), anti-phospho-AKT 










7.4.2 Effects of pharmacological inhibition of IGF-1R kinase activity on breast cancer-
induced osteoblastogenesis in vitro 
7.4.2.1 The IGF-1 receptor kinase inhibitor PQIP exacerbates the inhibitory effects of 
breast cancer cells on osteoblast differentiation and bone nodule formation in vitro 
 Chapter 3 demonstrated that MDA-MB-231 conditioned medium caused a 
reduction in osteoblast differentiation and function without affecting viability. Here we 
treated osteoblast bone nodule assays with 10% MDA-MB-231 conditioned medium in the 
presence or absence of the IGF-1 receptor inhibitor PQIP (200-500 nM). Figure 7.6 shows 
that MDA-MB-231 conditioned medium alone did not cause a significant reduction in 
viability, however when in combination with PQIP (200 nM), osteoblast numbers 
significantly fell by 15%. Treatment of calvarial osteoblast with MDA-MB-231 conditioned 
medium caused a significant reduction in bone nodule formation (42%, p < 0.05) and this 
effect appears to be significantly worse in the presence of PQIP (200 nM) (Figures 7.6A and 
D). However, while 200 nM PQIP treatment did cause a further drop in mineralisation, after 
alizarin red levels were adjusted for number of viable cells this was not significantly 
different from cultures treated with conditioned medium alone. Osteoblast differentiation 
levels were again assayed by measuring alkaline phosphatase activity in all cultures. PQIP 
treatment (200 nM) further increased the MDA-MB-231 induced reduction in 
differentiation from 37% to 53%, however after adjusting for cell viability these differences 








Figure 7.6 The IGF-1 receptor kinase inhibitor PQIP inhibits osteoblast viability, differentiation and function in the presence of MDA-
MB-231 derived factors. Mouse calvarial osteoblasts were cultured in osteogenic medium containing 3 mM -glycerol phosphate and 50 ng/ml L-
ascorbic acid for 21 days in 10% control or MDA-MB-231 conditioned medium in the presence or absence of PQIP (100-200 nM). Quantitation of nodule 
formation and osteoblast differentiation were carried out using Alazarin red (D) and alkaline phosphatase (C) assays respectively, and corrected for cell 
number as measured by AlamarBlue assay (B). Representative photomicrographs from cultures are shown in panels A. Values in the graphs are mean ± 




7.4.2.2 The IGF-1 receptor kinase inhibitor PQIP prevents PI3K/AKT activation in mouse 
calvarial osteoblasts 
 Western blot was used to investigate whether the IGF-1 receptor kinase inhibitor 
PQIP affected MDA-MB-231-induced PI3K/AKT activation in osteoblasts. To allow 
comparison, IGF-1 induced activation was used as a positive control. Figure 7.7 shows that 
both IGF-1 (100 ng/ml) and MDA-MB-231 conditioned medium (10%) induced the 
phosphorylation of AKT. This activation was stronger following IGF-1 treatment, but both 
were clearly above the basal level seen in untreated cells. Pre-incubation with PQIP (200-
500 nM) significantly inhibited IGF-1 induced activation. More importantly, PQIP prevented 
MDA-MB-231-induced AKT activation at both serine and threonine sites in osteoblasts. Pre-
incubation with the specific PI3K inhibitor LY294002 (1µM) inhibited the activation of AKT 
by MDA-MB-231 conditioned medium, however this effect was not as strong as that 
observed with PQIP treatment. 
Figure 7.7 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 and MDA-MB-231 conditioned 
medium induced activation of AKT in calvarial osteoblasts. Mouse osteoblasts were treated with 
Ly294002 (1uM) or a range of PQIP concentrations (200 and 500 nM) for 1 hour prior stimulation with IGF-1 
(100 ng/ml) for 15 minutes or MDA-MB-231 conditioned medium (10%) for 30 minutes. Total cellular protein 
was subjected to western blot analysis using anti-phospho-AKT (Thr308,), anti-phospho-AKT (Ser473), anti-AKT 
antibodies. Actin was used as a loading control. Abbreviations: M – molecular weight marker; kD - kilo 





7.4.2.3 The IGF-1 receptor kinase inhibitor PQIP prevents upregulation of RANKL and OPG 
expression in mouse calvarial osteoblasts 
Chapter 3 demonstrated that MDA-MB-231 conditioned medium increased 
osteoblast production of both RANKL and OPG. Here I performed qPCR to determine the 
effect of PQIP treatment (200-500 nM) on MDA-MB-231-induced RANKL/OPG ratio in 
osteoblasts. Figure 7.8 shows that as shown in Chapter 3, MDA-MB-231 conditioned 
medium increased the RANKL/OPG ratio (64.7% increase ±39%, p<0.05). PQIP treatment at 
500 nM significantly reduced the MDA-MB-231 conditioned medium induced increase in 
RANKL/OPG ratio (28% reduction, p<0.05). 
 
Figure 7.8 The IGF-1 receptor inhibitor PQIP inhibits MDA-MB-231-induced RANKL mRNA 
expression in osteoblasts. Osteoblasts were seeded into 12 well plates and allowed to grow to 
confluence. They were then pre-treated with vehicle (0.1% DMSO) or PQIP (200-500 nM) for 2 hours prior 
to 16 hours in the presence of either control or MDA-MB-231 conditioned medium (10%) before being 
lysed in Trizol. mRNA was then extracted and analysed for OPG and RANKL expression using qPCR analysis. 
All results were adjusted to account for expression of 18S and GAPDH housekeeping genes. This graph 
shows the average mRNA RANKL/OPG expression ratio relative to control.  Data is from three independent 
experiments (N=3) performed in triplicate and error bars represent +/- one standard deviation. * =P<0.05 





7.4.3 Effects of pharmacological inhibition of IGF-1R kinase activity on breast cancer-
induced osteoclastogenesis in vitro 
7.4.3.1 The IGF-1 receptor kinase inhibitor PQIP suppresses breast cancer – induced 
osteoclast formation without affecting mature osteoclast survival and resorption in vitro 
 Chapter 3 demonstrated that MDA-MB-231 cells and conditioned medium strongly 
increased the number and size of osteoclasts formed in M-CSF and RANKL generated 
cultures. The techniques devised there were now used to study the effect of the IGF-1 
receptor kinase inhibitor PQIP on tumour cell-bone cell crosstalk. First, we tested the 
effects of PQIP on osteoclast formation in breast cancer – BM co-cultures. Figure 7.9 
demonstrates that, as before, MDA-MB-231, 4T1, and MCF7 cells all increased osteoclast 
number, size and nuclearity. 300 cells of each type were used and they increased osteoclast 
number as follows MDA-MB-231 by 83% (p<0.05), 4T1 by 81% (p<0.05), MCF7 by 89% 
(p<0.58) when compared to vehicle. Figure 7.9B demonstrates that this change was due to 
increases in osteoclast size and nuclearity, as when only osteoclasts with ten or more nuclei 
were counted this increase changed to 375% with MDA-MB-231 (p<0.05), 319% with 4T1 
(p<0.01) and 294% with MCF7 (p<0.05). For every cell type PQIP (200-1500 nM) significantly 














Figure 7.9 The IGF-1 receptor kinase inhibitor PQIP inhibits osteolytic tumour cell enhanced osteoclast formation. Mouse bone marrow cells were cultured in the 
presence of M-CSF (100ng/ml) for 3 days and then exposed to RANKL (100 ng/ml) and M-CSF (25 ng/ml) for 24 hours, prior to the addition of 300 MDA-MB-231, 4T1, or MCF7 
cells in the presence of vehicle (0.1% DMSO) or PQIP (200-1500 nM). Osteoclast numbers were assessed by counting multinucleated TRAcP positive cells with three or more 
nuclei (A), or 10 or more nuclei (B). Osteoclast numbers are shown in panels A and B, representative photomicrographs from the cultures in panel C. Values in the graph are mean 





Figure 7.10 shows that again MDA-MB-231 conditioned medium significantly 
enhanced osteoclast number at all concentrations tested (43-55% increase, p < 0.05) and at 
10% and 20% conditioned medium increased osteoclast size (79-110% increase, p < 0.01).  
The effect on osteoclast number was not suppressed following treatment with PQIP (200 
nM), with the exception of the 5% MDA-MB-231 conditioned medium where it was reduced 
from 146% of vehicle to 60% (p < 0.05). It was noted that osteoclasts that were present in 
cultures treated with PQIP appeared to be smaller and with less nuclei. Figure 7.10B 
demonstrates that PQIP significantly suppressed the MDA-MB-231 conditioned medium 
induced increase in the number of osteoclasts with 10 or more nuclei at all concentrations 
tested. This also demonstrated the lesser effect 5% conditioned medium had, as in this 
count it failed to increase osteoclast numbers. This suggests that IGF-1R kinase inhibition is 












Figure 7.10 The IGF-1 receptor kinase inhibitor PQIP inhibits MDA-MB-231 conditioned medium enhanced osteoclast formation. Mouse bone 
marrow cells were cultured in the presence of M-CSF (100 ng/ml) for 3 days and then exposed to RANKL (100 ng/ml) and M-CSF (25 ng/ml) for 24 hours, prior to 
the addition of 300 MDA-MB-231 cells or treatment with control (20%) or MDA-MB-231 (5-20%) conditioned medium in the presence of vehicle (0.1% DMSO) or 
PQIP (200 nM). Osteoclast numbers were assessed by counting multinucleated TRAcP positive cells with three or more nuclei (A), or 10 or more nuclei (B). 
Osteoclast numbers are shown in panels A and B, representative photomicrographs from the cultures in panel C. Values in the graph are mean ± SD and are 





To determine whether PQIP exerted inhibitory effects on mature osteoclast survival 
and activity, I conducted further studies in mature osteoclast cultures that were treated 
with PQIP in the presence and absence of MDA-MB-231 conditioned medium. I found that 
PQIP had no inhibitory effects on osteoclast survival (Figure 7.11A) or bone resorption 



















Figure 7.11 The IGF-1 receptor kinase inhibitor PQIP does not effect MDA-MB-231 
conditioned medium enhanced osteoclast survival or function. Mouse bone marrow 
cells were cultured in the presence of M-CSF (100 ng/ml) for 3 days and then transferred to 
Osteo Assay Surface plates and exposed to RANKL (100 ng/ml) and M-CSF (25 ng/ml) for 24 
hours, prior to the addition of MDA-MB-231 or control conditioned medium (10%) in the 
presence of vehicle (0.1% DMSO) or PQIP (200 nM). After 96 hours osteoclast numbers were 
assessed by counting multinucleated TRAcP positive cells with three or more nuclei (A). 50% 
bleach was used to remove adherent osteoclasts and resorption assessed by image analysis 
using ImageJ. Osteoclast numbers are shown in panel A and resorbed area in panel B, 
representative photomicrographs of the resorption pits are shown in panel C. Values in the 




7.4.3.2 The IGF-1 receptor kinase inhibitor PQIP prevents PI3K/AKT activation in mouse 
osteoclasts 
 Western blot was used to investigate whether the IGF-1 receptor kinase inhibitor 
PQIP affect IGF-1- and MDA-MB-231-induced PI3K/AKT activation in osteoclasts. Figure 7.12 
shows that both IGF-1 (100 ng/ml) and MDA-MB-231 CM (10%) treatments induced the 
phosphorylation of AKT. This activation was stronger with IGF-1 treatment, but both were 
clearly above the basal level seen in untreated cells. Pre-incubation with PQIP (200-500 nM) 
significantly inhibited IGF-1 and MDA-MB-231-induced AKT activation at both serine and 
threonine sites in osteoclasts. 
 
Figure 7.12 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 and MDA-MB-231 
induced activation of AKT in osteoclasts. Mouse osteoclasts were treated with a range of 
PQIP concentrations (200 and 500 nM) for 1 hour prior stimulation with IGF-1 (100 ng/ml) for 15 
minutes or MDA-MB-231 conditioned medium (10%) for 30 minutes. Total cellular protein was 
subjected to western blot analysis using anti-phospho-AKT (Thr308,), anti-phospho-AKT (Ser473), 
anti-AKT antibodies. Actin was used as a loading control. Abbreviations: M – molecular weight 















































7.4.3.3 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 but not ERK1/2 activation 
in mouse osteoclasts 
 Western blot was used to investigate whether the IGF-1 receptor kinase inhibitor 
PQIP affected MDA-MB-231 conditioned medium induced the activation of ERK1/2, a key 
signalling pathway downstream of IGF-1 receptor (285). To allow comparison IGF-1 
treatment was used as a positive control.   Figure 7.13 shows that both IGF-1 (100 ng/ml) 
and MDA-MB-231 CM (10%) treatments induced the phosphorylation of ERK1/2. 
Interestingly, pre-incubation with PQIP (200-500 nM) significantly inhibited IGF-1 but not 
















Figure 7.13 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 but not MDA-MB-231 
induced ERK1/2 activation in osteoclasts. Mouse osteoclasts were treated with a range of 
PQIP concentrations (200 and 500 nM) for 1 hour prior stimulation with IGF-1 (100 ng/ml) for 15 
minutes or MDA-MB-231 conditioned medium (10%) for 30 minutes. Total cellular protein was 
subjected to western blot analysis using anti-phospho-ERK1/2, anti-ERK1/2 antibodies (B). 
Abbreviations: M – molecular weight marker; kD - kilo Dalton; p – phosphorylated. Identical 






































7.4.3.4 The IGF-1 receptor kinase inhibitor PQIP inhibits IGF-1 and cancer-induced 
spreading and motility of osteoclasts and their precursors 
 Xcelligence analysis was used to further elucidate the impact of IGF-1 receptor 
inhibition on the crosstalk between MDA-MB-231 cells and osteoclasts and their 
precursors. M-CSF generated macrophages were plated on Xcelligence plates and allowed 
to grow for 24 hours. In the presence and absence of PQIP, they were then treated with M-
CSF (25 ng/ml), RANKL (100 ng/ml), and either control conditioned medium (10%), IGF-1 
(100 ng/ml) or MDA-MB-231 conditioned medium (10%).  
Figure 7.14 shows a representative graph of the complete changes in cell index over 
the 96 hours of the experiment. Long term changes in cell index value are normally thought 
to represent changes in proliferation rate.  As seen in Chapter 3, MDA-MB-231 conditioned 
medium causes an immediate, rapid increase in cell index unlikely to represent 
proliferation, but also causes a change in the long term rate of increase in cell index that 
does represent cell proliferation. Here, between 24 and 72 hours, the proliferation rate of 
MDA-MB-231 conditioned medium treated cells was significantly higher (283% increase 
p<0.05). This was not inhibited by the IGF-1 receptor kinase inhibitor PQIP. Neither IGF-1 
nor PQIP treatment alone significantly altered the long-term proliferation rate of RANKL 
















Figure 7.14 The IGF-1 receptor inhibitor PQIP inhibits long-term IGF-1 and MDA-MB-231 
conditioned medium induced increases in osteoclast impedance values in Xcelligence analysis. 
M-CSF generated macrophages were seeded onto xcelligence plates and allowed to grow for 24 hours with 
M-CSF (25 ng/ml). Cells were then treated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) plus vehicle, IGF-1 
(100 ng/ml), or 10% MDA-MB-231 conditioned medium, in the presence or absence of PQIP (200 nM). 
Treatment was refreshed after 48 hours. A) shows a representative graph of the cell index values (derived 
from their electrical impedance) over the full 96 hours of the experiment and normalized to the last time 
point before the first treatment. B) A graph showing the average slope of the graph between hours 39 and 






To investigate the effect of the IGF-1 receptor inhibitor PQIP on IGF-1 and breast 
cancer induced changes in osteoclast spreading and motility, changes in cell index value in 
the first three hours after treatments were investigated in detail. These changes are taken 
to represent different aspects of treatment effects between different time points. The first 
30 minutes after treatment represent changes in cell morphology or spreading, the next 
two hours represent changes in cell motility or migration measured by the rate of change in 
cell index value. After two and a half hours cell index values are taken to represent long 
term proliferation. Figure 7.15 shows that MDA-MB-231 conditioned medium causes both 
changes in cell morphology and a large and significant increase in cell motility (442% 
increase p<0.01).  PQIP treatment does not inhibit either the cancer conditioned medium 
induced changes in cell morphology, or the rate of increase in cell motility. However, PQIP 
does seem to reduce the final cell index value reached during this period, suggesting an 
inhibition of the overall migration of these cells. IGF-1 treatment does not cause the 
complex changes in cell morphology observed with MDA-MB-231 conditioned medium 
treatment. However, IGF-1 does cause a modest but significant increase in the motility of 








Figure 7.15 The IGF-1 receptor inhibitor PQIP inhibits initial IGF-1 and MDA-MB-231 conditioned 
medium induced increases in osteoclast impedance values in Xcelligence analysis. M-CSF generated 
macrophages were seeded into xcelligence plates and allowed to grow for 24 hours in M-CSF (25 ng/ml). Cells 
were then treated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) plus vehicle, IGF-1 (100 ng/ml), or 10% 
MDA-MB-231 conditioned medium, in the presence or absence of PQIP (200 nM). Treatment was refreshed 
after 48 hours. A) shows a representative graph of the cell index values (derived from their electrical 
impedance) for the first 3 hours after the start of treatments and normalized to the last time point before the 
treatment. B) A graph showing the average slope of the linear portion of the graph between hours 24 and 25. 








 The insulin-like growth factor/insulin system of receptors and ligands are thought 
to play a major role in the proliferation and migration of various tumour types, and are 
likely to be involved in the development of bone metastases (277, 471). Evidence from a 
number of pharmacological, clinical and epidemiological studies demonstrates that high 
levels of circulating IGF-1 and lower levels of its binding proteins are associated with 
increased risk of various cancers including breast cancer (493, 499). In view of this, recent 
studies have focused on IGF-1 receptor as a possible therapeutic target for the treatment of 
tumour cell growth and metastases (277, 287, 471, 500, 501). 
 IGF-1 receptor inhibition has previously been shown to inhibit the viability of a 
variety of tumour cells (483). In this study we looked at the possibility that it may directly 
reduce the number of cancer cells in a bone metastasis. MDA-MB-231 cell viability was not 
affected by either IGF-1 or PQIP treatment after 72 hours, though IGF-1 did induce AKT 
phosphorylation which was inhibited by PQIP; indicating that IGF-1 signalling is active in 
these cells. Other osteolytic tumour cells showed a variable response, while neither 4T1 nor 
MC57G cells were affected by PQIP treatment, the growth of MCF7 cells was strongly 
inhibited. Xcelligence analysis of MDA-MB-231 cells and 4T1 cells showed no long-term 
effects of either IGF-1 or PQIP, though 4T1 cells did show reduced initial spreading in 
response to PQIP. The viability, adherence and spreading of MCF-7 cells on the other hand 
were strongly induced by IGF-1 and inhibited by PQIP.  This finding is in agreement with 
previous studies which have shown that inhibition of IGF-1 signalling by PQIP inhibits 
tumour proliferation in a variety of human breast cancer cells including MCF7, while other 
cell lines were unaffected by PQIP (483). This selective inhibition of tumour cell 
proliferation by PQIP correlates with the co-expression of ligand-receptor pairs within the 
IGF axis (502). 
 Next, I investigated the effect of the novel IGF-1 receptor kinase inhibitor PQIP on 
breast cancer-induced bone cell activity in vitro. While not effecting MDA-MB-231 viability, 
PQIP was capable of suppressing osteoclast formation stimulated by the addition of 
conditioned medium from MDA-MB-231 cells. When all osteoclasts were counted this 
reduction was only apparent using the weakest conditioned medium treatment. However, 




conditioned medium induced increase in osteoclast number was abolished. This suggests 
that this effect is mainly on osteoclast size and therefore may be in response to an 
inhibition of osteoclast fusion, rather than their initial genesis. Testing using other 
osteolytic tumour cells showed that this inhibitory effect was true in each case, and was 
particularly strong for MCF7 cells where tumour cell viability was also affected. MDA-MB-
231 cells were previously shown to induce increases in osteoblast production of RANKL 
(Chapter3). In this chapter we show that PQIP inhibits MDA-MB-231-induced increases in 
the RANKL/OPG ratio in osteoblasts.  These results, together with the finding that PQIP 
inhibited RANKL production by osteoblasts (Chapter 6), show for the first time that IGF-1R 
inhibition is sufficient to disrupt both osteoblast and tumour cell support for 
osteoclastogenesis. The fact that PQIP inhibited AKT phosphorylation but not ERK1/2 
activation by conditioned medium from MDA-MB-231 cells suggests that inhibition of 
PI3K/AKT pathways downstream of IGF-1 may be responsible for these effects. 
 In osteoblast cultures, treatment with PQIP exacerbated the inhibitory effects of 
MDA-MB-231 derived factors on osteoblastogenesis. Not only was inhibition of osteoblast 
differentiation and function significantly worsened, but while individually PQIP and MDA-
MB-231 conditioned medium had little effect on cell viability, together they drastically 
reduced cell number. This may be a non-specific toxic effect, or may result from the 
removal of the positive effect of IGF-1-receptor mediated signals from the conditioned 
medium treatment. Regardless, these results indicate that PQIP treatment is likely to inhibit 
osteoblast survival, differentiation and activity in bone metastatic environment.  
In both osteoblasts and osteoclasts the PI3K/AKT signalling pathway was stimulated 
by MDA-MB-231 conditioned medium. Importantly in both cases PQIP inhibited this tumour 
induced effect.  However PQIP failed to inhibit ERK1/2 activation by conditioned medium 
from MDA-MB-231 cells, suggesting that inhibition of tumour induced PI3K/AKT pathways 
downstream of IGF-1 may be responsible for the effects seen, while ERK1/2 is activated by 
other tumour cell produced factors.  Although our studies clearly indicate that PQIP exerts a 
direct inhibitory effect on IGF-1 induced PI3K/AKT signalling, we cannot exclude the 
possibility that the tumour cells may produce other factors that can act through IGF-1 
receptor, or indeed through the insulin receptor, and may also contribute to signalling via 




 Xcelligence analysis seems to confirm the hypothesis that inhibition of IGF-1 
signalling induced by cancer cell conditioned medium by PQIP is responsible for the effects 
seen. IGF-1 treatment caused a similar pattern of effects to that seen with MDA-MB-231 
conditioned medium treatment, albeit at a far lower efficiency and with less complexity at 
the initial treatment. In both cases PQIP significantly reduced the cell index values seen, 
and with IGF-1 treatment abolishing the increases seen. At the initial treatment point IGF-1 
caused an increase in the rate of cell index increase, and this was the only early aspect of 
the MDA-MB-231 conditioned medium treatment inhibited by PQIP. This period is likely to 
represent induced increase in cell migration and spreading, fitting with the hypothesis that 
PQIP inhibits tumour cell induced osteoclast fusion by inhibiting IGF-1 signalling, though 
further work using complementary techniques is needed to confirm this. Altogether, the 
findings presented here imply that targeting IGF-1R signalling may be useful in the 
treatment of osteolytic bone disease, even if tumour growth is not directly affected.  
 In conclusion, the studies performed here demonstrate that preventing IGF-1 
signalling using the novel selective human IGF-1R kinase inhibitor PQIP directly suppresses 
tumour cell support for osteoclastogenesis in vitro. Moreover, the results presented in this 
chapter have successfully shown the usefulness of the techniques developed in the 
preceding chapters for studies investigating tumour cell-bone cell crosstalk. Therefore, 
selective small molecule tyrosine kinase inhibitors of IGF-1R such as PQIP and its analogue 
OSI-906 (503), which is currently in advanced clinical development, may have clinical value 









The effects of the novel IGF-1 receptor 
kinase inhibitor PQIP on breast cancer-






 In previous chapters, IGF-1 signalling was found to regulate normal bone cell 
function, tumour cell-bone cell cross-talk and it is known to influence tumour cell migration 
in vitro. It was therefore hypothesised that inhibiting the IGF-1R may prevent high bone 
turnover and osteolysis associated with breast cancer in vivo by inhibiting cancer-induced 
osteoclastic and osteoblastic changes and perhaps also indirectly reduce the proliferation 
of tumour cells. In view of this, the effect of PQIP on bone turnover and osteolysis 
associated with breast cancer was studied ex vivo and in vivo. 
Ex vivo, the effects of PQIP on osteolysis were studied using the human MDA-MB-
231 - mouse calvarial co-culture system. Treatment with PQIP (500 nM) prevented 
osteolysis and caused a significant gain in bone volume in comparison to vehicle treated 
cultures.  This effect was likely mediated through direct effects on bone cells and tumour 
cell-bone cell cross-talk as PQIP had no effect on MDA-MB-231 viability and growth. 
 To investigate the effects of oral PQIP treatment on the development of osteolytic 
bone metastases in vivo, the mouse 4T1 breast cancer cell model was used. Oral daily 
administration of PQIP (100 mg/kg) inhibited osteolysis and caused a significant gain in 
bone volume when compared to sham mice. A detailed bone histomorphometric analysis 
showed that osteoclast numbers and active resorption surfaces were increased following 
4T1 cell inoculation in vehicle treated mice, whereas these effects were totally prevented 
following treatment with PQIP. Treatment with PQIP (100 mg/kg) also reduced osteoblast 
number, osteoid surface, mineral apposition rate and bone formation rate, indicative of a 
significant reduction in osteoblast activity and bone formation. Analysis of tumour size in 
histological sections showed that PQIP had no effect on tumour volume within osteolytic 
lesions. 
 Overall, this chapter succeeded in demonstrating the effectiveness of the ex vivo 
and in vivo bone metastasis model techniques developed in Chapter 4 for examining breast 
cancer-induced osteolysis; though the in vivo model is in need of refinement. IGF-1 
receptor inhibition by PQIP treatment was found to reduce osteolytic bone destruction in 
both ex vivo and in vivo studies. Therefore, PQIP, or its analogue OSI-906, may be a useful 
clinical tool in the treatment of osteolytic bone metastasis, though its effects on reducing 





 As discussed in Chapters 6 and 7, IGF-1 and its receptor have been shown to be 
involved in the regulation of both bone and cancer.  Previous in vivo experiments using 
knockout mice demonstrated that IGF-1 receptor deficiency causes a unique and complex 
skeletal phenotype with 24% less cortical bone and shortened femurs, but increased 
trabecular bone density and connectivity (293, 478, 479). Without IGF-1 signalling present 
both osteoblast and osteoclast function are severely reduced (290, 294, 477). Until this 
thesis no in vivo work had been performed studying the effect of IGF-1 receptor inhibition 
on osteolytic bone metastasis. 
In Chapter 6 of this thesis the effects of IGF-1 receptor inhibition by PQIP on bone 
cell cultures in vitro was demonstrated. In all cell types IGF-1 induced PI3K/AKT signalling 
was inhibited by pre-treatment with PQIP and it was found that PQIP inhibited IGF-1 
induced increases in various bone cell attributes. These included osteoblast differentiation, 
function, migration and RANKL production, as well as osteoclast formation and survival. No 
effects on cell viability were observed in all cultures tested.  
IGF-1 and its receptor are known to be involved in the development of various 
cancers as well as the stimulation of both cancer cell proliferation and migration (275, 495). 
It appears to be particularly important for the development and progression of bone 
metastases from breast cancer. (273, 496, 497). In Chapter 7 of this thesis we investigated 
the effects of PQIP on cancer cell behaviour and cross-talk with bone cells in vitro. These 
studies showed that the IGF-1 receptor inhibitor PQIP inhibited breast cancer induced 
increases in osteoclast formation, resorption and fusion, as well as osteoblast support for 
osteoclastogenesis. Breast cancer cell conditioned medium caused a signalling cascade 
through the PI3K/AKT pathway and PQIP treatment was able to prevent this. However, in 
two of the three cell lines studied PQIP did not cause any direct inhibition of cancer cell 
viability. 
 While oral treatment with PQIP has been previously been shown to regress tumour 
cell growth in vivo in certain cell lines (483), no previous work has studied its effects on 




explored in Chapter 4 were used to investigate the effects of PQIP on breast cancer-induced 
osteolysis ex vivo and in vivo.  







 The aim of this chapter was to test the use of PQIP as a potential therapeutic agent 
for the treatment of bone metastasis. This was achieved using the adapted calvarial organ 
culture and intratibial injection models of bone metastasis devised in Chapter 4. The effect 
of IGF-1 receptor inhibition on overall osteolysis levels and the activity of bone cells in the 







8.4.1 PQIP protects against breast cancer-induced osteolysis in human MDA-MB-231-
calvaria organ culture  
 To determine the effect of IGF-1 receptor inhibition on breast cancer-induced 
osteolysis ex vivo the adapted calvarial organ cultures were used. Calvaria were divided 
down the median sagital suture into two equal halves. These halves were then separately 
placed onto mesh platforms above pre-seeded MDA-MB-231 cells in 48 well plates. Halves 
were treated with either vehicle (DMSO 0.1%) or PQIP (500 nM) for one week and bone 
mass then quantified by µCT analysis. Figure 8.1 shows representative μCT images of the 
calvaria halves. In the vehicle treated cultures bone loss is clearly visible throughout the 
calvarial tissue, indicating osteolysis. In contrast, treatment with PQIP (500 nM) can visually 
be seen to have prevented osteolysis in the three dimensional images and when quantified 
percent bone volume is 75% higher (p<0.01) than that found in the vehicle treated calvaria. 
AlamarBlue was used to determine if the effects seen may be due to a loss of MDA-MB-231 
cell viability. PQIP had no significant effect on MDA-MB-231 viability and growth thereby 







Figure 8.1 The IGF1 receptor kinase inhibitor PQIP prevents MDA-MB-231-induced 
osteolysis in mouse calvaria organ cultures. Panel A shows representative photomicrographs 
of mouse calvarias. Panel B shows the relative number of viable MDA-MB-231 cells in the wells 
below the calvaria as measured by the AlamarBlue assay. These were exposed to vehicle or PQIP 
(500 nM) through out the experiment. Panel C shows bone volume in neonatal mouse calvarias 
isolated from 7 day-old mice and then co-cultured with human MDA-MB-231 breast cancer cells 
prior exposure to vehicle (veh; 0.1% DMSO) or PQIP (200 nM) for 7 days. *=p<0.01 from MDA-MB-





8.4.2 PQIP protects against breast cancer-induced osteolysis in mice  
 To determine the effects of IGF-1 receptor inhibition on osteolytic bone metastasis 
in vivo an intratibial injection experiment using 4T1 cells was performed. 12 six-week old 
Balb/c wild type mice were randomly divided into two groups of six, one group received 
once daily oral treatment with vehicle (tartaric acid 25 mM) and the other with 100 mg/kg 
PQIP. After the injection of 4T1 cells, 7 days were allowed for recovery and establishment 
of metastases before oral treatment began. The effects of PQIP on 4T1 intratibial injection 
induced bone loss were then monitored by examining trabecular bone loss at the proximal 
tibiae metaphysis using in vivo μCT analysis.  All results were compared to data derived 
from in vivo μCT of the tibiae prior to intratibial injection.  
 Figure 8.2B shows that by day 7 after intratibial injection the presence of 4T1 cells 
had caused significant osteolysis. Before the start of oral treatment (day 7) there was no 
difference between the mice to be treated with vehicle (24.41% bone loss±1.67) and those 
to be treated with PQIP (23.38% bone loss ±4.83). In both groups bone loss was significantly 
higher than that seen in the sham injected legs (p<0.01). After treatment (Figure 8.2C) in 
the mice treated with vehicle the percentage of bone lost continued to increase through 
the treatment period (43.5% bone loss ±3.85). In contrast, in the mice treated with PQIP 
trabecular volume did not significantly differ from the start of the treatment period and 
was significantly lower than in the vehicle treated mice (17.84% bone loss ±2.84, p<0.01). It 














Figure 8.2 The IGF1 receptor kinase inhibitor PQIP prevents 4T1-induced osteolysis in vivo. 6-week old female Balb/c WT mice received 
intratibial injections of 5x10
3
 4T1 breast cancer cells into their right leg and a sham injection of PBS into their left leg. After 7 days once daily oral 
treatment with either vehicle or PQIP (100 mg/kg) was begun and continued for one week. Tibia were analysed by in vivo microCT analysis. 
Animals were sacrificed 14 days after intratibial injection. Panel A shows representative microCT images of the proximal tibia metaphysis at the 
conclusion of the study. Panels B and C show the percent change in the trabecular bone volume of the tibia from the beginning of the study to 
when treatment was started (B) after 7 days and the conclusion of the experiment (C). Values are means ± standard deviation. 6 mice per group. 





Detailed μCT analysis of several features of the trabecular bone in the proximal 
tibial metaphysis was performed. The results seen complement the pattern of bone loss 
shown above. Figure 8.3 shows that 7 days after inoculation with 4T1 cells there was a 
significant reduction in trabecular thickness when compared to sham (loss of 6.47% ±1.78 
or 9.51% ±2.26, p<0.05). While the presence of 4T1 cells appeared to cause a reduction in 
trabecular number and an increase in trabecular pattern factor, at the start of treatment 
this was not significantly different from sham. Prior to the start of PQIP treatment there 
was no difference between the two sets of 4T1 injected tibiae. By the end of the treatment 
period the trabecular bone of vehicle treated, 4T1 inoculated tibia had significantly lost 
both trabecular thickness (11.97% ± 1.53 loss, p<0.05) and number (35.70% ± 3.20 loss, 
p<0.01) when compared to sham. Trabecular pattern factor was increased but was not 
significantly different from sham. In mice treated with PQIP, by the end of the experiment 
4T1 injected tibiae were no longer significantly different from sham injected tibia. In 
comparison to the 4T1 injected tibia of vehicle treated mice, PQIP treatment had 
significantly reduced the loss of trabecular thickness, number and increases pattern factor 






Figure 8.3 The IGF1 receptor kinase inhibitor PQIP prevents 4T1-induced changes to trabecular 
thickness, number and pattern factor. 6-week old female Balb/c WT mice received intratibial 
injections of 5x10
3
 4T1 breast cancer cells into their right leg and a sham injection of PBS into their left leg. 
After 7 days once daily oral treatment with either vehicle or PQIP (100 mg/kg) was begun and continued 
for one week. Tibia were analysed by in vivo microCT analysis. Animals were sacrificed 14 days after 
intratibial injection. Trabeculae were analysed at day 7, the start of treatment (A, C and E), and at the 
conclusion of the experiment (B, D, and F) Trabecular aspects analysed were trabecular thickness (A, B), 
number (C, D) and pattern factor (E, F). Values are means ± standard deviation. 6 mice per group. 





8.4.3 PQIP inhibits breast cancer-induced osteoclast formation and resorption in mice  
  
 Detailed histomorphometry analysis was carried out to determine the cellular 
mechanisms behind the effects of PQIP on trabecular bone volume and attributes observed 
in Figures 8.2 and 8.3. Figure 8.4 shows that both osteoclast number (68% increase, p<0.01) 
and active resorption surfaces (88% increase, p<0.01) increased following 4T1 cell 
inoculation in vehicle treated mice, indicating a significant increase in osteoclast formation 
and function in vivo. Treatment with PQIP (100 mg/kg) totally prevented the increase in 
osteoclast number (31.8% reduction, p<0.05) and significantly reduced the 4T1-induced 
stimulation of active resorption surfaces (38.5% reduction, p<0.05). Serum was analysed for 
concentrations of C-terminal telopeptide of type I collagen (CTX) to allow conformation of 
the reduction in bone metabolism uncovered by histomorphometry. Figure 8.4B shows that 
both vehicle and PQIP treated mice demonstrated an increased concentration of CTX in 
serum, indicating increased bone resorption (56% increase, p<0.05). No reduction in serum 







Figure 8.4 The IGF1 receptor kinase inhibitor PQIP prevents 4T1-induced increases in 
osteoclast number and activity in vivo. 6-week old female Balb/c WT mice received 
intratibial injections of 5x10
3
 4T1 breast cancer cells into their right leg and a sham injection of 
PBS into their left leg. After 7 days once daily oral treatment with either vehicle or PQIP (100 
mg/kg) was begun and continued for one week. At the conclusion of the experiment serum was 
collected and tibia were analysed by histomorphometry.  Panel A is a table displaying the 
number of osteoclasts per bone surface (Oc.N/BS) and the percentage of bone surface 
undergoing resorption (ES%) in each group studied. Panel B displays representative images of 
histological sections from 4T1 injected tibia of mice treated with vehicle or oral PQIP (100 
mg/kg). These are stained with Aniline blue (collagen) and TRAcP stain (Red) for the osteoclasts. 
Panel C shows a graph of the serum concentrations of C-terminal telopeptide of type I collagen 
(CTX) in the mice used in this study and control mice.  Values are means ± standard deviation. 6 





8.4.4 PQIP inhibits basal and breast cancer-induced bone formation in mice 
 Detailed histomorphometry and calcein double labelling analysis was performed to 
examine the effect of 4T1 intratibial injection and oral PQIP treatment on osteoblasts and 
bone formation in vivo. Figure 8.5A shows that inoculation with 4T1 cells did not cause any 
significant change in osteoblast number, bone formation rate or osteoid surface or width. 
Mineral apposition rate however was moderately but significantly increased (13% increase, 
p<0.05) in the presence of the cancer cells. During the 7 days of treatment, inhibition of the 
IGF-1 receptor by PQIP in the absence of tumour cells did not cause a reduction in the 
number of osteoblasts or the area where they were producing osteoid. It did however 
significantly reduce the width of the osteoid (15% less, p<0.05), the mineral apposition 
rates (19% less, p<0.01) and most strikingly the bone formation rate (31% less, p<0.01). In 
tibiae where 4T1 cells were present, the effect of PQIP was enhanced.  The 4T1 induced 
increase in mineral apposition rate was abolished (35% less, p<0.01), and bone formation 
rate was more than halved (53% less, p<0.01).  In addition to the significant loss of osteoid 
width also observed with PQIP treatment alone, when 4T1 cells were also present PQIP 
decreased the percentage of bone surface covered with osteoid (29% less, p<0.01). Overall, 
PQIP treatment inhibited bone formation in the absence of cancer cells, inhibited any 
positive effects on bone formation observed in response to  intratibial injection of 4T1 cells, 
and caused further negative changes to osteoblasts when in combination with cancer cells. 
 Serum was analysed for concentrations of procollagen type 1 amino-terminal 
propeptide (P1NP) to allow conformation of the reduction in bone formation observed in 
response to PQIP treatment. Figure 8.5B shows that the presence of 4T1 cells caused a 
significant increase in serum P1NP (52% increase, p<0.05), this effect was abolished in mice 

















Figure 8.5 The IGF1 receptor kinase inhibitor PQIP inhibits basal and 4T1-induced 
increases in bone formation. 6-week old female Balb/c WT mice received intratibial 
injections of 5x10
3
 4T1 breast cancer cells into their right leg and a sham injection of PBS into 
their left leg. After 7 days once daily oral treatment with either vehicle or PQIP (100 mg/kg) was 
begun and continued for one week. At the conclusion of the experiment serum was collected 
and tibia were analysed by histomorphometry and calcein double labelling analysis. Panel A is a 
table displaying the number of osteoblasts per bone surface (Ob.N/BS), the percentage of bone 
surface covered with osteoid (Os.S), Osteoid width (Os.W), Mineral Apposition rate (MAR) and 
Bone Formation Rate (BFR) in each group studied. Panel B shows representative images of  
calcein double labelling from 4T1 injected legs of mice treated with vehicle or oral PQIP (100 
mg/kg). Panel C shows a graph of the serum concentrations of C procollagen type 1 amino-
terminal propeptide (P1NP) in the mice used in this study and control mice.  Values are means ± 
standard deviation. 6 mice per group. *=p<0.05 reduction from vehicle treated, #=p<0.05 





8.4.5 PQIP has no effects on tumour growth and size in mice  
 The effect of oral PQIP treatment (100 mg/kg qd) on the growth of 4T1 breast 
cancer cells within the proximal tibial metaphysis was analysed through measurement of 
tumour volume in histological sections. Figure 8.6 shows that no significant change in 







































Figure 8.6 The IGF1 receptor kinase inhibitor PQIP did not inhibit 4T1 tumour growth 
in vivo. 6-week old female Balb/c WT mice received intratibial injections of 5x103 4T1 breast 
cancer cells into their right leg and a sham injection of PBS into their left leg. After 7 days once 
daily oral treatment with either vehicle or PQIP (100 mg/kg) was begun and continued for one 
week. At the conclusion of the experiment tumour size was analysed by histological analysis. 
Representative images of the histological sections stained with Von Kossa and paragon staining 
are shown in A. A graph of the tumour area as a percentage of total volume is displayed in B.  





8.4.6 PQIP reduced body weight in mice  
 IGF-1 is known to play an important role in the regulation of development and 
growth (504-506). As shown in Figure 8.7, treatment with PQIP (100 mg/kg, qd) caused a 
significant reduction in body weight (13% reduction, p < 0.05) in mice after 7 days of 







 8.4.7 PQIP has no effects on mortality in mice  
 No animals associated with this study died before or during the experimental 
period.  
Figure 8.7 The IGF1 receptor kinase inhibitor PQIP caused a significant reduction in 
body weight. 6-week old female Balb/c WT mice received intratibial injections of 5x103 4T1 
breast cancer cells into their right leg and a sham injection of PBS into their left leg. After 7 days 
once daily oral treatment with either vehicle or PQIP (100 mg/kg) was begun and continued for 
one week. The weights of mice were recorded every day and are displayed above. Values are 






 IGF-1 signalling is known to be important for both bone homeostasis and in the 
development and metastasis of tumour cells to bone. A number of recent studies have 
reported that tyrosine kinase inhibitors and monoclonal antibodies that inhibit the IGF-1 
receptor, alone or in combination with inhibition of other receptors, exert anti-tumour 
effects in animal models of cancer (507). A derivative of PQIP, OSI-906, that inhibits both 
IGF-1R and IR is currently in clinical trials for this very purpose (503). Here, instead of 
focusing on the possible effect on tumourgenesis and viability, we investigated the 
potential synergistic effects of IGF-1 receptor kinase inhibition on osteolytic bone disease. 
IGF-1 is known to be produced by tumour cells, as well as being the most abundant growth 
factor in the bone microenvironment, in particular being released from the bone matrix by 
resorption. We therefore hypothesised that inhibiting IGF-1 signalling would lead to 
reduced tumour induced osteolytic damage, and may also reduce the proliferation of 
tumour cells supported by bone and tumour derived IGF-1 production. 
  First, we investigated the effects of PQIP on the osteolysis associated with human 
breast cancer using the human MDA-MB-231 - mouse calvarial organ culture developed in 
chapter 4. In this culture system treatment with PQIP completely prevented MDA-MB-231-
induced osteolysis leading to the observation of significantly higher calvarial bone volumes 
both visually in 3 dimensional μCT reconstructions, and quantifiably through μCT analysis. 
At concentrations that prevented osteolysis, PQIP had no effects on the survival of MDA-
MB-231 breast cancer cells. This implies that IGF-1R signalling in or from breast cancer 
and/or bone cells may contribute to breast cancer-induced osteoclast formation and 
osteolysis. In this study, PQIP has been shown to reduce osteoclast number and size as well 
as the production of the key osteogenic factor RANKL by osteoblasts (Chapter 6). Based on 
these findings, it seems likely that a combination of direct inhibition of basal and tumour 
induced osteoclast formation, and indirect inhibition through reduction in RANKL 
production is responsible for the reduction in osteolysis observed.  
 The in vivo intratibial experiment presented here suffered from a variety of 
problems. The most obvious of which is the strong induction of trabecular bone loss 
observed in the sham injected legs. This was probably to be expected. Whilst every effort 




bone loss is due to physical destruction caused by the needle during intratibial injection, or 
by the pressure of the PBS fluid pushing out bone marrow as it was injected into the bone 
cavity. Even once the process of injection was finished, inflammatory and immune 
responses within the injection site are likely to have led to further loss of bone mass. In 
addition to this, the highly proliferative nature of the 4T1 cells and low initial seeding 
density meant that there was a high degree of variability between 4T1 injected legs and 
that only a small therapeutic window of PQIP treatment (one week) was possible.  
 Despite these problems the experiment was a success. 4T1 cells caused the 
significant reduction in trabecular bone mass indicative of osteolysis, without causing the 
extensive cortical damage seen in long term experiments (Chapter 4). This 4T1-induced 
osteolysis was characterised by a significant reduction in both trabecular number and 
thickness, as well as an increase in trabecular pattern factor, indicating a reduction in bone 
connectivity. This suggests a loss of bone caused by an increase in bone resorption, which 
was confirmed as histological analysis demonstrated a significant increase in both 
osteoclast number and resorption. Oral PQIP treatment resulted in a significant reduction 
but not complete prevention of these changes at the experiments conclusion. Analysis of 
serum from the mice at the end of the experiment showed an increase in CTX levels in mice 
inoculated with 4T1 cells; another indication of increased bone resorption. However in this 
case PQIP treatment failed to reduce the cancer induced increase. This failure is 
disappointing but may be explained by the high levels of variability associated with serum 
CTX. While every effort was made to maintain similar conditions between grouping of mice 
relatively minor differences in diet and time of sampling are known to cause serum CTX 
values to vary by up to 60% (508). 
Analysis of tumour size in histological sections showed that PQIP (100 mg/kg, qd) 
had no effect on tumour volume within osteolytic lesions in the metaphysis of the proximal 
tibia. While this is disappointing, it is consistent with the results shown in Chapter 7. There 
it was shown that while PQIP treatment does cause apoptosis in some cancer cells (483), it 
had no effect on 4T1 cell viability or proliferation in vitro. The direct effect of PQIP on 
cancer cell viability has been demonstrated to be related to co-expression of ligand-
receptor pairs within the IGF axis (502). It was hypothesised that preventing osteolytic 




‘vicious cycle’ signalling inducing the proliferation of tumour cells. This may still be true but 
was not observed in this short-term study. Either the fact that 4T1 cells proliferate rapidly 
or the short period of treatment time could explain why this effect was not seen. 
 Osteoblasts were the most affected cells when PQIP was analysed in vitro (Chapter 
6), and so osteoblast cell number and function were here analysed by histomorphometry 
and calcein labelling analysis. In both sham and 4T1 injected legs PQIP caused a significant 
reduction in both mineral apposition rates and bone formation rates. This reflects work by 
Zhang et al (2002) who showed that an osteoblast conditional knockout of IGF-1 receptor 
resulted in reduced mineralisation (290). Interestingly this reduction was stronger in the 
4T1 injected tibia, and this could not be fully explained by the modest increase in mineral 
apposition rate induced by the presence of 4T1 cells. Tellingly, when osteoblast cells and 
osteoid were analysed by histomorphometry, only in 4T1 injected tibia did PQIP treatment 
cause a significant reduction in osteoblast cell number and the percentage of trabecular 
bone covered by osteoid. This finding is consistent with the effects of PQIP on bone nodule 
formation in vitro (Chapter 6), where only in combination did MDA-MB-231 conditioned 
medium and PQIP cause a reduction in osteoblast viability. Analysis of serum from the mice 
at the end of the experiment showed that PINP levels were significantly reduced by PQIP, 
thereby indicating a significant reduction in bone turnover and to some extent confirming 
the inhibition of bone formation and mineral apposition observed in the PQIP treated mice.  
 Overall, the results of the present study show that inhibition of IGF-1 receptor 
kinase activity in bone and tumour cells caused a significant reduction in cancer-induced 
osteoclastic and osteoblastic changes thereby leading to a significant reduction in bone 
turnover and the osteolysis associated with breast cancer. Despite this, more work is 
needed and there are several questions that must be answered by future research. Firstly, 
is the inhibition of bone loss observed significant enough to prevent further skeletal 
complications such as bone pain and fractures? Secondly, does the inhibition of IGF-1 
receptor signalling cause a reduction in tumour cell proliferation induced by the vicious 
cycle? And lastly is the positive effect of the inhibition of bone loss out-weighed by the 
negative effects of reduced bone formation and severe side effects including dramatic 
weight loss? Might not PQIP treatment be of more use in the treatment of osteoblastic 




experiments need to be carried out in the future. These should be models of osteoblastic 
bone metastases. Or if osteolytic metastases are to be studied, models should allow a 
greater therapeutic treatment period, should allow measurement of tumour cell numbers, 
and should causes less inherent damage to the bone microenvironment. Preferably they 
should do this whilst retaining the control of metastasis site seen in this model. To achieve 
this, a number of different models may have to be used including a refined intraossious 
injection model, and either/or an intracardiac or mammary fat pad injection model. To 
allow tracking and quantative observation of the tumour cells, a luminous or fluorescently 
tagged cell line should be used.   
 The aim of this chapter was not simply to evaluate the therapeutic value of PQIP, 
but also to test the value of the in vivo models of bone metastasis designed in Chapter 4. It 
succeeded in this, showing that while the ex vivo adapted calvarial organ culture is fully 
functional, the intratibial injection model, while still usable, has several problems. Future 
work should refine, expand or replace this in vivo model. 
 In conclusion, oral treatment with PQIP was demonstrated to successfully inhibit 
tumour cell induced osteolytic bone destruction ex vivo and in vivo. IGF-1 receptor 
inhibition may therefore be of use as a therapeutic treatment for osteolytic bone 
metastases; though the results presented here suggest it may be associated with a 
significant loss in both bone formation and body weight. The usefulness of the ex vivo 
adapted calvarial organ culture for bone metastases studies was successfully demonstrated, 
and while the in vivo intratibial injections provided usable results, more work is clearly 
needed to improve this bone metastasis model. 



















9.1 Discussions and Conclusions 
Bone metastasis is a common, painful, and often fatal occurrence associated with a 
number of the most common human cancers. Current treatments are insufficient and our 
understanding of the mechanisms underlying the interactions between bone and cancer 
cells is incomplete. The presence of malignant cancer cells in the bone microenvironment 
disrupts the bone remodelling cycle leading to imbalances in the relative amounts of bone 
formation and bone resorption; this then causes either excess bone formation, excess bone 
resorption or both. The origins of the cancer cells strongly correlate with the overall effect 
the malignant tumour cells have on the bone microenvironment. This clearly indicates that 
cancers of the same type likely interact with bone cells through crosstalk involving similar 
factors and signalling pathways. While some of the molecular mechanisms behind these 
interactions are known, most are incompletely understood, or are entirely unknown.  This 
thesis set out with the aim to use existing and novel techniques to set up in vitro, ex vivo 
and in vivo models to study the interactions between osteolytic breast cancer cells and the 
main bone cell types. These models were then used to identify a novel therapeutic target 
for the treatment of osteolytic bone metastasis, and this target used to test the 
effectiveness of the models in a study demonstrating the effects of this novel therapeutic 
intervention on bone metastasis. 
 In Chapter 3, the initial steps of this study broke the ‘vicious’ cycle of bone 
metastasis down into three basic cellular components to allow the development of in vitro 
techniques. These components were the bone forming osteoblast cells, the bone resorbing 
osteoclast cells, and the osteolytic tumour cells themselves. Basic primary cell cultures and 
cell lines of all of these are individually frequently used and various assays are possible to 
look at different aspects of these cell types. To model the interactions between the cancer 
cells and the two bone cell types in isolation from any other influences two techniques 
were used; co-cultures of the cell types, and cancer conditioned medium treatments of 
bone cells. This allowed the development of a comprehensive in vitro model of these 
interactions involving studies using cell cultures, western blot, quantitative RT-PCR, 
Xcelligence analysis, and assays for cell viability, formation, differentiation, and function. 
Prior to this study few groups had used the simple technique of co-culturing cells to look at 




medium, few of these groups had studied the effects on bone cells using these techniques 
in as much depth as is presented in this study. 
 In Chapter 4, two separate models were used to study the overall effects of the 
osteolytic tumour cells on the bone microenvironment. An ex vivo model was used that 
studied tumour cells separated from the bone microenvironment in the form of organ 
cultures. While using an intratibial injection model allowed studies of the overall effects of 
interventions in an environment where all cell types and other local or global factors 
influencing bone turnover were present. In contrast to the success of the in vitro models 
both of these attempts to model the tumour cell-bone cell interactions had flaws, both 
minor and serious. In the ex vivo model, while the adapted calvarial organ culture was 
highly successful at modelling interaction in a flat bone formed by intramembraneous 
ossification, the adapted femoral organ cultures were a failure and clearly need further 
work before a ex vivo model of the more common long bone – bone metastasis is usable. 
As for the intratibial injection model, despite several flaws associated both with the 
technique itself and the circumstances of this study, it was shown to be a usable model of 
in vivo bone metastasis focusing purely on the effects of interactions between the bone 
cells and the tumour cells and ignoring the process of metastasis itself. 
  Chapters 3 and 4 established that osteolytic cell lines cause osteolysis through a 
number of different mechanisms. The human MDA-MB-231 – mouse calvaria organ cultures 
and 4T1 intratibial injections showed that the presence of these tumour cells leads to 
severe osteolysis. While the in vitro studies provided various mechanisms to explain this; 
osteolytic tumour cells caused direct stimulation of osteoclast formation, fusion, and 
function, indirect stimulation of bone resorption through the stimulation of RANKL 
production by osteoblasts, and reduction of bone formation through the inhibition of 
osteoblast differentiation and function. The mechanism behind this was not investigated in 
detail, but it was demonstrated that conditioned medium from tumour cells induced 
signalling through the PI3K/AKT and MAPKinase signalling pathways in both osteoclasts and 
osteoblasts. 
As M-CSF and RANKL are the two key factors in the formation and survival of 
osteoclasts, the possibility of these factors being produced by osteolytic breast cancer cells 




et al (244, 425, 468), but not Nicolin et al (469), I found no evidence of any expression, let 
alone secretion of RANKL by MDA-MB-231 cells. However, as previously noted by Mancino 
et al, Gallet et al and Pederson et al (228, 244, 464) MDA-MB-231 cells express and possibly 
even secrete M-CSF. While it was felt that this was notable and M-CSF is likely to be an 
important factor involved in cell-cell interaction, further studies on the impact of MDA-MB-
231 produced M-CSF showed that either they were negligible, or that due to the 
dependence on exogenous M-CSF in the specific cultures used in this thesis this was not an 
appropriate protein to study. In light of this, it was decided to investigate other factors 
produced by the MDA-MB-231 cells.  PTHrP, TGFβ, IL-1β and IGF-1 were identified and IGF-
1 receptor was chosen for further investigation.  
 The IGF system has long been known to affect both bone and cancer cells in a 
variety of ways, but little is known about its importance in bone metastasis.  Following the 
pattern set down by the in vitro models designed in Chapter 3, the effect of treatment with 
both IGF-1 and the novel inhibitor of IGF-1 receptor kinase, PQIP, on the individual cell 
types was established in Chapter 6. This was followed by looking at PQIP’s effect on 
osteolysis and the interactions between the osteolytic cancer cells and the bone cells in 
Chapters 7 and 8. 
 The mRNA levels of IGF-1 and its receptor were measured in bone cells and it was 
found that IGF-1 was more highly expressed by osteoclasts while the IGF-1 receptor was 
found in all cell types with the highest levels being in osteoblasts. This agrees with the 
hypothesis that IGF-1 acts as a local autocrine/paracrine agent in the bone 
microenvironment, and can act as a linking agent between bone resorption and bone 
formation. PQIP has been previously shown to inhibit the viability of tumour cells in vitro 
and prevent their growth in vivo (483). In this study, except at extremely high doses, PQIP 
treatment did not affect the viability of any of the cell types with the exception of the MCF7 
human breast cancer cell previously shown to be susceptible to IGF-1 receptor inhibition 
(483). Buck et al 2010 demonstrated that in many cell types inhibiting only IGF-1 receptor 
led to the upregulation of other signalling pathways including through the insulin receptor 
(509). This may explain the lack of any effect on viability with PQIP treatment in the cancer 




In the individual cell types PQIP was found to inhibit various IGF-1 induced aspects. 
This included in osteoblasts, differentiation, function, migration and RANKL production, in 
osteoclasts, formation and fusion, and in cancer cells cell adhesion and spreading in some 
cell types. More importantly PQIP was found to modulate the effects cancer cells have on 
bone cells with opposing effects depending on the bone cell type being treated with 
osteolytic cancer cell conditioned medium. 
 In osteoblasts, PQIP increased the effect of the cancer conditioned medium, 
causing a further reduction in osteoblast differentiation and bone nodule formation. In 
addition, when in combination with the conditioned medium PQIP caused a loss of cell 
viability that was not seen when either treatment was given in isolation. It seems likely that 
the observed effects are due to separate pathways being influenced by the two treatments. 
The loss of IGF-1 signalling, known to be important in osteoblast differentiation and 
function, is compounding the overall negative effect on osteoblasts of the large number of 
factors produced by the cancer cells. This includes TGFβ, which is known to inhibit 
osteoblast differentiation and function. PQIP had two other important modulating effects in 
conditioned medium treated osteoblasts. First, it completely inhibited conditioned medium 
induced increases in the RANKL/OPG ratio, implying that in vivo it may prevent any indirect 
stimulation of osteoclast formation due to cancer cells acting on osteoblasts. Secondly, 
western blot experiments demonstrated that PQIP inhibited PI3K/AKT signalling induced by 
the osteolytic cancer conditioned medium. This provides a possible mechanism for the 
cancer cell induced effects on osteoblasts described above and the modulation of them by 
PQIP. 
 In contrast to osteoblasts, in osteoclasts PQIP reduced the impact the cancer cell 
and their derived factors had. In both co-cultures and conditioned medium studies PQIP 
reduced the cancer induced increase in osteoclast size and formation. These effects were 
focused on early formation and fusion of osteoclasts as PQIP had no effect on mature 
osteoclasts or cancer induced bone resorption. 
 The mechanisms behind the effects of PQIP at inhibiting both IGF-1 and cancer 
induced effects on bone cells were investigated. IGF-1 is known to stimulate signalling 
through the PI3K/AKT and MAPkinase signalling pathways and western blot analysis 




play roles in cell survival and proliferation in general, and osteoclast formation in particular 
through RANKL and M-CSF signalling. Western blot analysis excluded any indirect effect of 
PQIP on RANKL or M-CSF actions in osteoclasts. In each cell type IGF-1 induced 
phosphorylation of AKT or ERK, and pre-treatment with PQIP totally ablated this effect at 
concentrations as low as 200-500 nM. In osteoclasts and osteoblasts, MDA-MB-231 cancer 
conditioned medium was shown to stimulate PI3K/AKT and MAPKinase signaling pathways. 
PQIP treatment prevented any cancer conditioned medium induced stimulation of the 
PI3K/AKT pathway, but had no effect on activation of the MAPKinase pathway. This 
suggests that the inhibition of tumour-derived factors signalling through the IGF-1 receptor 
may have been responsible for the effects of PQIP observed in this model. IGF-1 is the 
factor produced by tumour cells most likely to be signalling through the IGF-1 receptor but I 
cannot rule out other factors acting on the receptor including IGF-2 and insulin.  
 I therefore hypothesised that PQIP inhibits cancer induced osteoclast formation by 
inhibiting the actions of tumour derived IGF-1 and other factors that act through the IGF-1 
receptor as well as the autocrine/paracrine actions of bone cell derived IGF-1. This would 
explain the partial inhibition observed as PQIP would not inhibit the effects of the other 
factors produced. Further support of this hypothesis was provided by Xcelligence studies, 
which showed that IGF-1 treatment had a lesser but similar effect on osteoclast spreading 
and fusion to MDA-MB-231 conditioned medium treatment. PQIP completely abolished the 
IGF-1 effects in this study, but only partially reduced the impact of the conditioned medium 
treatment, suggesting inhibition of only the IGF-1 component of the conditioned medium. 
 The ex vivo and in vivo results (Chapter 8) confirmed what was seen in vitro, as in 
both cases PQIP treatment was able to inhibit cancer induced osteolysis. In particular the in 
vivo results mirrored much of the in vitro work, as cancer induced increases in osteoclast 
number were significantly reduced but not totally ablated in vivo, and osteoblast numbers 
were only significantly reduced when both cancer cells and PQIP were present. It can be 
assumed that the reduction in osteoclast numbers was due to multiple effects PQIP had on 
different cell types. It directly inhibited IGF-1 enhanced osteoclast formation both from the 
basal IGF-1 found in the bone microenvironment and osteoclast formation induced by the 
cancer cells, and also indirectly inhibited osteoclast formation and survival by inhibiting the 




however it should be noted that this was by necessity only a short term study of the effects 
of PQIP and the reduction in bone loss observed may have only been a temporary effect. In 
addition PQIP, as expected, strongly inhibited osteoblast function in vivo in sham injected 
legs, and even more strongly in the legs where cancer cells were present. This along with 
the 13% loss of weight observed in PQIP treated mice suggests that PQIP is probably not 
suitable as a long term treatment for osteolysis, but could be of use as a short term 
treatment for severe acute bone metastasis where long term effects are not a 
consideration. Alternatively PQIP may be of more use in the treatment of osteoblastic bone 
metastases such as those typified by prostate tumours. There it may both inhibit the overall 
bone gain, and reduce any excess osteoclast activity also stimulated by the presence of the 
tumour cells. 
Overall, while much could be improved upon, the results reported in this thesis 
clearly demonstrate that the overall aims at the outset have been met. A system for 
specifically exploring each component part of the crosstalk between osteolytic tumour cells 
and bone has been designed using existing and novel techniques. The utility of this system 
has then been demonstrated using the example of IGF-1 receptor kinase inhibition by PQIP, 
and its possibilities as a novel therapeutic in this area successfully explored. Future work 
should complete and improve upon these model systems by developing the ex vivo femoral 
organ culture and improving upon or replacing the existing intratibial injection model of 
bone metastasis. Investigations into the utility of PQIP should be continued, focusing on 
inhibition of IGF-2 signaling, and the long term effects of PQIP treatment in vivo. In 
conclusion, this bone metastasis investigation system has been successfully implemented 
and makes it possible to screen targeted novel therapeutics for their effects on bone cell to 
cancer-cell interactions. Components of it could even be used as a high throughput 
screening mechanism allowing the identification of further novel targets for bone 
metastasis therapy. Finally, this study has highlighted the intricate nature of the molecular 
mechanisms and cellular cross-talk involved in bone metastasis. This reinforces the need for 
future investigations of potential therapeutic agents to use a combination of complex in 





9.2 On going and future work 
 Much of this thesis has involved the setting up and testing of existing and novel 
models of the interactions between bone cells and cancer cells. These models should now 
be utilised and expanded upon in a number of different projects. In fact several projects in 
the Edinburgh Bone and Cancer group are already doing this. 
 The first project to continue this work should, as dicussed above, complete 
investigations into the potential theraputic use of PQIP or indeed its analogue OSI-906 using 
expanded in vivo models of bone metastasis. These should include models of osteoblastic 
metastases such as those from prostate cancers, as well as models of osteolytic disease 
that either allow a longer treatment period for study, or also model the process of 
metastasis itself. 
  Work is ongoing to complete and expand the models described in this thesis. New 
MDA-MB-231 cells have been obtained that have been shown to grow in the bone 
microenvironment. These are being used both for intraossious implantation and 
intracardiac injection models of bone metastasis. They have also had bioluminescent or 
flourescent reporter genes incorporated into them that allow the in vivo monitoring and 
tracking of the progress of metastases. Efforts are also underway to complete the ex vivo 
model with tests of variations of the femoral organ culture in progress to determine a 
working version. Conditioned media experiments have also been expanded, with ongoing 
work demonstrating that the in vivo injection of MDA-MB-231 CM above the calvaria 
causes osteolytic bone destruction. 
 Another ongoing line of inquiry that arose in this thesis is the role that RANK 
expression in breast cancer cells may play in both the targeting of metastasising cancer cells 
to bone and the osteolytic damage caused by them once they are there.  This has formed 
the basis of a new PhD project which is using the models described here to compare the 
metastatic potential and osteolytic effects of cancer cells with or without RANK expression 
knocked down using RNAi techniques. Both the RANK signalling pathway in these cells and 
their responses of to RANKL are also being studied in depth. 
 A second major project that has sprung from this thesis is an effort to identify the 




of specific candidate factors and fractional analysis of the conditioned media followed by 
mass spectrometry to identify new candidates. This is then followed by similar efforts using 
the models to compare the effects of cancer cell with or without the candidate factors 
knocked down by RNAi. 
 In addition to these larger projects several candidate therapeutic agents have 
already been tested or are being tested using the models described here. These include 
hydrogen sulphide releasing NSAIDs (440), canabanoid agonists and antagonists, IKK 
inhibitors and TGFβ inhibitors. 
 Finally, I would propose two further projects based on this thesis. Firstly, a high 
throughput screen of a small molecule library could be performed using the conditioned 
media-osteoclast in vitro models. This could help to identify candidate therapeutic agents 
for the treatment of bone metastasis.  Secondly, I would propose a reversal of the work 
presented here and look instead at the effect of factors produced by bone cells on cancer 
cells using the same conditioned media techniques presented here. This could help to 
identify the reasons why bone metastasis is so common, and may aid in the identification of 
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Appendix 1: Materials, Reagents, Apparatus and Software 
 
1.1 Materials and Reagents used in this study: 
Materials and reagents Supplier 
1.5ml eppendorf tubes with cap Greiner Bio-One Inc, Gloucestershire, UK 
10mM dNTP Mix  Invitrogen, Paisley, UK 
1ml pasteur pipette Fisher Scientific, Leicestershire, UK 
2-methoxyethyl acetate (MEA) Sigma Aldrich, Dorset, UK 
2-Propanol Sigma Aldrich, Dorset, UK 
4T1 ATCC, Manassas, VA-USA 
5X first-strand buffer Invitrogen, Paisley, UK 
99.7-100% AnalaR Ethanol VWR International LTD, Leicestershire, UK 
Acetic Acid Glacial Sigma Aldrich, Dorset, UK 
alamarBlueTM reagent Invitrogen, Paisley, UK 




Amersham HybondTM-P GE Healthcare Life Sciences, 
Buckinghamshire, UK 
Basic fuchsin Sigma Aldrich, Dorset, UK 
Bicinchoninic acid (BCA) protein assay Sigma Aldrich, Dorset, UK 
Borax Taab Lab, Berkshire, UK 
Boric Acid Taab Lab, Berkshire, UK 
Bovine serum albumin Sigma Aldrich, Dorset, UK 
Bromophenol Blue BDH Laboratory Supplies, Poole, Dorset, UK 
Calcein Sigma Aldrich, Dorset, UK 
Centrifuge tubes (15 and 50ml) Fisher Scientific, Leicestershire, UK 
Cetyl pyridinium chloride monohydrate Sigma Aldrich, Dorset, UK 
Chloroform Sigma Aldrich, Dorset, UK 
Collagenase (type 1A) Sigma Aldrich, Dorset, UK 
Copper (II)-sulfate Sigma Aldrich, Dorset, UK 
Cover slips Scientific Laboratory supplies Ltd, Hessle, UK 
CriterionTM XT pre-cast gels (12% Bis-Tris) Bio-Rad Laboratories, Hertfordshire, UK 
CTX serum assay (RatLapsTM EIA) Immunodiagnostic Systems Ltd. (IDS), Boldon 
Colliery, UK 
DEPC Treated Water Invitrogen, Paisley, UK 
Dibenzoylperoxide Leica Microsystems, Milton Keynes, UK 
Dibutyl Phthalate Sigma Aldrich, Dorset, UK 
Diethanolamin Sigma Aldrich, Dorset, UK 
DL-Dithiothreitol (DTT) Sigma Aldrich, Dorset, UK 
DMSO Sigma Aldrich, Dorset, UK 
DNA Ladder 1kb New England Biolabs, Hitchin, Hertfordshire, 
UK 
dNTPs Promega, Southampton, UK 
DPX mounting medium Sigma Aldrich, Dorset, UK 
DTT Invitrogen, Paisley, UK 
EDTA Sigma Aldrich, Dorset, UK 
Electrophoresis power supply Anachem, Bedfordshire, UK 
Embedding baskets Leica Microsystems, Milton Keynes, UK 
Embedding molds Custom-made by the University workshop 
Embedding rings Leica Microsystems, Milton Keynes, UK 
Ethanol Absolute Fisher Scientific, Leicestershire, UK 
EU One-piece, non-skirted thin wall plate natural Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 
EU One-piece,sub-skirted Thin wall plate white Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 
EU OP flat cap thin wall 8-cap strip Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 




Fetal calf serum (FCS) Fisher Scientific, Leicestershire, UK 
Filter Paper Fisher Scientific, Leicestershire, UK 
Filter Tips Axygen Thistle Scientific, Glasgow, UK 
Forceps watchmaker’s Fisher Scientific, Leicestershire, UK 
Fuchsin Acid Taab Lab, Berkshire, UK 
Gelatin Sigma Aldrich, Dorset, UK 
Glycerol 2 phosphate Sigma Aldrich, Dorset, UK 
Glycine BDH Laboratory Supplies, Poole, Dorset, UK 
Hanks buffer (HBSS) Sigma Aldrich, Dorset, UK 
HistoResin Mounting Medium (solution and 
powder) 
Leica Microsystems, Milton Keynes, UK 
Human insulin-like growth factor 1 R & D Systems, Abingdon, UK 
Hydrochloric acid BDH Laboratory Supplies, Poole, Dorset, UK 
Invisorb® Spin Tissue Mini Kit Thistle Scientific, Glasgow, UK 
Isopropanol Sigma Aldrich, Dorset, UK 
Jackson ImmunoResearch Anti-rabbit secondary ab  Stratech Scientific Unit, Newmarket Suffolk, 
UK 
Kaleidoscope Bio-Rad Laboratories, Hertfordshire, UK 
Kisol foil Taab Lab, Berkshire, UK 
Knife 16cm long tungsten carbide tipped profile D Leica Microsystems, Milton Keynes, UK 
Knife Holder NZ Leica Microsystems, Milton Keynes, UK 
L-Glutamine Invitrogen, Paisley, UK 
Low molecular weight DNA ladder New England Biolabs, Hitchin, Hertfordshire, 
UK 
Magic Marker Invitrogen, Paisley, UK 
Magnesium chloride Sigma Aldrich, Dorset, UK 
MC3T3-E1 ATCC, Manassas, VA-USA 
MC57G ATCC, Manassas, VA-USA 
MCF7 ATCC, Manassas, VA-USA 
M-CSF mouse recombinant R & D Systems, Abingdon, UK 
MDA-MB-231 ATCC, Manassas, VA-USA 
MDA-MB-231-BS ATCC, Manassas, VA-USA 
Medium density linkage panel Illumina Inc., California, US 
Methanol Fisher Scientific, Leicestershire, UK 
Methyl Methacrylate Sigma Aldrich, Dorset, UK 
Mettler Toledo Titrator Fisher Scientific, Leicestershire, UK 
Microtubes (0.5, 1.5, 2ml) Sarstedt Ltd, Leicester, UK 
N,N-Dimethylformamide Fisher Scientific, Leicestershire, UK 
N,N-dimethyl-p-toluidine Leica Microsystems, Milton Keynes, UK 




Needles (19, 21 and 25G) Fisher Scientific, Leicestershire, UK 
Neubauer Haemocytometer Hawksley, Lancing, UK 
Nitrile gloves Fisher Scientific, Leicestershire, UK 
Oligo(dt)20 Primer Invitrogen, Paisley, UK 
Orange G loading dye Sigma Aldrich, Dorset, UK 
Paraformaldehyde Taab Lab, Berkshire, UK 
Pararosanilin Sigma Aldrich, Dorset, UK 
PBS tablets Invitrogen, Paisley, UK 
PC3 ATCC, Manassas, VA-USA 
PCR lid strip Fisher Scientific, Leicestershire, UK 
PCR microplate 96 well and lids Fisher Scientific, Leicestershire, UK 
PCR primers Invitrogen, Paisley, UK 
PCR microtubes  Fisher Scientific, Leicestershire, UK 
Penicillin/Streptomycin Invitrogen, Paisley, UK 
Petri Dishes Becton Dickinson, Berkshire, UK 
Pierce SuperSignal® West Dura Extended Duration 
Substrate 
Fisher Scientific, Leicestershire, UK 
PINP serum assay (Rat/Mouse PINP EIA) Immunodiagnostic Systems Ltd. (IDS), Boldon 
Colliery, UK 
Pipette tips (all sizes) Starlab, Milton Keynes, UK 
p-Nitrophenol Sigma Aldrich, Dorset, UK 
p-Nitrophenol-phosphate Sigma Aldrich, Dorset, UK 
Polysciences Silane coated microscope slides Park Scientific Ltd., Northampton, UK 
PQIP OSI Pharmaceuticals., Farmingdale, NY-USA 
PTH Sigma Aldrich, Dorset, UK 
QIAquick PCR Purification Kit Qiagen (UK), West Sussex, UK 
Quant-iTTM PicoGreen® assay Invitrogen, Paisley, UK 
Rabbit Anti-Actin (AA20-33) IgG Sigma Aldrich, Dorset, UK 
RANKL  human recombinant Gift from Dr. Patrick Mollat (Proskelia SASU) 
RNase-free water Invitrogen, Paisley, UK 
RnaseOut Recombinant Rnase Inhibitor Invitrogen, Paisley, UK 
Scalpel, disposable VWR International LTD, Leicestershire, UK 
Scissors (fine points and spring bow handles) S Murray & Co Ltd, Surrey, UK 
SensiMix(dT) Taq polymerase GC Biotech, Alphen aan den Rijn, The 
Netherlands 
Silver nitrate Sigma Aldrich, Dorset, UK 
Slide press cover slips Taab Lab, Berkshire, UK 
Sodium acetate anhydrous Sigma Aldrich, Dorset, UK 
Sodium barbiturate BDH Laboratory Supplies, Poole, Dorset, UK 
Sodium chloride Sigma Aldrich, Dorset, UK 




Sodium hydroxide VWR International LTD, Leicestershire, UK 
Sodium phosphate Sigma Aldrich, Dorset, UK 
Sodium tartrate dibasic dihydrate Sigma Aldrich, Dorset, UK 
Sodium tetraborate BDH Laboratory Supplies, Poole, Dorset, UK 
Steel Knife 16cm “c” Leica Microsystems, Milton Keynes, UK 
Sterile filter (0.45μm) Sartorius Mechatronics UK Ltd., Epsom 
Surrey, UK 
Stripettes (5, 10, 25 and 50ml)  Sarstedt Ltd, Leicester, UK 
SuperScript III Reverse Transcriptase Invitrogen, Paisley, UK 
SYBR Safe DNA gel stain Invitrogen, Paisley, UK 
SYBR Safe Invitrogen, Paisley, UK 
Syngene BIO imaging system Fisher Scientific, Leicestershire, UK 
Syringes (all sizes) Becton Dickinson, Berkshire, UK 
Taq DNA Polymerase Invitrogen, Paisley, UK 
TaqMan® Gene Expression Assay Mix for 18S rRNA Applied Biosystems, Cheshire, UK 
TBE buffer 10X Invitrogen, Paisley, UK 
Tissue culture 75cm2 flasks Fisher Scientific, Leicestershire, UK 
Tissue culture microplates (6, 12, 24, 48 and 96-well 
plates) 
Fisher Scientific, Leicestershire, UK 
Toluidine Blue Sigma Aldrich, Dorset, UK 
Tris Bio-Rad Laboratories, Hertfordshire, UK 
Tris-EDTA buffer Sigma Aldrich, Dorset, UK 
Triton X-100TM Sigma Aldrich, Dorset, UK 
Trizol reagent Invitrogen, Paisley, UK 
Trypsin/EDTA Sigma Aldrich, Dorset, UK 
Tween-20 Bio-Rad Laboratories, Hertfordshire, UK 
Ultraclear Xylene Taab Lab, Berkshire, UK 
UPL probes Roche Diagnostics Ltd., East Sussex, UK 
UV 96 well plates for plate reader Fisher Scientific, Leicestershire, UK 
Vacuum desiccator Fisher Scientific, Leicestershire, UK 
Vitamin C (Ascorbic acid) BDH Laboratory Supplies, Poole, Dorset, UK 
xCELLigence System Roche Diagnostics Ltd., East Sussex, UK 
XT-MOPS Bio-Rad Laboratories, Hertfordshire, UK 
Xylene Sigma Aldrich, Dorset, UK 
Minimum Essential Medium (αMEM) Sigma Aldrich, Dorset, UK 







1.2 Apparatus used in this thesis: 
 
Apparatus Supplier 
AA Hoefer® protein transfer apparatus Fisher Scientific, Leicestershire, UK 
Astec Bioquell Monair 5 fume cabinet Jencons PLS, East Grinstead, UK 
Automatic tissue processor Leica Microsystems, Milton Keynes, UK 
AxioImager A1 upright research microscope Carl Zeiss Ltd., Hertfordshire, UK 
Axiovert 200 inverted research Microcope Carl Zeiss Ltd., Hertfordshire, UK 
Axiovert 40 CFL inverted microscope Carl Zeiss Ltd., Hertfordshire, UK 
Balancer Fisherbrand Fisher Scientific, Leicestershire, UK 
Bench-top centrifuge SciQuip, Shropshire, UK 
Bench-top Eppendorf centrifuge Fisher Scientific, Leicestershire, UK 
Bio-Tek Synergy HT plate reader Fisher Scientific, Leicestershire, UK 
Envair Bio2 safety cabinets  H&V Commissioning Services Ltd., Ayrshire, UK 
Grant OLS 200 water bath Thistle Scientific, Glasgow, UK 
Horizontal electrophoresis tanks Fisher Scientific, Leicestershire, UK 
Hotplate/stirrer Thistle Scientific, Glasgow, UK 
Ika Vortex Thistle Scientific, Glasgow, UK 
MJ Research Chromo 4 Real Time PCR 
thermocycler 
Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 
MJ Research Tetrad Thermal cycler Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 
Nichiryo America Inc. Pipettes (2, 10, 100, 200 
and 1000μl) 
Thistle Scientific, Glasgow, UK 
NoAir Class II Biological safety cabinet TripleRed Ltd., Buckinghamshire, UK 
Origo PSU-400/200 power supply for 
electrophoresis 
Anachem, Bedfordshire, UK 
PowerPac basicTM Bio-Rad Laboratories, Hertfordshire, UK 
QImaging Retiga 4000R CCD camera Media Cybernetics UK, Berkshire, UK 
Rotary Microtome Leica Microsystems, Milton Keynes, UK 
Rotary tool Dremel UK, Uxbridge, UK 
SkyScan 1172 X-ray Microtomography system SKYSCAN, Kontich, Belgium 
SkyScan 1176 in-vivo micro-CT SKYSCAN, Kontich, Belgium 
Syngene GeneGenius Gel Bio-Imaging system Fisher Scientific, Leicestershire, UK 
SynSyngene GeneGnome Bio-Imaging system for 
chemiluminescence 
Fisher Scientific, Leicestershire, UK 









1.3 Software used in this thesis: 
 
Software Supplier 
Aphelion Image Analysis tool kit ADCIS, Hérouville-Saint-Clair, France 
Bio-Tek Gen5TM plate reader software Fisher Scientific, Leicestershire, UK 
GraphPad Prism (version 4) GraphPad Software Inc., CA-US 
ImageJ U. S. National Institutes of Health Bethesda, 
MA-US 
Opticon Monitor analysis software version 3 Genetic Research Instrumentation Ltd (GRI), 
Essex, UK 
QCapture Pro software Media Cybernetics UK, Berkshire, UK 
Skyscan 1172 MicroCT software SKYSCAN, Kontich, Belgium 
Skyscan CTAn analysis software SKYSCAN, Kontich, Belgium 
Skyscan CTVol software SKYSCAN, Kontich, Belgium 
Skyscan NRecon reconstruction system SKYSCAN, Kontich, Belgium 
SPSS version 13 SPSS Ltd. UK, Surrey, UK 
Syngene GeneSnap software Fisher Scientific, Leicestershire, UK 
Syngene GeneTool software Fisher Scientific, Leicestershire, UK 







Appendix 2 : Solutions and Recipes 
Appendix 2.1 Solutions for TRAcP staining 
 
Naphthol-AS-BI-phosphate 
10 mg/ml Naphthol-AS-BI-phosphate in Dimethylformamide 
Veronal buffer 
1.17 g sodium acetate anhydrous and 2.94g sodium barbiturate both dissolved in 100 ml 
of dH2O 
Acetate buffer 
0.82 g sodium acetate anhydrous dissolved in 100 ml of dH2O and pH adjusted to 5.2 with 
0.6 ml glacial acetic acid made up to 100 ml with dH2O 
Pararosanilin 
1 g Pararosanilin dissolved in 20 ml of dH2O and 5 ml of 5M HCl added to it 
The solution was heated carefully whilst stirring and filtered after cooling. 
TRAcP Staining Solution 
The TRAcP staining solution was freshly prepared by mixing solution A and B as outlined 
below. 
Solution A 
150 ml of Napthol-AS-BI-phosphate 
750 ml of Veronal buffer 
900 ml Acetate buffer 
900 ml Acetate buffer with 100 mM Sodium Tartate 
Solution B 
120 ml of Pararosanilin 






Appendix 2.2 Solutions for ALP assay 
 
Diethanolamine (DEA)/MgCl2 buffer 
1 M DEA and 1 M MgCl2 made up in 100 ml dH2O and pH adjusted to 9.8. Left at room 
temperature for 24 hours 
ALP Lysis buffer 
0.05% Triton X-100 added to DEA/MgCl2 buffer 
p-Nitrophenol standard solution 
p-Nitrophenol standards (1.25 – 30 nM) prepared in lysis buffer 
Substrate solution 




Appendix 2.3 Solution for cell Lysis  
 
RIPA Lysis buffer 
1% Triton 100X, 0.5% (w/v) Sodium Deoxycholate, 0.1% (w/v) Sodium Dodecyl Sulphate 















Appendix 2.4 Solutions for PAGE and western blot 
 
Electrophoresis running buffer 
50 ml of XT-MOPS (20X) in 1000 ml of dH2O 
Samples loading protein buffer (5X stock) 
5.2 ml of 1M Tris-HCl pH adjusted to 6.8, 1 g of DL-Dithiothreitol (DTT), 3 g SDS, 6.5 ml 
glycerol and 130 l of 10% (w/v) Bromophenol Blue. Stored at -20 C.   
Transfer buffer 
3.63 g of Tris, 14.4g of Glycine, 200 ml of Methanol and 3.75 ml of 10% (w/v) SDS made up 
to 1000 ml with dH2O. Stored at room temperature. 
TBS 
1 M of Tris and 1 M Tris-HCl. pH adjusted to 7.9 prior to addition of 3 M Sodium Chloride. 
Stored at room temperature. 
TBST 
0.1% (v/v) Tween-20 in TBS. Stored at room temperature. 
Stripping buffer 






















Appendix 2.5 Solutions for Histology 
 
Infiltrating solution 
89 g MMA, 10 g Dibutyl phthalate, 1 g Perkadox 16, and 0.01 g Novoscave for 100 g of 
infiltration solution 
Embedding solution 
Same as infiltration solution but 1 week old 
Paragon staining solution 
0.625 g basic fuchsin and 1.875 g toluidine blue in 250 ml 30% (v/v) ethanol 
Borax buffer 







Appendix 3: qPCR Primers and Probes 
Gene (all human 
unless stated) 






















































































Appendix 4 : Publications from Thesis 
 
